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Background: Diabetic microvascular complications can lead to long-term morbidity and 
mortality, significantly drive healthcare costs, and impair quality of life of patients with type 
1 diabetes (T1D). Early prediction and prevention of microvascular complications, including 
nephropathy, retinopathy, and neuropathy in T1D patients can support informed clinical 
decision making and potentially delay the progression to long-term adverse outcomes. 
Although machine learning (ML) methods have been applied for disease prediction in 
healthcare, there is very limited research using advanced ML methods (e.g., neural networks) 
for the prediction of microvascular complications in T1D patients. Moreover, there is no 
study that has explicitly compared the performance of different predictive models. In 
addition, none of the predictive models in previous studies incorporated A1C variability as a 
predictor, specifically in ML models.  
Objectives: The first objective of this study was to develop and compare predictive models, 
namely, ML and conventional statistical models for 3 microvascular complications (diabetic 
nephropathy, retinopathy, and neuropathy) in T1D patients. The second objective of this 
study was to develop and compare predictive models, namely, ML and conventional 
statistical models and evaluate whether A1C variability can help better predict each of the 3 
microvascular complications (diabetic nephropathy, retinopathy and neuropathy) in T1D 
patients. 
Methods: This was a factorial experimental study using retrospective real-world registry 
data. Adult T1D patients participating in the T1D Exchange Clinic Registry and met the 
eligibility criteria were included for the analysis. Baseline characteristics of eligible T1D 
patients that were measured between 2010 and 2012 were used to predict three microvascular 
complications that were measured till 2017. Two ML methods, i.e., support vector machine 
(SVM) and neural network (NN) and one conventional statistical method, i.e., logistic 
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regression (LR) were used to develop predictive models. The three microvascular 
complications, i.e., diabetic nephropathy, retinopathy and neuropathy were operationalized as 
binary variables (yes/no). Predictors for each microvascular complication were selected. 
Specifically, A1C variability was manipulated into the following 5 levels: a) single A1C, b) 
mean A1C, c) combination single, d) combination mean, and e) multiple. Models were first 
developed through 10-fold cross-validation on the train set. Then the model was fit on the 
entire train set and evaluated on the test set. Hence, for each microvascular complication, 11 
(10+1) predictive models were developed using each modeling method with each predictor 
set. A total of 495 models (11 x 5 predictor sets x 3 modeling method x 3 microvascular 
complications) were developed, 165 models for each microvascular complication. 
Performance measure was operationalized as F1 score. Factorial analysis of variance 
(ANOVA) was used to test research hypotheses. Post hoc Tukey-Kramer test was performed 
to evaluate which levels within a factor were significantly different. An alpha level of <0.05 
was used to determine statistical significance of an association. Data preparation process, 
summary statistics, correlation analysis and LR were performed using SAS 9.4 (SAS 
Institute, Inc. Cary, NC). Predictive modelling by SVM and ANN were performed through 
Scikit-learn 0.22.1 and the Keras application programming interface (API) of TensorFlowTM 
online version 1.0.0.  
Results: A total of 4476, 3595, and 4072 patients met the eligibility criteria and included in 
the cohort of nephropathy, retinopathy, and retinopathy, respectively. Within each cohort, 
510 (11%), 659 (18%) and 579 (14%) developed nephropathy, retinopathy, and neuropathy, 
respectively during the follow-up period. Patients of the three cohorts were on average 38-40 
(±14.5-15.4) years and had been diagnosed with T1D for an average (±SD) of 19-21 (±11.3-
12.5) years. Slightly more than half (53-55%) of patients were women. For the first objective, 
the mean (±SD) F1 score of 33 LR models were 0.19±0.10, lower than that of 33 SVM 
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models (0.38±0.03) and 33 NN models (0.38±0.03). Two-way ANOVA indicated a 
significant interaction between the effects of modeling method and microvascular 
complication on performance measure (F1 scores, p<.0001). ML models performed 
significantly better than LR models within each study cohort. Post hoc Tukey-Cramer test 
indicated there was no statistical difference between F1 scores of SVM and NN models. For 
objective 2, three-way ANOVA indicated significant interactions between modeling method, 
microvascular complication and A1C variability. Hence, two-way ANOVA was performed 
within each cohort. F test indicates that A1C variability had significant effect on F1 score of 
the nephropathy cohort when the modeling method was NN (F=6.78, p<.0001). Post hoc 
Tukey-Kramer test indicates that mean F1 scores of the nephropathy cohort from NN models 
using d) combination mean or e) multiple were significantly higher than using b) mean A1C 
or c) combination single. In the cohort of retinopathy, there is no effect of A1C variability on 
performance measure. Lastly, in the cohort of neuropathy, F test indicates the A1C variability 
had significant effect on performance measure when the modeling method was LR (F=8.19, 
p<.0001). Post hoc Tukey-Kramer test indicates that mean F1 score of the neuropathy cohort 
from LR models using e) multiple was significantly lower than using other A1C variability 
measures. Across all three cohorts, ML models performed significantly better than LR 
models. 
Conclusion: The study indicates that ML models compared to LR models produced 
significantly higher F1 scores for predicting all three types of microvascular complications 
irrespective of which A1C variability measure was used. The study indicates that it is better 
to use A1C variability combination mean or multiple for evaluating A1C variability when 
predicting diabetic nephropathy in T1D patients using NN machine learning models. Future 
research is needed to develop decision support systems that can advise clinicians based on the 
results from predictive models.    
ix 
 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS ...................................................................................................... iv 
ABSTRACT ............................................................................................................................. vi 
CHAPTER 1 ............................................................................................................................. 1 
Introduction .............................................................................................................................. 1 
Artificial Intelligence & Machine Learning ........................................................................... 1 
Big Data Has Facilitated Application of ML in Health Care ................................................. 1 
Terminology and Classification of ML .................................................................................. 2 
Overview of Predictive Modeling in Healthcare.................................................................... 3 
Two Approaches to Achieve Prediction................................................................................. 3 
Performance Measures of Predictive Models......................................................................... 5 
Choosing the Right Performance Measure for Classification of Imbalanced Data ............... 6 
ML Predictive Models in Diabetes Management ................................................................... 7 
Overview of Type 1 Diabetes and its Management ............................................................... 7 
Glycemic Control in T1D Management ................................................................................. 8 
Treatment for T1D ................................................................................................................. 9 
Three Types of T1D Related Microvascular Complications ................................................. 9 
Current Screening Approach for the Three Types of Complications................................... 11 
Predictive Models may Enhance the Screening and Prevention of the Three Types of 
Microvascular Complications .............................................................................................. 11 
Research Objective ............................................................................................................... 14 
CHAPTER 2 ........................................................................................................................... 15 
x 
 
Literature Review .................................................................................................................. 15 
Risk Factors for Microvascular Complications .................................................................... 15 
Impact of Glycemic Variability on Microvascular Complications ...................................... 15 
Comparison of A1C and Glucose Variability ...................................................................... 16 
Predictive Models for Microvascular Complications in T1D Patients Using ML ............... 17 
Research Objectives ............................................................................................................. 19 
Significance ............................................................................................................................. 20 
Innovation ............................................................................................................................... 21 
CHAPTER 3 ........................................................................................................................... 23 
Theoretical Framework ......................................................................................................... 23 
Statistical Learning Theory .................................................................................................. 23 
Empirical Risk Minimization ............................................................................................... 24 
Overfitting ............................................................................................................................ 25 
Logistic Regression .............................................................................................................. 25 
Support Vector Machines (SVMs) ....................................................................................... 26 
Hyperparameters for SVMs ................................................................................................. 28 
Neural Networks (NNs) ....................................................................................................... 29 
Hyperparameters for NNs .................................................................................................... 31 
Predictor Selection – Andersen Behaviour Model ............................................................... 33 
Research Hypotheses............................................................................................................ 36 
CHAPTER 4 ........................................................................................................................... 37 
xi 
 
Methods ................................................................................................................................... 37 
Study Design ........................................................................................................................ 39 
Data Source & Patient Population ........................................................................................ 39 
Operational Definition of Study Measures........................................................................... 41 
Cohort Formation ................................................................................................................. 43 
Train Set and Test Set .......................................................................................................... 47 
Predictor Selection ............................................................................................................... 47 
Feature Manipulation for ML Models .................................................................................. 48 
Over-Sampling ..................................................................................................................... 49 
Determination of Sample Size.............................................................................................. 49 
Data Analysis ....................................................................................................................... 51 
Statistical Hypotheses .......................................................................................................... 55 
Protection of Human Subjects .............................................................................................. 57 
CHAPTER 5 ........................................................................................................................... 58 
Results ..................................................................................................................................... 58 
Patient Attrition .................................................................................................................... 58 
Cohort of Nephropathy......................................................................................................... 60 
Cohort of Retinopathy .......................................................................................................... 78 
Cohort of Neuropathy........................................................................................................... 96 
Testing of Statistical Hypotheses ....................................................................................... 115 
CHAPTER 6 ......................................................................................................................... 122 
xii 
 
Discussion, Recommendation, and Conclusions ............................................................... 122 
Discussion .......................................................................................................................... 122 
Strengths & Limitations ..................................................................................................... 126 
CHAPTER 7 ......................................................................................................................... 129 
Summary ............................................................................................................................... 129 
APPENDICES ...................................................................................................................... 131 
Appendix 1. Summary of commonly used insulin and its analogues in the United States 131 
Appendix 2. Definition of “definite T1D” ......................................................................... 132 
Appendix 3. Operational definition of study measures ...................................................... 133 
Appendix 4. Examples of accuracy and loss curves of the train and validation set using the 
5 predictor sets A through E in cohorts of nephropathy, retinopathy and neuropathy ...... 140 
Appendix 5. Performance metrics of predictive models of the nephropathy cohort .......... 144 
Appendix 6. Performance metrics of predictive models of the retinopathy cohort ........... 149 
Appendix 7: Performance metrics of predictive models of the neuropathy cohort ........... 154 




LIST OF TABLES 
Table 1. Comparison of conventional statistical and ML modeling methods ........................... 4 
Table 2. The confusion matrix ................................................................................................... 5 
Table 3. The formula of single-threshold performance metrics ................................................ 5 
Table 4. Sample size estimates based on different effect sizes for hypothesis 1 ..................... 50 
Table 5. Sample size estimates based on different effect sizes for hypothesis 2 ..................... 51 
Table 6. Baseline characteristics of patients in the nephropathy cohort .................................. 62 
Table 7. Baseline A1C measures of patients in the nephropathy cohort ................................. 67 
Table 8a. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with single A1C .................................................................................................. 71 
Table 8b. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with mean A1C ................................................................................................... 72 
Table 8c. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with combination single ...................................................................................... 73 
Table 8d. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with combination mean ....................................................................................... 74 
Table 8e. Final GEE model for prediction of development of diabetic nephropathy using 
predictor set with multiple ....................................................................................................... 75 
Table 9. Baseline characteristics of patients in the retinopathy cohort.................................... 80 
Table 10. Baseline A1C measures of patients in the retinopathy cohort ................................. 85 
Table 11a. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with single A1C .................................................................................................. 88 
Table 11b. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with mean A1C ................................................................................................... 89 
xiv 
 
Table 11c. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with combination single ...................................................................................... 90 
Table 11d. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with combination mean ....................................................................................... 91 
Table 11e. Final GEE model for prediction of development of diabetic retinopathy using 
predictor set with multiple ....................................................................................................... 92 
Table 12. Baseline characteristics of patients in the neuropathy cohort .................................. 98 
Table 13. Baseline A1C measures of patients in the neuropathy cohort ............................... 104 
Table 14a. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with single A1C ................................................................................................ 108 
Table 14b. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with mean A1C ................................................................................................. 109 
Table 14c. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with combination single .................................................................................... 110 
Table 14d. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with combination mean ..................................................................................... 111 
Table 14e. Final GEE model for prediction of development of diabetic neuropathy using 
predictor set with multiple ..................................................................................................... 112 
Table 15. Two-way ANOVA testing the effect of modeling method and microvascular 
complication on F1 scores  .................................................................................................... 116 
Table 16. Three-way ANOVA testing the effect of modeling method, microvascular 
complication and A1C variability on F1 scores  .................................................................... 118 
Table 17. Two-way ANOVA testing the effect of modeling method and A1C variability on 
F1 scores of the nephropathy cohort  ..................................................................................... 118 
xv 
 
Table 18. Two-way ANOVA testing the effect of modeling method and A1C variability on 
F1 scores of the retinopathy cohort  ....................................................................................... 120 
Table 19. Two-way ANOVA testing the effect of modeling method and A1C variability on 




LIST OF FIGURES 
Figure 1. Adapted model using the statistical learning theory ................................................. 24 
Figure 2. Illustration of general process of predictive modeling ............................................. 25 
Figure 3. Illustration of an SVM (made-up example, not based on actual data) ..................... 27 
Figure 4. Illustration of an ANN with two hidden layers ........................................................ 30 
Figure 5. Andersen Behavioral Model ..................................................................................... 34 
Figure 6. Model conceptualization using Andersen Behavioral Model .................................. 35 
Figure 7. Proposed model ........................................................................................................ 36 
Figure 8. Overview of the study design ................................................................................... 38 
Figure 9. Study timeline ........................................................................................................... 40 
Figure 10. Patient attrition chart .............................................................................................. 59 
Figure 11. Box plot of F1 scores of nephropathy cohort by modeling method and A1C 
variability ................................................................................................................................. 78 
Figure 12. Box plot of F1 scores of retinopathy cohort by modeling method and A1C 
variability ................................................................................................................................. 95 
Figure 13. Box plot of F1 scores of retinopathy cohort by modeling method and A1C 
variability ............................................................................................................................... 115 
Figure 14. Box plot of F1 scores using predictor sets with single A1C by modeling method 
and microvascular complication ............................................................................................ 115 
Figure 15. Interaction plot for F1 scores by microvascular complication and modeling method
................................................................................................................................................ 116 
Figure 16. Post hoc Tukey-Kramer multiple comparisons of least squares means for effect of 
modeling method ................................................................................................................... 117 
Figure 17. Interaction plot for F1 scores of the nephropathy cohort by microvascular 
complication and A1C variability .......................................................................................... 119 
xvii 
 
Figure 18. Interaction plot for F1 scores of the neuropathy cohort by microvascular 






Artificial Intelligence & Machine Learning 
Artificial intelligence (AI) is a wide-ranging area in computer science. There is no unanimous 
definition of AI. Russell and Norvig (2009) defined AI in terms of its goals: “AI is the field 
that aims at building systems that think/act rationally (like humans)” ( Russel & Norvig, 
2009; Bringsjord & Govindarajulu, 2018). AI techniques have been widely applied across 
industries, including manufacturing, retail, travel and hospitality, financial services, energy, 
feedstock, utilities, and healthcare and life sciences (Tripathi, 2016). Movie 
recommendations, speech recognition, Google's customization of individual searches based 
on previous web data, and driving a car using GPS navigation are some of the examples of AI 
applications that have already remarkably changed and improved our lives (Tripathi, 2016).  
Machine learning (ML) is a sub-domain of AI. ML refers to the process that allows 
computers to learn automatically without human assistance to achieve the aim of learning 
from data. It stems from statistics and computer science and is the way to realize AI (Geron, 
2017).  
Big Data Has Facilitated Application of ML in Health Care 
The term “big data” vividly describes the complex, diverse, and massive amount of data that 
is available nowadays (Murdoch & Detsky, 2013). It not only refers to the data per se, but 
also the science of managing, integrating, analysing, and sharing data (Manyika et al., 2011). 
In health care, “big data” pools include claims and cost data (owned by payers and 
providers), clinical data (owned by providers), pharmaceutical research and development 
(R&D) data (owned by pharmaceutical companies and academia), and patient behaviour data 
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(owned by consumers and stakeholders outside health care such as retail and apparel) 
(Groves, Kayyali, Knott, & Van Kuiken, 2013). These databases have been utilized to answer 
research questions in health outcomes research for a long time. Typically, researchers try to 
learn from the data in order to either predict future events/health outcomes or understand 
relationships between variables (Breiman, 2001).  
Because of the remarkable capability, efficiency, and flexibility of ML algorithms to handle 
data and achieve a solution, there has been a rapid expansion of ML application to the health 
care sector (Murdoch & Detsky, 2013). In fact, over a hundred start-up companies have 
emerged and applied ML to specialties of patient data and risk analytics, medical research, 
imaging and diagnostics, lifestyle management and marketing, mental health, emergency 
room and surgery, inpatient care and hospital management, drug discovery, virtual assistants, 
wearables, and clinical decision support software.(Mazzanti, Shirka, Gjergo, & Hasimi, 2018)  
Terminology and Classification of ML 
As developed by computer scientists, in ML terminology, “variables” are called “attributes”. 
Attributes in combination with their values are termed “features”, although in many cases, 
features and attributes are used interchangeably. “Outcomes” or “dependent variables” in 
health outcomes research are referred to as “labels” or the “solution”. There are various 
criteria for classifying ML systems and very often these criteria can be used in combination 
for classification purposes. Based on the extent and type of supervision an ML system 
receives during the data learning process, it can be broadly categorized as supervised 
learning, unsupervised learning, semi-supervised learning, and reinforcement learning. In 
supervised learning, the data used for learning contains information of the desired solution 
(i.e., label or the dependent variable). Typical tasks of supervised ML are classification, in 
3 
 
which the dependent variable or label is categorical variable and regression, in which the 
dependent variable is continuous (Geron, 2017). 
Overview of Predictive Modeling in Healthcare 
Predictive modelling refers to the process of developing a mathematical tool or model to 
predict the probability of an outcome (Geisser 1993; Kuhn  & Johnson 2013). A predictive 
model for a health outcome such as a disease is a model that outputs the likelihood or risk of 
a disease based on the input information from a patient (Steyerberg, 2019). In health care, the 
outcome can be, but not limited to a clinical/disease status, hospitalization, health resource 
utilization and expenditure, medication adherence, and patient satisfaction. Input information 
can be patient demographics, clinical characteristics, and lifestyle factors that are available 
from electronic medical records, patient claims, or survey data (Steyerberg, 2019). Once a 
model is developed and validated, it can be applied to predict future events in patients. 
Healthcare stakeholders including payers and providers can use predictive models for 
decision support such as risk stratification and targeting patients for interventions 
(Steyerberg, 2019). 
Two Approaches to Achieve Prediction 
Prediction can be achieved through two approaches: conventional statistical methods and 
advanced ML models (Shalev-Shwartz & Ben-David, 2014).  
Conventional statistical predictive model is a formalization of relationship between variables 
in the form of mathematical equations (Shalev-Shwartz & Ben-David, 2014). Conventional 
statistical methods assume a stochastic data model. In other words, they assume observed 
data are from a random probability distribution. The outcome to be predicted can be 
represented as a function of independent input variables plus random noise (Shalev-Shwartz 
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& Ben-David, 2014). Commonly used statistical methods include regression, logistic 
regression (LR) and time-to-event or survival analysis.  
On the other hand, ML predictive model is an algorithm that operates on input variables to 
predict the outcome variable(s) (Shalev-Shwartz & Ben-David, 2014). ML methods usually 
do not assume a parametric model between independent and dependent variables and are 
more liberal in techniques and approaches to achieve prediction (Contreras & Vehi, 2018). 
Commonly used advanced ML methods include linear support vector machines (SVMs), 
artificial neural networks (NNs), classification and regression trees (CARTs) & random 
forests (RFs) and k-nearest neighbors (Geron, 2017). The comparison of conventional 
statistical modeling versus ML modeling is summarized in Table 1. 
Table 1. Comparison of conventional statistical and ML modeling methods 
 
 Statistical Modeling ML Modeling 
Definition “Parametric formalizations of 
relationships between independent 
and dependent variables in the form 
of mathematical equations” 
“Algorithms that operate on 
independent variables to predict 
the dependent variable(s) without 




Linear regressions, logistic 
regressions, Cox models 
SVMs, NNs, CARTs & RFs, k-
nearest neighbors 
Assumptions Rigid assumptions about the 
relationship and data distributions 
No rigid assumptions about the 
problem and data distributions in 
general 





Conservative in techniques and 
approaches 
More liberal in techniques and 
approaches 
Predictors Often require independent predictor 
variables and less number of 
predictors 
Can handle multicollinearity, 




Performance Measures of Predictive Models 
The performance of predictive models can be evaluated mainly by two types of measures: 
basic single-threshold measures and threshold-free measures (He & Garcia, 2009). 
Commonly used single-threshold measures include accuracy, sensitivity, specificity, 
precision and F1 score; and commonly used threshold-free measure includes area under 
receiver-operating characteristics curve (AUC) (Jiao & Du, 2016). The confusion matrix and 
the calculation of single-threshold measures are listed in Tables 2 and 3. As ML models can 
be ‘trained’, a single performance metric can be chosen as the target for improvement. Hence, 
it is critical to choose the appropriate performance metric in order to serve the researchers’ 
specific prediction goals.  
Table 2. The confusion matrix  
 
Table 3. The formula of single-threshold performance metrics 
 Predicted Positive Predicted Negative Total 
Actual Positive True Positive (TP) False Negative (FN) TP + FN 
Actual Negative False Positive (FP) True Negative (TN) FP + TN 
Total TP + FP FN + TN TP + TN + FP + FN 
Performance Metric Formula 
Accuracy 𝑇𝑇𝑇𝑇 + 𝑇𝑇𝑇𝑇

















Choosing the Right Performance Measure for Classification of Imbalanced Data  
In healthcare, we face classification problems a lot, e.g., to categorize patients into 
diseased/non-diseased, high-risk/low-risk or case/control groups. In most cases, the data 
contains unequal number of cases and controls and specifically, the number of cases is less 
than the number of controls. This is the simplest manifestation of imbalanced data. More 
generally, imbalanced data refers to the unequal representation of different levels of the class 
(Li & Mao, 2014). The imbalance nature of the data not only makes correct prediction of the 
less represented class more difficult, but also results in misleading perceptions of model 
performance based on commonly used performance metrics, such as accuracy and AUC ( He 
& Garcia, 2009; Valverde-Albacete & Peláez-Moreno, 2014; Akosa, 2017). For example, 
among a total of 1000 individuals, 10 are ‘diseased’ and 990 are not. In the most extreme 
case, a model correctly predicted the 990 non-diseased individuals while misclassifying those 
10 patients as non-diseased, the accuracy of the model is as high as 99%. However, the model 
fails to identify any diseased patients. This exemplifies the so-called ‘accuracy paradox’ 
where a high accuracy does not indicate a ‘good’ model performance (Valverde-Albacete & 
Peláez-Moreno, 2014; Akosa, 2017). This causes a problem especially when researchers aim 
to correctly identify the ‘diseased’ cases. Accuracy and AUC are calculated based on the 
predictive model’s capability of identifying both ‘cases’ and ‘controls’. If we focus more on 
the correct identification of the ‘cases’ or the less prevalent class from imbalanced data when 
developing predictive models, the F1 score (the harmonic mean of precision and sensitivity) 






ML Predictive Models in Diabetes Management 
The number of published articles in Google Scholar that involve both diabetes and ML have 
increased remarkably, from around 500 in the year of 2000 to over 10,000 in 2017 (Contreras 
& Vehi, 2018). A review of literature from PubMed on ML in diabetes management 
published between 2010 and 2018 found a total of 141 English articles, majority of which 
were published between 2015 and 2018. These literatures cover diverse aspects of diabetes 
management, the top three being closed-loop systems (“artificial pancreas”, 22%), daily-life 
support in diabetes management (e.g., a decision support system or DSS that monitors a 
patient’s diet, physical activity, medication use, and glucose measurements and applies ML 
algorithms to learn from recorded data in order to assist patients and clinicians with informed 
decision making, 21%), and real-time blood glucose prediction (e.g., prediction of blood 
glucose excursion using data captured by continuous glucose monitor or CGM, 19%). Other 
areas include risk and patient stratification (13%), detection of adverse glycemic events 
(10%), insulin bolus calculators and advisory systems (9%), and detection of meals, exercise 
and faults (6%) (Contreras & Vehi, 2018). 
As ML is a very powerful tool in prediction, this study tries to apply ML algorithms to 
research in type 1 diabetes (T1D). Following is an overview of T1D, its associated 
complications, and consequential clinical, economic, and social impacts. 
Overview of Type 1 Diabetes and its Management 
T1D is a chronic progressive disease characterized by elevated blood glucose level, 
abnormalities of carbohydrate, fat, and protein metabolism (Bluestone, Herold, & Eisenbarth, 
2010; Chiang, Kirkman, Laffel, & Peters, 2014; Todd, 2010). Common symptoms of T1D 
include frequent urination, excessive thirst, extreme hunger, unusual weight loss, increased 
fatigue and irritability, and blurry vision (Atkinson, Eisenbarth, & Michels, 2014). It’s 
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usually diagnosed at a younger age (in children and adolescents) (Chiang et al., 2014) and 
slightly more common in boys and men (Global report on diabetes, 2016; Ostman et al., 
2008). Seasonal variations also exist, in which more T1D cases are diagnosed in autumn and 
winter (Moltchanova, Schreier, Lammi, & Karvonen, 2009) and birth in the spring is 
associated with a higher chance of having T1D (Kahn et al., 2009). Worldwide, there are 
around 23 million individuals affected by the disease (Global report on diabetes, 2016; Cho 
et al., 2018). In the United States (U.S.), over 1.5 million people have T1D with 40,000 new 
cases diagnosed every year (Type 1 Diabetes, 2019). Treating T1D and its complications is 
expensive: the total cost is approximately $15 billion every year in the US (Tao, Pietropaolo, 
Atkinson, Schatz, & Taylor, 2010). A recent study found that the per patient per year (PPPY) 
cost for T1D was over $18,817, which was significantly higher than the costs for treating 
type 2 diabetes (T2D) (Joish et al., 2020). 
Glycemic Control in T1D Management  
Glycemic control is critical in preventing and slowing the progression of diabetic 
microvascular complications (Association, 2019d). Glycated hemoglobin (A1C) level is a 
useful indicator of blood glucose control. It estimates a patient’s blood glucose level over a 
period of three months (Ontario, 2018). Excellent glycemic control can substantially reduce 
the incidence of ESRD, retinopathy, neuropathy, myocardial Infarction, stroke, and all-cause 
mortality. It can also improve patients’ QoL and reduce healthcare costs due to avoidable 
complications (Herman et al., 2018). Thus, treatment guidelines usually recommend a certain 
A1C level as a goal to assist clinicians and patients in judging whether their diabetes are well 
managed or not. The American Diabetes Association (ADA) 2019 guidelines sets a glycemic 
target of A1C < 7.0% for many nonpregnant adult patients (Association, 2018a). However, 
normoglycemia is not achieved by around 80% of adult T1D patients, even with the many 
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advances in treatment modalities (Juarez, Ma, Kumasaka, Shimada, & Davis, 2014; Foster et 
al., 2019) 
Treatment for T1D  
Insulin therapies are essential in helping patients achieve glycemic control and are the current 
standard of care for T1D patients (Association, 2019b). They are categorized as rapid-acting 
(aspart, lispro, glulisine, and insulin human), short-acting (regular R), intermediate-acting 
(NPH or isophane insulin), and long-acting (glargine, detemir, albulin, and degludec) based 
on the drug’s time of onset and duration of action. Short-acting and rapid-acting insulins are 
used at meal times (bolus) and are often used together with an intermediate-acting or long-
acting insulin, which keeps consistent blood glucose levels during periods of fasting (basal) 
(Association, 2019c). Since 2000, newer generations of insulin and its analogues as well as 
their modes have been developed (Appendix 1). Other advances in diabetes management 
include devices for glucose monitoring such as blood glucose meters and continuous glucose 
monitors (CGM), closed loop systems, and transplantation (Aathira & Jain, 2014). Lifestyle 
management including diabetes self-management education and support, nutrition therapy 
(weight management and carbohydrates), and physical activity is also important (Association, 
2019a).  
Three Types of T1D Related Microvascular Complications 
T1D is associated with chronic complications. Elevated glucose level can promote 
pathological change of the blood vessels (such as sclerosis and abnormal proliferation of 
vascular endothelial cells inside the capillary), which can affect the kidneys, eyes, and nerves 
and lead to diabetic nephropathy, retinopathy, and neuropathy (Fowler, 2008).  
The prevalence of diabetic nephropathy or kidney disease among T1D patients is around 
15%-40% (Viswanathan, 2015). Microalbuminuria is the earliest phenotype of diabetic 
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nephropathy and has an annual incidence rate of 2-3% (Marshall, 2012). Certain 
race/ethnicity groups including South Asians, American Hispanics, and African-Americans 
are at higher risk of developing diabetic nephropathy (Ameh, Okpechi, Agyemang, & 
Kengne, 2019). Diabetic nephropathy is associated with long term macrovascular 
complications such as end-stage renal disease (ESRD)/renal failure and cardiovascular 
diseases (Fowler, 2008; Viswanathan, 2015) and it can significantly drive health care cost: 
Patients with diabetic nephropathy have between $3,580 - $12,830 more costs than patients 
without (Zhou et al., 2017).  
Diabetic retinopathy is the most common microvascular complication among the three types 
(Fowler, 2008). It is associated with other two types of microvascular complications, 
macrovascular complications and blindness (Fong, Aiello, Ferris, & Klein, 2004; Pearce, 
Simó, Lövestam-Adrian, Wong, & Evans, 2018), adversely impacts health-related quality of 
life (HRQoL) (Chen et al., 2010), and drives healthcare resource utilization(Candrilli, Davis, 
Kan, Lucero, & Rousculp, 2007). 
Diabetic neuropathy is a group of complications that is composed of both diabetic peripheral 
neuropathy (DPN) and diabetic autonomic neuropathy (DAN) (Association, 2018b). DPN is 
symptomized by numbness, burning, and tingling pain in extremities, although up to 50% of 
patients can be symptomless (Association, 2018b). The prevalence of DPN based on 
European data ranges from 6% to 34% in diabetic patients (Alleman et al., 2015). DPN 
increases the risk for foot ulceration and amputation, which further associates with mortality 
and worse HRQoL in diabetic patients (Alleman et al., 2015; Pop-Busui et al., 2017). The 
PPPY medical costs for diabetic patients with DPN ranged between $12,492 and $30,755 in 
2015, which were significantly higher than those patients with diabetes only ($6,632) 
(Sadosky et al., 2015). On the other hand, DAN is less prevalent than DPN. DAN is a group 
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of disorders including gastroparesis, constipation or diarrhea, bladder dysfunction, erectile 
impotence, and cardiovascular autonomic dysfunction (CAN) (Boulton et al., 2005).  
These three types of microvascular complications are often synergic and if not well managed, 
can lead to poor prognosis, adversely impact HRQoL, and drive healthcare costs (Atkinson et 
al., 2014; Kähm, Laxy, Schneider, & Holle, 2019). The costs for treating diabetes-related 
complications in T1D patients was estimated to be $7,816 PPPY (Joish et al., 2020). Hence, 
early screening and prevention of these complications is critical in T1D management 
(Association, 2019d).  
Current Screening Approach for the Three Types of Complications  
The ADA treatment guidelines recommend annual screening for nephropathy, retinopathy, 
and neuropathy starting at five years after diagnosis of T1D (Association, 2019d). For 
subgroups of patients with or without specific conditions, timing and frequency of 
examinations can be changed. For example, all T1D patients with comorbid hypertension 
should have nephropathy assessment at least once a year. More frequent eye examination is 
recommended for patients with existing evidence of retinopathy (Association, 2019d).  
Predictive Models may Enhance the Screening and Prevention of the Three Types of 
Microvascular Complications  
However, there is still space for improvement in screening and prevention of microvascular 
complications.  
For the diagnosis of diabetic nephropathy, which also applies to all clinical tests, positive 
results will need to be confirmed by a second or repeated tests due to differences in 
laboratory methods, urine samples, and definition of nephropathy (de Jong & Curhan, 2006). 
A 2017 study suggested that utilization of kidney disease risk scores may be helpful and cost-
effective in identifying at-risk patients (Yarnoff et al., 2017). 
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Many studies tried to establish a screening schedule of eye examination that would be more 
efficient in managing T1D. The Diabetes Control and Complications Trial (DCCT) and 
Epidemiology of Diabetes Interventions and Complications (EDIC) group recommended an 
individualized eye screening approach based on patient’s state of retinopathy in 2017 (Nathan 
et al., 2017). Status of retinopathy is categorized into no retinopathy, mild, moderate, or 
severe non-proliferative retinopathy, and advanced retinopathy (including proliferative 
diabetic retinopathy, clinically significant macular edema, or previous self-reported treatment 
with panretinal or focal photocoagulation, intraocular glucocorticoids, or anti-VEGF agents). 
They reported that patients with lower risk of retinopathy progression (such as those with no 
retinopathy) can receive less frequent screening (i.e., at 4-year or 3-year intervals) whereas 
those at higher risk need to receive more frequent eye exams (i.e., at 6-month or 3-month 
intervals). Personalized screening schedules would result in 58% reduction (10.7 fewer) of 
retinal examinations and cost savings of approximately $1 billion (43% decrease) over a 20-
year period compared to annual screening after 5 years (Nathan et al., 2017). A 2016 
systematic review compared cost-effectiveness of eye exam by clinic camera and 
telemedicine and concluded that telemedicine screening can save cost and improve access, 
especially in low- and middle-income countries, where nearly 80% of all diabetic patients 
live (Pasquel et al., 2015). Researchers also revealed lack of compliance in receiving eye 
examinations in low-socioeconomic-status patients (Margaret M. Byrne et al., 2014; Pasquel 
et al., 2015). One study found community-based retinal screening can be cost-effective 
(slightly over $100 per person screened) (M. M. Byrne et al., 2014).  
Lastly, for the screening of diabetic neuropathy, a study compared different screening tests 
for DPN, including Michigan Neuropathy Screening Instrument (MNSI), Semmes-Weinstein 
Monofilament (SWM), vibration sensation and ankle reflex, in terms of simplicity, reliability, 
and accuracy (Al-Geffari, 2012). The author indicated that even though methods correlated 
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with each other, they often came to very different conclusions. A combination of screening 
methods for diabetic neuropathy would increase sensitivity and specificity (Al-Geffari, 2012). 
A more recent study examined effectiveness of different screening approaches (Brown, 
Pribesh, Baskette, Vinik, & Colberg, 2017). It echoed previous findings that different tools 
can be used in combination and suggested that future study is needed to refine and develop 
new screening methods. Significant increase in cost occurred during the diagnostic period 
compared to the baseline period. Similarly, a retrospective study using Health and Retirement 
Study (HRS) - Medicare Claims linked database indicated that research is needed to improve 
efficiency in DPN evaluation (Callaghan et al., 2012). 
Inefficiency of healthcare resource and expenditure use is one aspect of concern. Moreover, 
patients may not benefit the most following current screening approaches. This is because 
with current screening guidelines, patients would probably assume or have the misconception 
that their risks of developing certain microvascular complications are equal after 5 years, 
which is not true. This would especially pose a problem for patients at higher risk of disease 
progression. This may partly explain the low compliance of patients to attend annual 
screening (Molitch et al., 2004).  
A economic study in 2003 suggested that a predictive risk model was the most efficient tool 
for screening patients compared to lab tests, although it may not be the most accurate method, 
probably due to lack of accuracy in models developed by conventional statistical methods 
(Zhang et al., 2003). A predictive model to differentiate patients who are at risk for each of 
the three microvascular complications can be useful in informing healthcare providers and 
patients and may change patients’ perceptions and potentially change their health behavior, 
including but not limited to attending screening appointments, becoming more watchful for 
signs of disease progression, better compliance to insulin therapies and glucose monitoring, 
healthier diet and more exercise. Predictive models for microvascular complications in T1D 
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patients may also facilitate intervention in at-risk patients and result in long-term cost 
savings. 
Research Objective 
Hence, this study intended to develop and compare predictive models for diabetic 
nephropathy, retinopathy, and neuropathy in T1D patients using both conventional statistical 
and ML methods. It also aimed to incorporate predictors that were not included in previous 
studies in prediction and assess whether inclusion of the predictor would impact the 
prediction of each of the three microvascular complications. This study directly compared the 
performance of conventional statistical methods and ML methods in prediction by using the 
same predictors for each microvascular complication. It supplements current knowledge in 
understanding relationship between patient, clinical and contextual characteristics and each 
complication. It may serve as a preliminary screening tool to identify at-risk patients for 
further confirmatory laboratory tests and help patients and their health care providers (HCPs) 
for better informed T1D management. 
In CHAPTER 2, microvascular complication risk factors and previous predictive models for 
each of the three microvascular complication in T1D patients that employed ML methods 






Risk Factors for Microvascular Complications  
With major improvement in diabetes management, progression to long term macrovascular 
morbidity and mortality is delayed (Association, 2019d). Because microvascular 
complications can put patients at risk of developing major morbidity and mortality, the ADA 
guideline emphasizes the importance of screening for, preventing, and delaying the 
progression of diabetic nephropathy, retinopathy, and neuropathy (Association, 2019d). 
Extensive researches have been conducted to assess risk factors (besides hyperglycemia) for 
diabetic complications. Common ones include older age, certain races, longer duration of 
T1D, dyslipidemia, hypertension, overweight and obesity, smoking, and inactive lifestyle 
(Risk factors for complications, 2018; Association, 2019d). Retinopathy itself is a risk factor 
for the other two types of microvascular complications (Association, 2019d). Ulceration is a 
specific risk parameter for neuropathy (Donnelly, Emslie-Smith, Gardner, & Morris, 2000). 
On the other hand, use of (angiotensin-converting enzyme) ACE inhibitors may reduce the 
risk of progressing to microvascular complications in T1D patients (Donnelly et al., 2000).  
Impact of Glycemic Variability on Microvascular Complications 
A level of A1C <= 7% was established as the gold standard of glycaemic control from the 
DCCT, the largest clinical trial in T1D patients in the U.S. However, patients with similar 
mean A1C levels had quite differential risk of developing retinopathy (Group, 1995). Thus, 
researchers have been looking for other parameters to account for diabetes progression. There 
is on-going debate on the association between glycemic variability (both short-term and long-
term) and diabetes complications. A SLR implied that within-day glucose variability (or 
short-term variability) could predict complications in type 2 diabetes (T2D) patients 
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independent of A1C levels. However, the evidence for T1D patients is inconclusive 
(Nalysnyk, Hernandez-Medina, & Krishnarajah, 2010). A SLR and meta-analysis in 2015 
indicates that in both T1D and T2D patients, A1C variability (or long-term variability) was 
adversely associated with both micro- and macro- vascular complications and mortality 
independently of the mean A1C value (Gorst et al., 2015). Nevertheless, many factors can 
contribute to the variation rather than the true biological variability (Sacks, 2011). Future 
research is needed to better understand the role of glycemic variability in the progression of 
diabetic complications and apply it in clinical risk assessment (Nalysnyk et al., 2010; Gorst et 
al., 2015).  
Comparison of A1C and Glucose Variability 
A1C is formed by the attachment of glucose to haemoglobin and it is contained by red blood 
cells (erythrocyte). Because the lifespan of erythrocytes is around 120 days, an A1C usually 
indicates the glucose level over a period of three months (Nathan et al., 2008). Commonly 
used measures of A1C variability include standard deviation (SD: measures how much values 
differs from the group mean), adjusted SD (accounting for the number of measures) and 
coefficient of variation (CV: = SD/mean). Biological variation of A1C within a non-diabetic 
individual over time is usually minimal (Kilpatrick, Maylor, & Keevil, 1998), whereas 
variation between individuals is greater (Sacks, 2011). Unlike blood glucose level, which can 
be affected by numerous pre-analysis factors such as food ingestion, prolonged fasting, 
exercise, medications, venous stasis, posture, sample handling, the source of blood, acute 
disease that can alter glucose concentration, and even acute stress, A1C is mainly influenced 
by an individual’s erythrocyte life span, race, and presence of iron-deficiency anemia (Sacks, 
2011). Hence, A1C variability provides a more stable estimate for glucose variation of an 
individual. Although inconclusive, greater extent of glycaemic variability, especially long-
term A1C variability can put T1D patients at higher risk of diabetes complications 
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independent of mean A1C (Nalysnyk et al., 2010; Gorst et al., 2015). A 2018 study evaluated 
different ways of measuring A1C variability and found that adjusted standard deviation (adj-
SD) of A1C was the best predictor of all-cause mortality among T2D patients in terms of 
statistical significance and odds ratio plus its 95% confidence interval (Orsi et al., 2018). 
Hence, SD of multiple A1C values were used as one operationalization of A1C variability in 
this study. 
Predictive Models for Microvascular Complications in T1D Patients Using ML 
Based on previous knowledge, predictive models for diabetes complications has ensued to 
assist informed clinical decision making (Lagani, Koumakis, Chiarugi, Lakasing, & 
Tsamardinos, 2013; Cichosz, Johansen, & Hejlesen, 2015; Lagani et al., 2015; Kavakiotis et 
al., 2017; Dagliati et al., 2018). Two published SLRs revealed that most existing prediction 
models in diabetes research were about long-term macrovascular outcomes such as 
cardiovascular diseases or mortality and were based on data from patients with T2D alone or 
a mixture of T2D (majority) and T1D patients (Lagani et al., 2013; Cichosz et al., 2015). 
How much are those findings applicable to T1D patients is unknown. We have also witnessed 
an emerging trend in the methodology used in the models: although conventional statistical 
methods (e.g. LR, Cox model) were adopted quite often, newer machine learning (ML) 
algorithms have been applied to the field (Kavakiotis et al., 2017; Contreras & Vehi, 2018; 
Dagliati et al., 2018).  
A SLR was conducted to identify predictive models for microvascular complications in T1D 
patients using ML algorithms and published in the Journal of Medical Artificial Intelligence 
(Xu, Wang, & Sansgiry, 2019). A total of six studies were found, among which, four studies 
used data obtained from T1D patients alone and two used data from both T1D and T2D 
patients (Skevofilakas, Zarkogianni, Karamanos, & Nikita, 2010; Vergouwe et al., 2010; 
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Aspelund et al., 2011; Lagani et al., 2015; Kazemi, Moghimbeigi, Kiani, Mahjub, & 
Faradmal, 2016; Ravizza et al., 2019). To briefly summarize the findings, only one study 
developed predictive models for all three types of microvascular complications whereas the 
other five focused on the prediction of either diabetic nephropathy, retinopathy or 
neuropathy. The outcomes of diabetic nephropathy and retinopathy were predicted 3 times, 
respectively and diabetic nephropathy predicted twice. There is considerable variation in the 
definition of each microvascular complication, due to which it is hard to directly compare the 
performance of predictive models for the same microvascular complication from different 
studies. There is a paucity of large contemporary longitudinal real-world data to evaluate 
disease progression in T1D patients, especially in the United States (Xu, Wang, & Sansgiry, 
2019).  
Common predictors used across studies and across three types of microvascular 
complications included age, gender, diabetes duration, body mass index (BMI), blood 
pressure, lipid level, and mean or a single HbA1C value. The study using the DCCT/EDIC 
data is most robust in terms of comprehensiveness of predictors – in addition to previous 
mentioned factors, they also included measures of insulin use (insulin regimen, total insulin 
daily dosage), additional patient demographics (marital status and occupation), post 
pubescent diabetes duration, presence of neuropathy, past history of severe hypoglycemia 
(SH) and hospitalization(s) due to diabetic ketoacidosis (DKA), family history of T1D and 
other types of diabetes, and even measures on patient attempted suicide and specific ideal 
body weight (Lagani et al., 2015). A SLR in 2017 summarized common clinical, 
environmental, and genetic risk factors for DPN, and indicated that future research is needed 
to confirm the relationship between psychological factors and progression of DPN (Hébert, 
Veluchamy, Torrance, & Smith, 2017). We did not find any study that incorporated A1C 
variability as a predictor. 
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Attempted ML algorithms included classification and regression tree (CART) and random 
forest (RF) (CART/RF, n=3), support vector machines (SVMs, n=2), logistic regression (LR, 
n=2) and neural networks (NNs, n=1) (Xu, Wang, & Sansgiry, 2019). Within ML models, 
SVMs and NNs were reported to perform better than other models in these studies. Hence, 
these two methods were chosen for our research. 
Model performance was evaluated using either AUC (n=4) or accuracy (n=2) (Xu, Wang, & 
Sansgiry, 2019). Moreover, none of these models targeted to improve the F1 score. How well 
these models can identify patients at risk is questionable, especially considering the 
imbalanced nature of the data. 
Research Objectives 
The first objective of this study was to develop and compare predictive models, namely, ML 
and conventional statistical models for 3 microvascular complications (diabetic nephropathy, 
retinopathy, and neuropathy) in T1D patients. 
The second objective of this study was to develop and compare predictive models, namely, 
ML and conventional statistical models and evaluate whether A1C variability can help better 
predict each of the 3 microvascular complications (diabetic nephropathy, retinopathy and 





Predictive models can serve as a convenient and less expensive way for patient risk 
identification (Zhang et al., 2003). While there are six studies that have developed predictive 
models for microvascular complications in T1D patients, none of them focused on enhancing 
the F1 score of the models, which is a better indicator for a model’s capability of identifying 
patients at risk with imbalanced data. Moreover, none of previous studies explicitly compared 
the performance of different modeling methods. This study adds to current knowledge by 
explicitly comparing the performance of two ML methods and conventional logistic 
regression using the same predictor sets. The development of these predictive models for 
diabetic microvascular complications has the following clinical implications: first, the focus 
on improving F1 score can better help identify those patients who are at higher risk for each 
microvascular complication (Harrell, Lee, & Mark, 1996), which can bring these high-risk 
patients to the attention of their HCPs; HCPs can use the estimates to make informed 
decisions. For example, they can order confirmatory lab tests earlier and provide more 
appropriate treatment and education for high-risk patients. Second, the study provides a better 
understanding of relative importance of risk factors for each microvascular complication 
among T1D patients. Specifically, the effect of A1C variability on T1D prognosis was 
evaluated. This can supplement current knowledge in terms of how multiple A1C measures 
of patients can be utilized in clinical settings for decision support. Specifically, HCPs can 
record multiple A1C values and calculate their standard deviations to represent A1C 
variability. Algorithms can also be developed to evaluate the variability in A1C and the 
information can be used in predictive models for identifying high risk patients for 
microvascular complications. The knowledge of risk factors can be used in designing future 
clinical trials involving T1D patients such as patient stratification based on important risk 
factors. Third, it can assess the relative therapeutic benefit of different types of contemporary 
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insulin therapies as well as diabetes management modalities. Last but not the least, it may 
help in efficiently allocating health care resources based on patients’ needs and thus, 
potentially save health care cost. Predictive models can be used as a preliminary screening 
tool in hospitals and other primary care settings to improve efficiency as well as test 
accuracy. For example, patients at lower risk can be ordered less frequent lab test for certain 
complications.  
Innovation 
This was among the first studies that utilized experimental design to explicitly compare the 
performance of different predictive modelling methods for each of the three microvascular 
complications. This was also among the first to develop predictive models for diabetic 
nephropathy, retinopathy and neuropathy in T1D patients with a specific focus on enhancing 
the F1 score, which is a better indicator of a model’s capability of identifying ‘cases’, 
whereas previous studies focused on other metrics such as accuracy and AUC, which may not 
be an appropriate indicator of model performance, especially when the data is imbalanced. 
Recent scientific findings point to the delay of progression to long-term macrovascular 
complications and emphasize the importance of early screening and prevention of micro-
vascular complications. Although annual physical examination of feet, eyes, and urine lab 
works are recommended for patients who have been diagnosed with T1D for at least 5 years, 
the screening approach can be individualized provided a dependable predictive model that 
identifies individual’s risk. This study is innovative in that it is among the first to utilize 
advanced ML methods, including SVMs and NNs for the prediction of microvascular 
complications among T1D patients. Only a few studies predicted microvascular 
complications in T1D patients in the United States. And even fewer studies predicted diabetic 
neuropathy among T1D patients. This study is among the first to comprehensively assess 
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patient risk of developing both peripheral and autonomic neuropathy in T1D patients. 
Furthermore, A1C variability was incorporated into the predictive models for the first time. 
In CHAPTER 3, the theories that guided this research will be discussed and followed by 





The conceptualization of this study was based on the Statistical Learning Theory and 
Andersen Behavioral Model. Statistical Learning Theory was used to guide the model 
development and Andersen Behavioral Model was used to guide the predictor selection. 
Statistical Learning Theory 
The statistical learning theory was used to guide model development, validation and 
comparison (Shalev-Shwartz & Ben-David, 2014). Specifically, we focused on prediction for 
binary classification. According to the statistical learning framework, a formal model 
contains the following:  
1. Input: includes a domain set, 𝑋𝑋, a label set 𝑆𝑆, and training data 𝑆𝑆 = (𝑋𝑋, 𝑆𝑆). The 
domain set, 𝑋𝑋 refers to all the objects that we want to classify. In this study, the 
domain set is all T1D patients. One domain point is an individual patient and is 
referred to as an instance. The instance can be represented by a vector of features, or 
characteristics of T1D patients (e.g., age, gender, etc.). 𝑋𝑋 is also referred to as the 
instance space. The label set 𝑆𝑆 refers to the classes we want to predict. In this study, 
𝑆𝑆 is a two-element set {0,1} where 0 denotes non-diseased (e.g., not having diabetic 
nephropathy) and 1 denotes diseased (e.g., having diabetic nephropathy). The 
training data 𝑆𝑆 = (𝑋𝑋,𝑆𝑆) are the data we have access to. 
2. Output: a classifier/predictive rule ℎ:𝑋𝑋  𝑆𝑆 that can be used to predict future 
domain points. In this study, the classifier can be conventional logistic regression 
(LR) models and advanced ML models (SVMs or NNs).  
3. A data-generation model: we assume 𝑋𝑋 are generated by an unknown probability 
distribution D. There is a correct labeling/classifying function 𝑓𝑓:𝑋𝑋  𝑆𝑆 that applies 
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to all instances that we want to learn. This condition can be relaxed as not all label 𝑆𝑆 
can be fully determined by the unknown features of 𝑋𝑋. 
4. Measure of success: The error of a predictive model, ℎ:𝑋𝑋  𝑆𝑆 is defined as the 
probability that it does not predict the correct label on a random data point generated 
by the underlining distribution D. It is denoted as 𝐿𝐿, or loss of a predictive model, 
when ℎ(𝑥𝑥) ≠ 𝑓𝑓(𝑥𝑥).  
The adapted model from the statistical learning theory is depicted in Figure 1. 
 
Figure 1. Adapted model using the statistical learning theory 
Empirical Risk Minimization  
Conventional statistical models such as LR do not normally have a training process. They 
rely heavily on predictor selection and use the whole training data for modeling and use the 
test set for evaluation. ML, on the other hand, can train the models to minimize the loss/error 
𝐿𝐿. As the training data is the only information that is known to us, ML methods try to 
minimize the error based on the training data. This error is referred to as the empirical error 
and the process of its minimization is called empirical risk minimization (ERM) (Shalev-







As a ML model trains and learns, it may predict on the training set excellently, yet poorly on 
the test/new data. This is called overfitting. To prevent overfitting, different ML methods take 
different approaches to prevent overfitting so that the model can perform well on the training 
set and potentially as well on the test/new data. 
 
Figure 2. Illustration of general process of predictive modeling 
The general process of the predictive modeling process is illustrated in Figure 2. The 
explanation of the three modeling methods is provided below. 
Logistic Regression 
A LR uses the maximum likelihood estimation and makes the following four assumptions of 
the label 𝑆𝑆 (Vittinghoff, Glidden, Shiboski, & McCulloch, 2012):  
1) 𝑆𝑆 follows a binomial distribution.  
2) The expected mean of y is given by the logit function:  
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𝐸𝐸[𝑆𝑆|𝑋𝑋] =  
exp(𝛽𝛽0 +  𝛽𝛽1𝑥𝑥1 + ⋯+ 𝛽𝛽𝑘𝑘𝑥𝑥𝑘𝑘)
1 + exp(𝛽𝛽0 +  𝛽𝛽1𝑥𝑥1 + ⋯+  𝛽𝛽𝑘𝑘𝑥𝑥𝑘𝑘)
 
3) Values of 𝑆𝑆 are statistically independent.  
4) The residuals after fitting the model should be normally distributed (for this 
assumption however, LR is very robust to violation of normality, especially when 
sample size is large enough).  
The sigmoid (S-shaped) logistic function outputs a number between 0 and 1, which is the 
probability of the outcome belongs to a class (e.g., diseased or not diseased). The most 
commonly used cutoff point for labeling is 0.5., i.e., if the probability is below 0.5, it predicts 
𝑆𝑆 to be 0 or ‘not diseased’, and 1 or ‘diseased’ otherwise. The advantages of LR include few 
assumptions made for predictors (such as their distributions), easy interpretation of parameter 
estimates, and known statistical significance of each predictor. For these advantages, LR has 
been widely used in health care research and accepted by clinicians (Vittinghoff et al., 2012). 
However, the implicit assumption of linear relationship of risk with respect to the log-odds 
parametric transformation may not hold (Westreich, Lessler, & Funk, 2010). Also, LR 
requires “long” data, in which the observations is more than the predictors used in modeling. 
Violation of either assumption or a small sample size will yield poor estimates (Geron, 2017).  
One note for LR is that, as with other conventional statistical methods, it cannot handle 
correlated predictors. For the measure of A1C variability, it usually has to adopt a summary 
measure such as the mean-A1C or SD-A1C to represent the variability of A1C measured at 
different time points. 
Support Vector Machines (SVMs) 
An SVM is an algorithm that can utilize a variety of parametric and nonparametric models 
for classification. An SVM attempts to find the best dividing hyperplane that maximizes the 
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margin between classes (called “large margin classification”) (Geron, 2017). The instances 
that locate at the edge of the separating hyperplane will determine the margin between classes 
and the decision of the best hyperplane, and hence, they are called ‘support vectors’. SVMs 
can easily handle high-dimensional data, and they do not assume a parametric relationship 
between the model predictors and outcome. 
Figure 3 illustrates how an SVM works on a two-dimensional plane to classify patients as 
diseased or not diseased (with two features or predictors of mean A1C and BMI).  
 
Figure 3. Illustration of an SVM (made-up example, not based on actual data) 
Assuming the labels of  𝑆𝑆 are +1 (diseased) or −1 (not diseased). A linear SVM classifier is 
based on a linear discriminant function of the form  𝑓𝑓(𝑋𝑋) =  𝑤𝑤��⃗ ∙ ?⃗?𝑥 + 𝑏𝑏. The vector 𝑤𝑤��⃗  is the 
weight vector, and 𝑏𝑏 is called the bias. The classification hyperplane is defined by 𝑤𝑤��⃗ ∙ ?⃗?𝑥 +
𝑏𝑏 = 0, as illustrated, a line (with 2 predictors). The line is perpendicular to vector 𝑤𝑤��⃗  and go 
through the origin. When more predictors are incorporated to inform the classification, the 
classification hyperplane will become a plane in three dimensions, and more generally, a 
hyperplane in higher dimensions. When  𝑤𝑤��⃗ ∙ ?⃗?𝑥 + 𝑏𝑏 ≥ 1, an instance is categorized as 
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diseased, and when  𝑤𝑤��⃗ ∙ ?⃗?𝑥 + 𝑏𝑏 ≤ −1, an instance is categorized as not diseased. The SVM 
optimizes the weight vector by minimizing the ‘hinge loss’: 
𝑙𝑙 = max (0, 1 − 𝑆𝑆 · 𝑆𝑆) 
Where 𝑆𝑆 = 𝑓𝑓(𝑋𝑋) and  𝑆𝑆 =  ±1 (𝑆𝑆ℎ𝑆𝑆 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑖𝑖𝑆𝑆𝑖𝑖 𝑃𝑃𝑜𝑜𝑆𝑆𝑜𝑜𝑜𝑜𝑆𝑆 𝑃𝑃𝑓𝑓 𝑃𝑃𝑙𝑙𝑐𝑐𝑆𝑆𝑆𝑆). When y is predicted 
correctly, hinge loss 𝑙𝑙 is 0; when predicted y is far from t, 𝑙𝑙 gets larger. The weight vector can 
be optimized to minimize the loss 𝑙𝑙. SVMs are also capable of non-linear classification. 
SVMs are sensitive to the scales (or data distribution) of predictors. Hence, predictors will 
need to be pre-processed such as standardized before the step of modelling (Geron, 2017). 
However, in practice, we usually don’t standardize predictors in a logistic model because of 
easy interpretability of parameter estimates.  
Hyperparameters for SVMs 
SVMs can be tuned to improve prediction via certain hyperparameters. These 
hyperparameters are not directly estimated from the data but specified a priori by the 
researcher. The hyperparameters for an SVM include 1) the soft-margin constant C and 2) 
parameters of the kernel function (Geron, 2017).  
1) Soft-margin constant C (also called the C hyperparameter) is used to balance the 
trade-off between margin maximization and violations of the margin (errors on the 
training set: observations that fall within the margin or are even misclassified). A 
smaller C value will lead to a larger margin but more margin violations. In practice, C 
is varied through a wide range of values and the optimal value is assessed through 
cross-validation using the training set.  
2) Kernel parameters are used to affect the decision boundary. The degree of the 
polynomial kernel and the width parameter of the Gaussian kernel can be specified to 
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make an SVM model more flexible. The lowest degree polynomial is the linear kernel 
(or no kernel at all). A linear SVM usually works well in many cases (Geron, 2017). 
Radial Basis Function (RBF) is another commonly used kernel function. It is 
expressed as  
𝐾𝐾�𝑥𝑥𝑖𝑖, 𝑥𝑥𝑗𝑗� = exp�−𝛾𝛾||𝑥𝑥𝑖𝑖 − 𝑥𝑥𝑗𝑗||�
2
 















In which 𝛾𝛾 is a number. The default value in Sci-Kit Learn SVC classifier is ‘scale’, 
which equals to 1 / (n_predictors * X.var()), where X represents the matrix of 
predictors and var() calculate the variance matrix of X.  ∑ 𝑆𝑆𝑖𝑖𝛼𝛼𝑖𝑖 = 0, 0 ≤ 𝛼𝛼𝑖𝑖 ≤ 𝐶𝐶𝑛𝑛𝑖𝑖=1 . 
The minimum value of the above problem depends on both hyperparameters C and 𝛾𝛾.  
Neural Networks (NNs) 
NNs were originally designed to mimic the behavior of biological neurons. Each individual 
biological neuron can receive and transmit signals to thousands of other neurons, and it seems 
that they are organized in consecutive layers. Together they constitute a complex biological 
neural system (Geron, 2017). A NN was first invented in 1943 by the neurophysiologist 
Warren McCulloch and the mathematician Walter Pitts (McCulloch & Pitts, 1943). NNs have 
evolved over the years and became one of the most powerful ML algorithms in handling 
large and complex problems (Geron, 2017).  
NNs are usually composed of an input layer, one or more ‘hidden’ layers, and an output 
layer. Each layer can have multiple neurons (nodes). For each training instance, the NN feeds 
the predictor values to the neurons in the input layer, randomly assigns weights to multiply 
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the value, computes the weighted sum plus a bias term (usually 1) to feed to the neurons in 
the consecutive hidden layer. This process is repeated until reaching the output layer, yielding 
the probability of the outcome. Thus, the algorithm makes a prediction each time (forward 
pass). This probability is compared to the observed value (yes-1 vs no-0) to calculate the 
error. Then the model goes through each layer in reverse to measure the error contribution 
from each connection and adjust the weights at each connection to reduce the error (reverse 
pass). This type of NNs is called feed forward NNs where the connection between neurons do 
not form any cycles (Geron, 2017).  
 
Figure 4. Illustration of an ANN with two hidden layers 
Figure 4 illustrates a feedforward NN with the input layer of 4 neurons (age, T1D duration, 
BMI and A1C variability), 2 hidden layers and an output layer for predicting diabetic 
nephropathy. Note that this is an example of fully connected NNs, i.e., every neuron in the 
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previous layer is connected to each and every neuron in the consecutive layer. The 
connections can be randomly dropped, making NN more flexible in modeling.  
The prediction error or loss 𝑙𝑙 is calculated as the binary cross-entropy loss or log loss, which 
is often used for binary classification problems: 
𝑙𝑙 = − (𝑆𝑆log(𝑜𝑜) + (1 − 𝑆𝑆)log(1 − 𝑜𝑜)) 
Where 𝑆𝑆 is the label and 𝑜𝑜 is the predicted probability. The loss 𝑙𝑙 is minimized through the 
process of gradient descent, in which the gradient is the slope of the loss function. The 
amount that the weight is adjusted is called the “learning rate”.  
Hyperparameters for NNs 
There are many hyperparameters for NNs, including 1) the number of hidden layers, 2) the 
number of neurons per layer, 3) percentage of randomly dropped connections at each layer, 4) 
the type of activation function in each layer, 5) the weight initializing logic, 6) the learning 
rate, 7) the number of iterations/epochs for training, and 8) the 𝑙𝑙2 penalty. 
1) Number of hidden layers: For many cases, a single hidden layer would work well 
provided it has enough neurons (Geron, 2017). But a NN with more hidden layers 
(also called a deep NN or deep learning) can model complex functions using much 
fewer neurons than a shallow NN and thus can be trained faster (Geron, 2017). 
2) Number of neurons per layer: This is defined by the researcher and it usually depends 
on the number of layers as well. Cross-validation is often used to find the optimal 
number. A simple approach to determine the number of hidden layers and number of 
neurons is to start from a model with more layers and neurons than we actually 
needed, then use early stop to prevent it from overfitting (Geron, 2017). 
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3) Percentage of randomly dropped connections at each layer: Similar to the number of 
layers and neurons, this is defined by the researcher and can be tuned through 
validation. 
4) Type of activation function in each layer: Different activation function can be defined 
in each layer. Commonly used activation functions include step (Heaviside step or 
sign), logistic (sigmoid), hyperbolic tangent, and RuLU (rectified linear activation 
unit, y = max(0, x)) functions (Geron, 2017). RuLU is commonly used in hidden 
layers. 
5) Weight initializing logic: Weights in NNs are generated by random number 
generators and are usually initiated with small values close to zero. After each round 
of learning, the weights increase to achieve lower loss (Hastie, Robert., & Friedman, 
2009). A random number generator is a mathematical function that produces random 
sequences of numbers (Shalev-Shwartz & Ben-David, 2014). By default, the random 
number generator uses a seed to initiate the number generation process. The seed is 
usually the current time in milliseconds in most implementations to ensure different 
sequences of numbers being generated every time. By specifying the seed with a 
number (such as 42), the random number generator will produce the same sequences 
of numbers every time it runs.  
6) Learning rate: The amount that each time the weight is adjusted is called the learning 
rate. As the loss for NNs is nonconvex, meaning there may be many local minima or 
lowest loss. If a learning rate is too large, the function may jump over the local 
minima and fail to find the optimal solution. When the learning rate is too small, the 
model may take too long to learn and be not efficient (Hastie et al., 2009).   
7) The number of iterations/epochs for training: One training epoch refers to the one 
time that a NN learns from the entire training set. Number of training epochs 
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determines how many time the NN will learn from the entire training data (Hastie et 
al., 2009). The optimal number of epochs depends on the loss of both training and 
evaluation data sets. Because if we keep training the model on the train set, it will 
reach the global minimum of loss for the training set, but a model fitting the training 
set too well may not predict the validation set well. Hence, the loss for both train and 
validation set need to be monitored and the training epochs can be stopped when the 
validation loss does not decrease any further. 
8) Lastly, a regularization term 𝑙𝑙2 can be added to the model to minimize the value of 
weights and prevent overfitting the training data (and hence the model can fit the test 
data better): 




One last note about NNs is that as there are many hyperparameters to be specified, the source 
of randomness sometimes cannot be controlled. In other words, the results may change after 
each time of running the model, even though we tried to control for randomness, e.g., by 
setting a seed for weight initialization. The common approach to tackle this is to repeat 
running the same model for 10 or 100 times and use the mean performance for its evaluation 
(Ripley, 1996). 
Both SVMs and NNs share one main drawback that make the application of these methods in 
health care research challenging – the resulting predictive model is unintuitive for 
interpretation, especially to clinicians, who are always looking for causality. So, the point 
here is, no one method is inherently better than another. The choice of the algorithms depends 
on the research purpose, and the performance of the model depends largely on the data itself 
(Steyerberg, Eijkemans, Harrell, & Habbema, 2001; Geron, 2017). 
Predictor Selection – Andersen Behaviour Model 
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The Andersen Behavioral Model (ABM) was used to guide the predictor selection of the 
research (Andersen, 2008). According to ABM, complex contextual, individual, and health 
behavioral factors can influence health outcomes directly and/or through other characteristics 
(Figure 5). Contextual and individual characteristics are categorized into predisposing, 
enabling, and need factors, and health behaviors are divided into personal health practices, 
process of medical care, and use of personal health services. Outcome measures can be 
perceived health, evaluated health, as well as satisfaction.  
 
Figure 5. Andersen Behavioral Model 
In the present study, ABM was adapted to evaluate individual and health behavioral 
determinants of diabetic microvascular complications. The outcomes were evaluated health – 
medical chart indication of diabetic nephropathy, retinopathy, and neuropathy (yes/no). 
Predicting factors were grouped into individual predisposing (e.g., socio-demographics), 
enabling (e.g., insurance) and need (e.g., comorbidities) factors, and health behavioral 
factors.  
Individual predisposing factors considered include patient’s age, gender, race, T1D duration, 
education level, and marital status. Enabling factors include patient employment status, 
household income (per capita), and insurance type. Need factors include A1C variability, 
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BMI, blood pressure, cholesterol level and history of past medical conditions (comorbidities). 
Health behavioral factors include type of insulin used and insulin delivery method, use of 
CGM (yes/no), use of other medications (including other antidiabetics, ACE inhibitors or 
angiotensin II receptor blockers (ARBs)) and smoking status. 
Specifically, in this study, the second main objective was to understand how A1C variability 
affects the prediction of each microvascular complication, especially within ML models. A1C 
variability was manipulated into the following 5 levels: 
a) Single A1C: 1 single A1C value, which serves as the reference (no variability) 
b) Mean A1C: the mean of multiple A1C values 
c) Combination single: 2 variables, single A1C and the standard deviation (SD) of 
multiple A1C values (SD A1C) 
d) Combination mean: 2 variables, the mean of multiple A1C values (mean A1C) and 
their SD (SD A1C) 
e) Multiple: the multiple individual A1C values and their SD (SD A1C) 
These 5 levels are nominal and not arranged in any order. By adding one of each of the five 
levels to the other selected covariates, a total of 5 predictor sets were developed and used for 
prediction of each microvascular complication. The adapted model from ABM is illustrated 
in Figure 6. 
 
Figure 6. Model conceptualization using Andersen Behavioral Model 
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The final proposed model using constructs from both statistical learning theory and ABM is 
illustrated in Figure 7.  
 
Figure 7. Proposed model 
Research Hypotheses 
H1: There is no significant difference in performance measures (F1 score) between ML 
(SVM and NN) and conventional statistical (LR) methods for predicting three microvascular 
complications (diabetic nephropathy, retinopathy and neuropathy) in T1D patients. 
H2: There is no significant difference in performance measure (F1 score) for ML (SVM and 
NN) and conventional statistical (LR) methods using A1C variability to predict each 
microvascular complication (diabetic nephropathy, retinopathy and neuropathy) in T1D 
patients. 






Due to the applied nature of this research, in order to compare the performance of different 
modeling methods on predicting the three different outcomes as well as evaluate the effect of 
modeling methods on utilizing different predictor sets, the following steps were conducted: 
1) Determination of study design 
2) Formation of three cohorts: diabetic nephropathy, retinopathy, and neuropathy 
3) Operational definition of study measures 
4) Splitting of train and test sets 
5) Selection of predictors 
6) Model development in each cohort using LR, SVM and NN with different predictor 
sets 
7) Performance evaluation and comparison using F1 score 
The overview of the study design is illustrated in Figure 8. Following that, detailed methods 










This study adopted a factorial experimental design to evaluate model performance by three 
types of modeling methods (i.e., SVM, NN and LR), three types of outcomes (i.e., diabetic 
nephropathy, retinopathy and neuropathy) and different predictor sets. The statistical learning 
theory was used to guide model development and evaluation. Three cohorts of patients based 
on the three outcomes were formed and within each cohort, data were split into train and test 
sets. The ABM was used to guide predictor selection. Individual and health behavioral factors 
were considered for predicting evaluated outcomes, i.e., diabetic nephropathy, retinopathy, 
and neuropathy. LR, SVM and NN were applied to develop the predictive models. Factorial 
analysis of variance (ANOVA) was used to evaluate the effect of modeling method, study 
outcomes, and predicting sets, specifically, measures of A1C variability on model 
performance (F1 score).  
Data Source & Patient Population 
The T1D Exchange Clinic Registry was used for the study. The registry was established by 
T1D Exchange, a nonprofit research organization that dedicates to drive research and 
improve care for T1D patients (https://t1dexchange.org/about/). A detailed description of the 
database was published previously (Beck et al., 2012). Briefly, the registry enrolled 
participants from clinical centers of T1D patients that represents most locations throughout 
the U.S. It extracts patient information from clinic chart including diagnoses, procedures, 
pharmacy, demographics, and lab test results. It also administers a participant questionnaire 
at enrollment and at annual follow-ups that assesses a participant’s health behavior and 
distress measures. The contents of the questionnaire have changed slightly over the years.  
Three sets of data were used for this study. The dataset collected between September 1, 2010 
and August 1, 2012 was used to assess baseline characteristics of adult T1D patients. These 
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baseline measures were used to predict outcomes of microvascular complications 
(nephropathy, retinopathy, and neuropathy) recorded in the dataset collected between April 
30, 2015 and July 31, 2016 or between May 1, 2016 and July 31, 2017 (Figure 9). Baseline 
dataset included information from 25,762 subjects at 68 sites and constituted of five files: 
A1C, labs, medical conditions, medications, and subject. The follow-up datasets contain 
20,842 patients from 73 clinics (2015-2016) and 18,743 participants from 79 clinic sites 
(2016-2017), respectively, and each was composed of four files: A1C, medical conditions, 
medications, and subject. The datasets were anonymized, but the same patients can be 
identified and linked by the same patient ID number. Although the registry data is cross-
sectional in nature, it contains multiple A1C values for the same patient, which made it 
possible to assess variability of A1C or long-term glycemic variability. 
 





Operational Definition of Study Measures 
1. Outcome measures 
Study outcomes are the three types of microvascular complications, i.e. diabetic 
nephropathy (kidney disease), retinopathy, and neuropathy assessed in the follow-up 
datasets. Each outcome is defined as a binary variable: “yes” as having the outcome 
and “no” as not having the outcome. Presence of each outcome is captured by 
measures from participant questionnaire as well as medical conditions recorded using 
Medical Dictionary for Regulatory Activities Terminology (MedDRA) terms in clinic 
chart. The operational definitions of nephropathy, retinopathy, and neuropathy are 
provided in Appendix 3. 
2. Baseline measures 
Baseline measures include individual characteristics and health behavioral factors. 
These measures were considered as predictors to be incorporated into the predictive 
models. Predictors considered in this study were chosen based on previous literature 
as well as considering attainability from patients clinic records (Lagani et al., 2015).  
A1C variability:  
The main predictor evaluated in this study is A1C variability, which refers to the 
change or fluctuation in glycosylated hemoglobin A1C level (%) over long term (from 
one visit to the next). In this study, it was operationalized using the last 3 A1C values 
(%) that were measured at least 3 months apart at baseline. Measures of A1C 
variability was manipulated as 5 levels: 
a) Single A1C: defined as the last A1C measured at baseline. It does not reflect 
any A1C variability. It serves as the reference level. Single A1C:  
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b) Mean A1C: defined as the mean of last 3 A1C values at baseline 
c) Combination single: 2 variables; defined as the last A1C (single A1C) and the 
standard deviation of the last 3 A1C values (SD A1C) 
d) Combination mean: 2 variables; defined as the mean of the last 3 A1C values 
(mean A1C) and their standard deviation (SD A1C) 
e) Multiple: 4 variables; defined as the individual values of the last 3 A1C at 
baseline and their standard deviation (SD A1C) 
As the most recent A1C (%) is commonly used in clinical settings as an indicator for 
glucose control, a single most recent A1C value was used as reference level for A1C 
variability. Mean-A1C and SD-A1C are used in previous literature as 
operationalization for A1C variability and hence, are used in this study.(Orsi et al., 
2018)  
Covariates: 
Other covariates considered as predictors include demographics (age, gender, race, 
marital status, education level, income, employment status, insurance coverage), T1D 
duration, blood pressure (mmHg), BMI, cholesterol level (LDL, HDL, triglyceride 
levels, lipid fasting status), microalbuminuria status (yes/no), baseline comorbidities 
including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, 
cardiovascular conditions (hypertension, dyslipidemia, CAD, PVD, cardiac arrythmia, 
cerebrovascular accident), endocrine diseases (hypothyroidism or Hashimoto disease, 
hyperthyroidism or Grave's disease and others), gastrointestinal diseases (Celiac 
disease, vitamin B12 deficiency/pernicious anemia, IBD), musculoskeletal 
/connective tissue conditions (rheumatoid arthritis, osteoporosis, Lupus, Sjogrens, 
dermatomyositis), psychiatric conditions (depression, anxiety, ADHD, psychosis, 
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eating disorders), and skin conditions (vitiligo, psoriasis, necrobiosis lipoidica 
diabeticorum, alopecia areata), and health behavioral factors include insulin used at 
baseline (insulin delivery method and name/type of insulin), use of other antidiabetics 
(DPP4 inhibitors, GLP1 agonists, metformin, pramlintide & others), use of ACE 
inhibitors or ARBs, use of continuous glucose monitor (CGM), and smoking status 
(Ever smoked and smoking status at baseline). They are defined using measures from 
the baseline dataset. The operational definitions of all variables are provided in 
Appendix 3. 
Cohort Formation 
1. Eligibility Criteria Across Cohorts: 
Inclusion criteria: Across cohorts, participants need to meet all of the following 
inclusion criteria to be eligible for the study: 
• Patients who had a definite T1D (see Appendix 2 for definition of definite T1D 
defined by the registry) and had records in the T1D Exchange Registry data collected 
during both baseline and one of the follow-up period. 
• Age >=18 years at baseline 
• Had a non-missing value for age of the diagnosis of T1D 
• Had a non-missing value of A1C at exam 
• Had >= 2 additional A1C measures that were assessed at least 3 months apart from 
each other to evaluate A1C variability 
Exclusion criteria: Across cohorts, participants who meet any of the following criteria 
will be excluded from the analyses:  
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• Participants with a history of cancer, including abdominal tumor, acoustic neuroma, 
basal cell carcinoma, bladder cancer, bone cancer, bone giant cell tumor, bone 
marrow transplant, brain tumor, breast cancer, breast ductal carcinoma, cancer (NOS), 
cancer of skin (excl melanoma), cervical cancer, chronic lymphocytic leukemia, colon 
adenoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, 
Hodgkin's lymphoma, kidney cancer, leukemia, liver cancer, lung cancer, lung cancer 
metastatic, lymphoma, malignant breast neoplasm, malignant melanoma, malignant 
melanoma of eyelid, meningioma, multiple myeloma, neoplasm (NOS), ovarian 
cancer, ovarian neoplasia, pituitary adenoma, prostate cancer, renal cell carcinoma, 
skin carcinoma, thyroid cancer, uterine cancer, and vulvar cancer. 
• Participants with a history of kidney, pancreas or islet cell transplantation, end-stage 
renal disease (ESRD) or kidney/renal failure (including receiving dialysis or kidney 
transplant) any time during the study period 
• Participants who were pregnant at the time of exam 
• Participants who were transgender 
2. Eligibility Criteria for the Cohort of Diabetic Nephropathy: 
Inclusion criteria: For the cohort evaluating development of diabetic nephropathy (kidney 
disease), in addition to the above eligibility criteria across cohorts (described in 
Eligibility Criteria Across Cohorts), patients need to meet all of the following criteria: 
• Had no missing information for the measure of diabetic nephropathy in the follow-up 
data 
Exclusion criteria: participants who meet any of the following criteria were excluded:  




• Had a clinic chart indication of history of renal failure in the baseline data 
• Had a clinic chart indication of receiving dialysis for renal failure in the baseline data 
• Had a clinic chart indication of kidney cancer in the baseline data 
• Was taking angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II 
receptor blockers (ARBs) for diabetic nephropathy (microalbuminuria) in the baseline 
data 
3. Eligibility Criteria for the Cohort of Diabetic Retinopathy: 
Inclusion criteria: For the cohort evaluating development of diabetic retinopathy, in 
addition to the above eligibility criteria across cohorts (described in Eligibility Criteria 
Across Cohorts), patients need to meet all of the following criteria: 
• Had no missing information for the outcome of diabetic retinopathy in the follow-up 
data 
Exclusion criteria: participants who meet any of the following criteria were excluded:  
• Had a clinic chart indication of retinopathy in the baseline data 
• Had a clinic chart indication of blindness in the baseline data 
• Had a clinic chart indication or patient-report of having been treated for diabetic 
retinopathy in either eye (including laser, injections to the eye, vitrectomy) in the 
baseline data 
• Had received cataract surgery or treatment for glaucoma reported by the patient in the 
baseline data 
• Was taking angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II 




4. Eligibility Criteria for the Cohort of Diabetic Neuropathy: 
Inclusion criteria: For the cohort evaluating development of diabetic Neuropathy, in 
addition to the above eligibility criteria across cohorts (described in Eligibility Criteria 
Across Cohorts), patients need to meet all of the following criteria: 
• Had no missing information for the outcome of diabetic neuropathy in the follow-up 
data 
Exclusion criteria: participants who meet any of the following criteria were excluded:  
• Had a clinic chart indication of diabetic peripheral neuropathy in the baseline data 
• Had a clinic chart indication of presence of foot ulcer in the baseline data 
• Had a clinic chart indication of erectile or sexual dysfunction in the baseline data 
• Had a clinic chart indication of Charcot joint in the baseline data 
• Had a clinic chart indication of orthostatic hypotension with fixed heart rate in the 
baseline data 
• Had a clinic chart indication of tachycardia with fixed heart rate in the baseline data 
• Had a clinic chart indication of gastroparesis in the baseline data 
• Had a clinic chart indication of medical history of amputation of toe or amputation 
below/above knee in the baseline data 
5. Criteria for Handling Missing Data: 
As with any real-world data, the registry database is prone to missing values. Although 
imputing missing values using certain algorithms such as regression or random forest can 
potentially reduce bias and increase sample size for prediction modelling, we want to 
focus our efforts to use available information that’s already in the database and assess and 
interpret associations between complete baseline measures and the outcomes during 
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follow-up. Thus, we are going to delete observations that are missing values on any 
predictor variable of interest for the respective cohort. For example, as diabetes duration 
is associated with prognosis of all three microvascular complications, observations that 
have missing information on T1D duration will be removed from our analysis. Candidate 
predictors are identified from previous literature as discussed previously.  
Train Set and Test Set 
Once applying the inclusion and exclusion criteria across board and for each microvascular 
complication, three cohorts of data were obtained: one for diabetic nephropathy, one for 
diabetic retinopathy, and the last for diabetic neuropathy. Before taking a closer look into the 
data, a test set was separated from each cohort and kept intact, which was used for model 
performance evaluation.  
A stratified random sampling approach based on the outcome variable (i.e., whether or not 
the patient progressed to diabetic nephropathy, retinopathy, and neuropathy) was used to 
select 20% data as the test set for each cohort (Geron, 2017). This ensured that in both 
training and test sets, similar proportions of patients were affected by each microvascular 
complication. 
Predictor Selection 
Predictors were selected based on previous literature, univariate analyses and correlation 
analyses of the train set for each cohort. Descriptive statistics (mean, SD, median, range, 
count, percentage) of diabetes related microvascular complications, treatment patterns, and 
patient demographics were calculated for each cohort during baseline period. Nominal 
variables that had more than two levels were transformed to binary dummies for each level. 
This was because ML algorithms usually assume that two nearby values are more similar 
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than two distant values, which is not true for nominal variables such as race, insurance type 
or income categories (Geron, 2017). 
Univariate comparisons between patients who progressed to each microvascular complication 
versus those not in each cohort were made using t tests for normally distributed continuous 
variables, Wilcoxon rank sum tests for non-normally distributed continuous variables, and 
chi-square and Fisher's exact tests for categorical variables. Pearson’s correlation analyses 
were performed to evaluate correlations between potential predictors and each outcome. 
Once covariates for each cohort were determined, the 5 different A1C measures were added 
to the model, making the following 5 predictor sets (PSs) for each cohort: 
Feature Manipulation for ML Models 
Feature manipulation refers to the process of transforming input values (Geron, 2017). This is 
one of the key steps in data preparation, because some ML algorithms don’t perform well 
when there is huge difference in feature scales (e.g., systolic blood pressure may range from 
90 to 140 whereas mean A1C ranges between 4%-14%) (Geron, 2017). Three methods were 
tried in this study: “min-max scaling” (also called “normalization”), standardization, and 
robust scaler.  
Min-max scaling works by subtracting the min value and dividing by the max minus the min, 
which yields values ranging from 0 to 1 (Geron, 2017). Standardization works by first 
subtracting the mean from the input value and dividing it by the standard deviation (SD) so 
that the transformed (or standardized) values have a zero mean and unit variance. 
Standardization does not restrict the values to a specific range (Geron, 2017). Robust scaler, 
on the other hand, subtracts the median from the input value and further divides the value by 





As only a relatively small proportion of patients developed the outcomes of interest during 
the follow-up period, Synthetic Minority Oversampling TEchnology (SMOTE) was used to 
over-sample the minority/disease-positive group to balance the data (Chawla, Bowyer, Hall  , 
& Kegelmeyer, 2002). SMOTE created synthetic samples by interpolation/perturbation. It 
bootstrapped over the cases, found the k-nearest neighbours (default k is 5) of each case, and 
calculated the difference between the sample’s characteristics vector and their neighbors’. 
The difference was weighted by a random number between 0 and 1, added to the original 
sample and hence, created ‘synthetic’ samples. SMOTE has been widely applied in predictive 
modelling in health care research such as in the study that predicted breast cancer in diabetic 
patients (Hsieh et al., 2019) and the study that predicted diabetes mellitus (Alghamdi et al., 
2017). In this study, synthetic samples were created so that in each training set, cases 
(disease-positive) and controls (disease-negative) had equal number. 
Determination of Sample Size 
There were two aspects of sample size consideration for this study: 1) sample size 
consideration for predictive modeling; and 2) sample size consideration for statistical 
hypothesis testing.  
1. Sample Size Consideration for Predictive Modeling 
One crucial factor affecting the performance of prediction models is the sample size of 
the data. The number of data observations/instances used for developing predictive 
models relative to the candidate predictors used in the model should be large enough for 
robust prediction. As more advanced ML algorithms are very robust in prediction using 
“wide” data (i.e. less observations relative to more predicting variables), this sample size 
estimation was based on the smallest sample needed for LR. A general rule of thumb is 
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events per variable (EPV) >=10. That is, the ratio of the number of events, i.e. number of 
observations in the smaller of the two outcome groups, divided by the number of degrees 
of freedom (parameters excluding the intercept term) should be at least 10 (Harrell et al., 
1996). Assuming 15 predictors in the LR model, multiply it by 10 yields a number of 150, 
which implies that at least 150 observations with the outcome of interest (in our case, 
occurrence of diabetic nephropathy, retinopathy, and neuropathy) should be enough for 
modeling using LR. With more advanced ML algorithms, this number would be even 
less. 
A feasibility test on the data revealed that a total of 5,010 adult patients whose 
information were collected in both baseline and 2016-2017 follow-up (which contains a 
relatively smaller sample compared to the 2015-2016 sample) period. Assuming the 
occurrence of each microvascular complication is 10%, we would have about 500 patients 
with each of the outcomes. Thus, we would have more than enough patients in each 
cohort for prediction modeling.  
2. Sample Size Consideration for Statistical Hypothesis Testing 
For the testing of hypothesis 1, power analysis for a two-way 3 by 3 factorial ANOVA 
was conducted in G*Power 3.0.10 to determine a sufficient sample size using an alpha (α) 
of 0.05, a power (1-β) of 0.80, numerator degree of freedom (df) of 2 (based on the df of 
the main effect ‘modeling method’) and number of groups of 9 (3x3) (Table 4) (Cohen, 
1992).  
Table 4. Sample size estimates based on different effect sizes for hypothesis 1 (keep constant 
of α= 0.05, power = 0.80, numerator df = 2 and number of groups = 9). 
Effect size  0.20 0.25 0.30 0.35 0.40 
Sample size 244 158 111 82 64 
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As we applied 3 modelling methods to 3 microvascular complications with 11 F1 scores 
obtained for each model (10 F1 scores from 10-fold cross validation and 1 F1 score from 
the test set), a total of 99 F1 scores would be obtained. Hence, the study was powered to 
test an effect size of 0.35. 
For the testing of hypothesis 2, power analysis for a two-way 3 by 5 factorial ANOVA 
was conducted in G*Power 3.0.10 to determine a sufficient sample size using an alpha (α) 
of 0.05, a power (1-β) of 0.80, numerator degree of freedom of 8 (df = (3-1) x (5-1)), 
based on the df of the interaction effect ‘modeling method’ and ‘predictor sets’) and 
number of groups of 15 (3x5) (Table 5) (Cohen, 1992).  
Table 5. Sample size estimates based on different effect sizes for hypothesis 2 (keep constant 
of α= 0.05, power = 0.80, numerator df = 8 and number of groups = 15). 
 
For each cohort, we applied 3 modelling methods to 5 different levels of A1C variability 
with 11 F1 scores obtained for each model. That resulted in a total of 165 F1 scores. 
Hence, the study was powered enough to test an effect size of 0.35. 
 
Data Analysis 
Estimation of Model Performance 
In order to estimating prediction error, 10-fold stratified cross validation was applied to the 
train set of each cohort for each modeling method. The 10-fold cross validation approach is 
the most widely used method for error estimation (Hastie et al., 2009). More generally, a k-
Effect size  0.20 0.25 0.30 0.35 0.40 
Sample size 284 249 176 131 103 
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fold cross validation divides the data into k equal-sized folds. Each time, the model leaves 1 
fold out for validation and uses the rest k-1 folds for model fitting. Hence, each time the 
model can be validated on a different validation dataset. Considering the imbalance nature of 
the data, stratified sampling approach based on the study outcome in each cohort was taken 
for the fold generation (Geron, 2017). 
In addition, the whole train set was fit to the predictive models and tested on the test set. 
Hence, a total of 11 performance measures were obtained for each modeling method with 
each predictor set in each cohort. 
Prediction Using LR 
In the cohort of diabetic nephropathy, prediction via LR was conducted using the afore-
defined predictor sets a) through d). 10-fold cross validation was conducted on the train set. 
Then the entire train set was fit on LR and evaluated on the test set.  
Specifically, for the last predictor set e), which included 3 A1C values as well as the SD of 
A1C, a generalized estimating equation (GEE) with logit link was employed to accommodate 
multicollinearity between A1C values measured at different time points (Hardin, 2005). The 
GEE model takes the form of  
𝑔𝑔�𝜇𝜇𝑖𝑖𝑗𝑗� =  𝑙𝑙𝑃𝑃𝑔𝑔�𝜇𝜇𝑖𝑖𝑗𝑗/(1 − 𝜇𝜇𝑖𝑖𝑗𝑗)� = 𝑋𝑋𝑖𝑖𝑗𝑗′ 𝛽𝛽 
Where 𝑗𝑗 = 1, 2, 3, …𝑆𝑆𝑖𝑖, and 
 𝑆𝑆 = 1, 2, 3, representing the 𝑗𝑗th measurement on the 𝑆𝑆th patient. 
The distribution was binomial (proportion):  
𝑉𝑉�𝜇𝜇𝑖𝑖𝑗𝑗� =  𝜇𝜇𝑖𝑖𝑗𝑗/(1 − 𝜇𝜇𝑖𝑖𝑗𝑗) 
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The regression parameter vector 𝛽𝛽 was estimated taking into account of the covariance 
structure of correlated measures. In this study, the correlated measures were the 3 A1C 
values. Age and T1D duration at the time when the 3 A1C were measured were recalculated. 
All other variables, including the study outcomes and other predictor covariates were 
assumed to be the same at the 3 different time points. An exchangeable working correlation 
matrix was assumed and used for the models: 
Exchangeable Corr�𝑆𝑆𝑖𝑖𝑗𝑗 ,𝑆𝑆𝑖𝑖𝑘𝑘� = �
1     𝑗𝑗 = 𝑘𝑘
𝛼𝛼     𝑗𝑗 ≠ 𝑘𝑘 
The fitted models from GEE was applied to the evaluation sets in the 10-fold cross validation 
as well as test sets to evaluate model performance. 
This same process was repeated for the cohorts of diabetic retinopathy and neuropathy.  
Prediction Using SVM 
In the cohort of diabetic nephropathy, prediction via SVM was conducted using afore-defined 
5 predictor sets a) to e). In order to train the SVM models, different values of soft-margin 
constant C, kernel functions and feature scaling methods were tried on the train set. Through 
10-fold cross-validation, model performance in terms of F1 score was calculated on the 10 
validation sets and the final model hyperparameters were chosen based on the highest mean 
F1 score of the 10 validation sets. These hyperparameters and feature scaling method were 
then applied to the entire train set and evaluated on the test set to obtain the 11th F1 score 
(Geron, 2017). 





Prediction Using NN 
In the cohort of diabetic nephropathy, prediction via NN was conducted using afore-
mentioned 5 predictor sets a) to e). A seed of number 42 was set to the weight initializing 
logic to reduce source of randomness. In order to train the NN models, different values of the 
following 7 hyperparameters were tried on the train set: 1) the number of hidden layers, 2) 
the number of neurons per layer, 3) percentage of randomly dropped connections at each 
layer, 4) the type of activation function in each layer, 5) the learning rate, 6) the number of 
iterations/epochs for training, and 7) the 𝑙𝑙2 𝑜𝑜𝑆𝑆𝑆𝑆𝑐𝑐𝑙𝑙𝑆𝑆𝑆𝑆. Each time, a set of 7 hyperparameters 
were trialed on the train set through 10-fold cross validation. The loss and F1 score of both 
train and validation folds were plotted against each epoch of training and the mean F1 score 
was calculated. Then one of the hyperparameters was changed to see how that would affect 
the loss and F1 score curve. The number of epochs was determined by the point where the 
loss curve of the validation set stopped decreasing. The final model hyperparameters were 
chosen based on the highest mean F1 score of the 10 validation folds (Geron, 2017). 
This same process was repeated for the cohorts of diabetic retinopathy and neuropathy.  
Performance Measure 
Model’s performance was evaluated in terms of F1 score. F1 score ranges between 0 and 1, 
with higher F1 score indicating better performance of the model. A probability cut point of 
0.5 was used to classify observations as events or nonevents. In each cohort, 11 F1 scores 
were obtained for each modeling method with each predictor set. In addition, in order to 
explain a model’s capability in identifying patients who were at risk and interpret F1 score, 





Statistical Hypothesis 1:  
𝜇𝜇𝐿𝐿𝐿𝐿 =  𝜇𝜇𝑆𝑆𝑆𝑆𝑆𝑆 =  𝜇𝜇𝑁𝑁𝑁𝑁  
Where 𝜇𝜇𝐿𝐿𝐿𝐿 = F1 scores for models using logistic regression method 
 𝜇𝜇𝑆𝑆𝑆𝑆𝑆𝑆 = F1 scores for models using support vector machine method 
 𝜇𝜇𝑁𝑁𝑁𝑁 = F1 scores for models using neural network method 
Statistical Hypothesis 2: There is no significant difference in the performance of LR, SVM 
and NN models in utilizing A1C variability for the prediction of diabetic nephropathy, 
retinopathy and neuropathy, respectively.  
Hypothesis 2a: 𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖   
Where Nep represents cohort of nephropathy and PS represents predictor sets, 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖 = F1 scores of logistic regression models with different predictor sets 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 = F1 scores of support vector machine models with different predictor sets 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖  = F1 scores of neural networks models with different predictor sets 
Hypothesis 2b: 𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖   
Where Ret represents cohort of retinopathy and PS represents predictor sets, 
𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖 = F1 scores of logistic regression models with different predictor sets 
𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 = F1 scores of support vector machine models with different predictor sets 
𝜇𝜇𝐿𝐿𝑁𝑁𝑅𝑅_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖   = F1 scores of neural networks models with different predictor sets 
Hypothesis 2c: 𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 =  𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖   
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Where Neu represents cohort of neuropathy and PS represents predictor sets, 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝐿𝐿𝐿𝐿_𝑃𝑃𝑆𝑆𝑖𝑖  = F1 scores of logistic regression models with different predictor sets 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑆𝑆𝑆𝑆𝑆𝑆_𝑃𝑃𝑆𝑆𝑖𝑖 = F1 scores of support vector machine models with different predictor sets 
𝜇𝜇𝑁𝑁𝑁𝑁𝑁𝑁_𝑁𝑁𝑁𝑁_𝑃𝑃𝑆𝑆𝑖𝑖   = F1 scores of neural networks models with different predictor sets 
 
Statistical Analysis  
Descriptive statistics (mean, SD, median, range, count, %) were generated for all study 
measures. Univariate analyses (t tests for normally distributed variables, Wilcoxon rank sum 
test for non-normally distributed continuous variables, chi-square and Fisher’s exact tests for 
categorical variables) were conducted to evaluate unadjusted association between baseline 
characteristics and each outcome. Pearson’s correlation analyses were conducted to assess the 
correlation between baseline characteristics and each outcome. Factorial analysis of variance 
(ANOVA) was used to test research hypotheses. Post hoc Tukey-Kramer test was performed 
to evaluate which levels within a factor were significantly different.  
An alpha level of less than 0.05 was used to determine statistical significance of an 
association. SAS 9.4 (SAS Institute, Inc. Cary, NC) was used to perform data preparation, 
descriptive, univariate and correlation analyses, multiple LR and GEE; the application 
programming interface (API) of SciKit-Learn version 0.22.1 (http://scikit-learn.org/) 
(Pedregosa et al., 2011) and TensorFlow.keras (http://tensorflow.org/) (Abadi, 2015) were 





Protection of Human Subjects 
This study was retrospective in nature. We analyzed observational data of T1D patients 
collected by the T1D Exchange Clinic Registry. The data contains only HIPPA-compliant de-
identified patient information. No recruitment of patients or intervention was involved or 
imposed on the subjects or their healthcare providers in the study. There is no potential risk to 
patients or their health care providers. This study approved as an exempt category by the 
Institutional Review Board (IRB) on ethics of human research at University of Houston 
before study initiation. The study was also conducted in accordance with the ethical 
principles that have their origin in the Declaration of Helsinki, the International Conference 
on Harmonization Good Clinical Practice (ICH GCP) and Good Epidemiology Practices 
(GEP), and other applicable regulatory requirements. 






This chapter presents results from the analysis. First, the formation of three patient cohorts, 
i.e., diabetic nephropathy, retinopathy and neuropathy is outlined in the attrition table. Then 
the results from each cohort will be presented, including a summary of the characteristics of 
the entire cohort (patient demographics, clinical characteristics, treatments and A1C 
measures), results from correlation analyses of the train set, parameters of the LR models, 
hyperparameters of the final SVM and NN models, and the performance metrics from the LR, 
SVM and NN models. Lastly, the results of statistical hypothesis testing are presented. 
Patient Attrition 
A total of 4476, 3595, and 4072 patients met the eligibility criteria for the cohort of 
nephropathy, retinopathy, and retinopathy, respectively. Figure 10 provides the patient 
attrition chart. For each cohort, 80% of data were used for model training, leaving 20% for 
model testing. The training sets of nephropathy, retinopathy, and neuropathy were composed 























Cohort of Nephropathy 
Baseline Characteristics 
Among the 4,476 patients in the nephropathy cohort, 510 (11%) developed diabetic 
nephropathy (cases) during the follow-up period. Slightly more than half (53%) were women. 
The mean (±SD) age of patients in the case group was 48 (±16.7) years, significantly older 
than those who did not develop nephropathy during follow-up (controls) (38±14.8, 
p<0.0001). The baseline demographic, clinical, and treatment characteristics between patients 
in the case and control groups were summarized in Table 6.  
Demographics: Univariate analyses indicated that compared to the control group (20±12.1 
years), cases had had T1D for a longer period at baseline (26±14.1 years, p<0.0001). Less 
proportion of the case group than the control group had bachelor’s or above education (46.0% 
vs 51.8%, p<0.05), had commercial health insurance (77.5% vs 86.3%, p<0.0001), and 
worked full-time or part-time (53.9% vs 64.6%, p<0.0001). A greater proportion of the case 
group than the control group were married or living together (65.3% vs 57.8%, p=0.001), had 
below $50k household income (35.1% vs 24.6%, p<0.0001), and had ever smoked (36.1% vs 
27.8%, p<0.0001). The two groups were similar in other demographics. 
Clinical characteristics: Patients in the case group on average had higher BMI (28±5.9 vs 
27±4.8, p<0.0001), SBP (124±15.0 vs 120±13.1, p<0.0001), and triglyceride level (101±76.5 
vs 89±78.4, p<0.0001) than the control group. As of notice, more than a third (36.1%) of 
patients had their lipid fasting status unknow. Among the 2,741 patients whose fasting status 
were indicated, 69.4% were fasting and 30.6% were not fasting. Hence, it was less 
meaningful to compare patients’ lipid levels directly, especially when some of them were 
fasting and others were not.  
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Medical history: The case group had a greater percentage of patients with a history of 
microalbuminuria (18.0% vs 2.4%, p<0.0001), diabetic retinopathy (33.1% vs 12.7%, 
p<0.0001) and neuropathy (28.2% vs 10.7%, p<0.0001), cardiovascular conditions including 
hypertension (50.8% vs 26.1%, p<0.0001), dyslipidemia (52.0% vs 35.4%, p<0.0001), 
coronary artery disease (CAD) (10.4% vs 2.8%, p<0.0001) and peripheral vascular disease 
(PVD) (2.3% vs 0.5%, p<0.001), cardiac arrythmia (2.3% vs 0.8%, p<0.001), hypothyroidism 
or Hashimoto disease (28.8% vs 21.6%, p=0.0002), gastrointestinal diseases (6.7% vs 4.1%, 
p<0.01), rheumatoid arthritis (RA) or osteoporosis (12.2% vs 4.3%, p<0.0001), depression 
(22.0% vs 12.1%, p<0.0001), and anxiety (6.1% vs 4.2%, p<0.05).   
Treatment: The two groups did not differ much in their treatment at baseline except that a 
greater proportion of the case group had used ACE inhibitors or ARBs (51.0% vs 27.5%, 
p<0.0001). More patients in the control group were using insulin aspart injection (Novolog®) 
(46.3% vs 41.0%, p<0.05) compared to the case group. 
A1C Measures: Measures of A1C were summarized in Table 7. Compared to the control 
group, the case group was on average higher in their most recent A1C level (8.1±1.6 vs 
7.7±1.3, p<0.0001), mean-A1C (8.1±1.5 vs 7.7±1.2, p<0.0001), SD-A1C (0.5±0.4 vs 
0.4±0.4, p<0.001) and CV-A1C (0.06±0.04 vs 0.05±0.04, p<0.05). In order to understand the 
frequency of A1C measure for each patient, the gap/time difference between the last 2 A1C 
values were evaluated. The gap between the last two A1C measures was on average 6.0 
months (range 3.0-130.0 months) with a median gap of 4.0 months. Among the 3580 patients 
in the train set, there were only 38 (1%) patients whose gap between the last two A1C values 





Table 6. Baseline characteristics of patients in the nephropathy cohort  
Characteristics  





Yes   
N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
Age at baseline             <0.0001
† 
      Mean (SD) 40 15.39 38 14.85 48 16.74   






      
<0.0001 
      18-27 years 886 19.79% 813 20.50% 73 14.31%   
      28-37 years 1,317 29.42% 1,235 31.14% 82 16.08%   
      38-47 years 885 19.77% 801 20.20% 84 16.47%   
      48-64 years 1,131 25.27% 936 23.60% 195 38.24%   
      ≥65 years 257 5.74% 181 4.56% 76 14.90%   
Age at T1D 
Diagnosis 
            <0.0001
† 
      Mean (SD) 19 13.36 19 13.00 22 15.54   
      Median (range) 15 0.0-76.0 15 0.0-76.0 17 0.0-76.0   
T1D Duration 
      
<0.0001
† 
      Mean (SD) 21 12.49 20 12.09 26 14.15   
      Median (range) 18 0.6-66.0 18 0.6-66.0 25 1.2-63.4   
Gender             0.032 
      Female 2,381 53.19% 2,087 52.62% 294 57.65%   
      Male 2,095 46.81% 1,879 47.38% 216 42.35%   
Race 
      
0.276 
      White 4,084 91.24% 3,623 91.35% 461 90.39% 
 
      Black/African 
American 
116 2.59% 98 2.47% 18 3.53% 
 
      Hispanic or 
Latino 
165 3.69% 150 3.78% 15 2.94% 
 
      Others 111 2.48% 95 2.40% 16 3.14% 
 
Education Level n = 4,350 n = 3,861 n = 489 0.010 
      Less than 
bachelor's degree 
2,123 48.80% 1,859 48.15% 264 53.99%   
      Bachelor's degree 1,387 31.89% 1,260 32.63% 127 25.97%   
      Master's, 
professional, or 
doctorate 
840 19.31% 742 19.22% 98 20.04%   
Insurance Coverage n = 4,126 n = 3,660 n = 466 <0.0001 
      Commercial 
health insurance  
3,520 85.31% 3,159 86.31% 361 77.47%   
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Table 6. Continued 
Characteristics  






N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
      Government-
sponsored insurance  
491 11.90% 402 10.98% 89 19.10%   
      Not specified  115 2.79% 99 2.70% 16 3.43%   
Marital Status n = 4,432 n = 3,925 n = 507 0.001 
      Married or living 
together 
2,599 58.64% 2,268 57.78% 331 65.29%   
      Divorced, 
separated, single, or 
widowed 
1,833 41.36% 1,657 42.22% 176 34.71%   
Annual household 
income  
n = 3,492 n = 3,105 n = 387 <0.0001 
      <$50,000 899 25.74% 763 24.57% 136 35.14%   
      $50,000 to < 
$100,000 
1,316 37.69% 1,171 37.71% 145 37.47%   
      >=$100,000 1,277 36.57% 1,171 37.71% 106 27.39%   
Employment Status 
      
<0.0001 
      Working full time 
or part-time at 
baseline 
2,838 63.40% 2,563 64.62% 275 53.92%   
      Student or 
homemaker 
904 20.20% 842 21.23% 62 12.16%   
      Unemployed, 
retired, disabled or 
other 
734 16.40% 561 14.15% 173 33.92%   
Smoking Status                
      Yes, smoking at 
baseline 
406 9.07% 352 8.88% 54 10.59% 0.205 
      Not smoking at 
baseline, but smoked 
before 
1,285 28.71% 1,101 27.76% 184 36.08% <0.0001 
BMI (kg/m2) 27.10 4.97 26.95 4.82 28.22 5.89 <0.0001
† 
      Mean (SD) 27.10 4.97 26.95 4.82 28.22 5.89  







BMI category             <0.0001 
      Under or normal 
weight 
1,693 37.82% 1,533 38.65% 160 31.37%   
      overweight 1,742 38.92% 1,554 39.18% 188 36.86%   
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Table 6. Continued 
 
Characteristics  
Cohort of Nephropathy 
Total Total Total Total 
N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
      obese 1,041 23.26% 879 22.16% 162 31.76%   
Blood Pressure 
(mmHg) 
n = 4,365 n = 3,864 n = 501  
Diastolic blood 
pressure 
            0.005 
      Mean (SD) 71.98 8.47 72.11 8.46 70.98 8.43   
      Median (range) 71 40-111 71 40-111  70  42-100   
Systolic blood 
pressure 
            <0.0001
† 
      Mean (SD) 120.74 13.40 120.33 13.12 123.85 15.02   
      Median (range) 120 60-198 120 82-195 124 60-198   
Cholesterol Levels        
HDL value   n = 3,978  n = 3,521 n = 457 0.842† 
      Mean (SD) 61.12 17.93 61.14 17.69 60.95 19.69   
      Median (range) 59 14-162 59 14-162 57 23-155   
LDL value   n = 4,201 n = 3,716 n = 485 0.334† 
      Mean (SD) 92.08 27.61 91.91 27.10 93.35 31.21   
      Median (range) 90 3-281 90 3-266 89 16-281   
Triglycerides value   n = 3,896 n = 3,439 n = 457 <0.0001
‡ 
      Mean (SD) 90.79 78.24 89.41 78.38 101.24 76.47  
      Median (range) 73 0-3000 72.00 0-3000 81.00 26-1058  
Lipids Fasting Status   n = 4,287  n = 3,797 n = 490 <0.0001 
      Fasting 1,901 44.34% 1,728 45.51% 173 35.31%  
      Not Fasting 840 19.59% 739 19.46% 101 20.61%  
      Unknown 1,546 36.06% 1,330 35.03% 216 44.08%  
Microalbuminuria 
at baseline (Yes) 
186 4.16% 94 2.37% 92 18.04% <0.0001 
Comorbidities at 
Baseline 
              
Diabetic retinopathy 672 15.01% 503 12.68% 169 33.14% <0.0001 
Diabetic neuropathy 570 12.73% 426 10.74% 144 28.24% <0.0001 
Cardiovascular 
conditions 
              
      Hypertension  1,293 28.89% 1,034 26.07% 259 50.78% <0.0001 
      Dyslipidemia 1,670 37.31% 1,405 35.43% 265 51.96% <0.0001 
      CAD 166 3.71% 113 2.85% 53 10.39% <0.0001 




Table 6. Continued 
Characteristics  
Cohort of Nephropathy 
Total Total Total Total 
N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
      PVD or 
amputation (knee or 
toe) 
39 0.87% 26 0.66% 13 2.55% 0.0002§ 
      Cardiac arrythmia 44 0.98% 32 0.81% 12 2.35% 0.001 
      Cerebrovascular 
accident 
25 0.56% 21 0.53% 4 0.78% 0.520§ 
Endocrine diseases               
      Hypothyroidism 
or Hashimoto disease 
1,002 22.39% 855 21.56% 147 28.82% 0.0002 
      Hyperthyroidism 
or Grave's disease 
92 2.06% 80 2.02% 12 2.35% 0.615 
      Other endocrine 
diseases 
37 0.83% 33 0.83% 4 0.78% 1.000§ 
Gastrointestinal 
diseases 




              
      RA or 
osteoporosis 
233 5.21% 171 4.31% 62 12.16% <0.0001 
Psychiatric 
conditions 
        
      Depression 593 13.25% 481 12.13% 112 21.96% <0.0001 
      Anxiety 197 4.40% 166 4.19% 31 6.08% 0.050 
      ADHD 87 1.94% 75 1.89% 12 2.35% 0.477 
      Psychosis 17 0.38% 13 0.33% 4 0.78% 0.120§ 
      Eating disorders 28 0.63% 24 0.61% 4 0.78% 0.552§ 
Skin conditions 101 2.26% 89 2.24% 12 2.35% 0.876 
CGM use       0.091 
      Yes 982 21.94% 885 22.31% 97 19.02%  
      No 3,494 78.06% 3,081 77.69% 413 80.98%  
Insulin use               
Type of insulin 
analog 
              
      Insulin lispro 
(Humalog) 
2,299 51.36% 2,019 50.91% 280 54.90% 0.089 
      Insulin aspart 
(Novolog) 
2,044 45.67% 1,835 46.27% 209 40.98% 0.024 
      Insulin detemir 
(Levemir) 
162 3.62% 146 3.68% 16 3.14% 0.536 
      Insulin glargine 
(Lantus) 
1,454 32.48% 1,291 32.55% 163 31.96% 0.789 
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Table 6. Continued 
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. 
Abbreviations: SD: standard deviation; BMI: Body mass index, calculated as the body mass 
in kilograms divided by the square of the body height in meters (kg/m2); SD: standard 
deviation; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CAD: coronary 
artery disease; ADHD: Attention-deficit/hyperactivity disorder; RA: rheumatoid arthritis; 
IBD: Inflammatory bowel disease; PVD: peripheral vascular disease; CHF: congestive heart 
failure; CVA: cerebral vascular accident; TIA: transient ischemic attack. See “Appendix 3” 
for operational definitions of all variables. 
Characteristics  
Cohort of Nephropathy 
Total Total Total Total 
N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
Insulin delivery 
method at baseline 
      0.601 
      Pump only 2,677 59.81% 2,365 59.63% 312 61.18%  
      Injections/pens 
only 
1,716 38.34% 1,524 38.43% 192 37.65%  
      Both pump and 
injections/pens 
83 1.86% 77 1.95% 6 1.18%  




358 8.00% 314 7.92% 44 8.63% 0.578 
Use of ACE 
inhibitors or ARBs 
1,352 30.21% 1,092 27.53% 260 50.98% <0.0001 
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Table 7. Baseline A1C measures of patients in the nephropathy cohort  
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. See “Appendix 3” for operational definitions of all 
variables. 
Characteristics  
Cohort of Nephropathy 
Total Nephropathy: No 
Nephropathy: 
Yes   
N % N % N % P-value 
4,476 100.00% 3,966 88.61% 510 11.39%  
Single A1C        <0.0001† 
      Mean (SD) 7.75 1.31 7.70 1.26 8.15 1.61 
 
      Median 
(range) 





Mean A1C        <0.0001† 
      Mean (SD) 7.75 1.25 7.70 1.20 8.13 1.49 
 
      Median 
(range) 







      
<0.0001 
      Quartile I 1,078 24.08% 991 24.99% 87 17.06%  
      Quartile II 1,195 26.70% 1,070 26.98% 125 24.51%  
      Quartile III 1,081 24.15% 955 24.08% 126 24.71%  
      Quartile IV 1,122 25.07% 950 23.95% 172 33.73%  
SD A1C        0.0007‡ 
      Mean (SD) 0.43 0.39 0.42 0.38 0.50 0.44  
      Median 
(range) 
0.34 0.00-5.15 0.32 0.00-5.15 0.36 0.00-3.76  
Quartiles of 
SDA1C 
      <0.0001 
      Quartile I 1,291  28.84% 1,155 29.12% 136 26.67%  
      Quartile II 948 21.18% 854 21.53% 94 18.43%  
      Quartile III 1,108 24.75% 1,002 25.26% 106 20.78%  
      Quartile IV 1,129 25.22% 955 24.08% 174 34.12%  
CV A1C       0.017‡ 
      Mean (SD) 0.05 0.04 0.05 0.04 0.06 0.04  
      Median 
(range) 
0.04 0.00-0.52 0.04 0.00-0.52 0.05 0.00-0.31  
Quartiles of 
CV A1C 
      0.002 
      Quartile I 1,115 24.91% 986 24.86% 129 25.29%  
      Quartile II 1,123 25.09% 1,019 25.69% 104 20.39%  
      Quartile III 1,119 25.00% 1,002 25.26% 117 22.94%  




Predictors were selected based on univariate and correlation analyses of the train set as well 
as previous literature. Significant characteristics from univariate analyses of the train set were 
similar as significant factors from univariate analyses of the entire cohort. Pearson’s 
correlation analyses were conducted on the train set to evaluate correlation between 
predictors and the outcome variable as well as test for multi-collinearity of predictor 
variables. Although most predictors were significantly correlated with the outcome variable 
(diabetic nephropathy), the absolute values of correlation coefficient were between 0.03-0.25: 
the top three correlated predictors were history of microalbuminuria (ρ=0.254), age 
(ρ=0.203), and history of diabetic retinopathy (ρ=0.201). 
Among predictors, most recent A1C level was strongly (|ρ|>0.7) correlated with mean-A1C 
(ρ=0.926) but weakly correlated with SD-A1C (ρ=0.365) or CV-A1C (ρ=0.203); history of 
hypertension was strongly correlated with use of ACE inhibitors and ARBs (ρ=0.710); use of 
Humalog was strongly and negatively correlated with Novolog (ρ=-0.885); age, marital 
status,  and working status were moderately correlated with each other (0.4<|ρ|<0.5); age, 
duration of T1D, history of hypertension, history of dyslipidemia, and use of ACE inhibitors 
or ARBs were also moderately correlated with each other (0.4<|ρ|<0.5). 
Considering previous literature, results from univariate analysis and correlation analysis of 
the train set, the following 21 variables were selected: A1C variability, age, duration of T1D, 
BMI, household income (>=100k vs <100k), insurance type, marital status (married vs 
others), smoking status (ever smoked vs never), comorbidities including microalbuminuria, 
diabetic retinopathy, diabetic neuropathy, hypertension, dyslipidemia, CAD, PVD, 
hypothyroidism or Hashimoto disease, gastrointestinal diseases, RA or osteoporosis, 
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depression and anxiety, and use of Novolog vs other insulins. When incorporating into 
machine learning models, multi-level categorical variables were dummy coded (0/1). 
Predictive Models by LR 
With each predictor set, a total of 11 LR models were developed: 10 from ten-fold cross-
validation of the train set and 1 final model based on the entire train set and evaluated on the 
test set. The odds ratios (ORs) and their 95% confidence intervals (CIs) of the final model 
with each predictor set were reported in the following Tables 8a through 8e.  
Final model LR-Nep-A: While controlling for other covariates, unit increase in A1C would 
increase a patient’s odds of developing diabetic nephropathy by 0.33 (OR 1.33, 95%CI 1.22-
1.46, p<0.0001); one year older in age would raise the odds by 0.03 (OR 1.03, 95%CI 1.02-
1.04, p<0.0001). The odds of developing diabetic nephropathy in patients with history of 
microalbuminuria were on average 6.67 (95%CI 4.62-9.63, p<0.0001) times that of patients 
without microalbuminuria. Having a medical history of diabetic retinopathy, diabetic 
neuropathy, hypertension, or musculoskeletal/connective tissue conditions also increase a 
patient’s odds of developing diabetic nephropathy, while having commercial insurance 
decreases the odds by about a fourth (OR 0.75, 95%CI 0.57-0.97, p<0.05) (Table 8a).      
Final model LR-Nep-B: This model indicates similar associations between predictors and 
diabetic nephropathy. Unit increase in mean-A1C would increase a patient’s odds of 
developing diabetic nephropathy by 0.33 (OR 1.33, 95%CI 1.21-1.46, p<0.0001) while 
controlling for other covariates (Table 8b). 
Final model LR-Nep-C & LR-Nep-D: Both models indicate that in addition to A1C or 
mean-A1C, SD-A1C is a significant predictor for the outcome of diabetic nephropathy. The 
odds of developing diabetic nephropathy increased by an average of 0.34 – 0.40 with unit 
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increase in SD-A1C (LR-Nep-C: OR 1.40, 95%CI 1.05-1.85, p<0.05; LR-Nep-D: OR 1.33, 
95%CI 1.00-1.76, p<0.05) (Tables 8c & 8d). 
Final model GEE-Nep-E: The GEE model indicates that while controlling for other 
covariates, both A1C values and SD-A1C over time were significantly associated with 
diabetic nephropathy. Unit increase in A1C would increase a patient’s odds of developing 
diabetic nephropathy by 0.001(OR 1.00, 95%CI 1.000-1.001, p<0.01) whereas unit increase 





Table 8a. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with single A1C 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; See “Appendix 3” for operational definitions of all variables. 
  
LR-Nep-A OR 95% CI P value 
Single A1C  1.334 1.222 - 1.457 <0.0001 
Age at Exam (years) 1.032 1.022 - 1.043 <0.0001 
Duration of T1D (years) 0.999 0.988 - 1.009 0.809 
BMI (kg/m2) 1.019 0.997 - 1.042 0.091 
Annual household income: >=100K vs <100K 0.781 0.589 - 1.034 0.084 
Commercial insurance vs Others 0.745 0.570 - 0.974 0.031 
Married vs divorced, separated, single (never 
married), or widowed 0.988 0.752 - 1.297 0.931 
Smoking status: ever smoked vs never 0.932 0.727 - 1.194 0.577 
Comorbidities at baseline    
      Microalbuminuria 6.670 4.621 - 9.628 <0.0001 
      Diabetic retinopathy 1.769 1.332 - 2.351 <0.0001 
      Diabetic neuropathy 1.451 1.087 - 1.936 0.012 
      Hypertension 1.369 1.042 - 1.799 0.024 
      Dyslipidemia 0.949 0.737 - 1.222 0.686 
      CAD 1.229 0.785 - 1.926 0.367 
      PVD 1.198 0.488 - 2.941 0.693 
      Hypothyroidism or Hashimoto disease 1.087 0.836 - 1.414 0.534 
      Gastrointestinal diseases 1.515 0.947 - 2.424 0.083 
      Musculoskeletal/connective tissue conditions 1.662 1.124 - 2.456 0.011 
      Depression 1.311 0.967 - 1.777 0.081 
      Anxiety 1.271 0.773 - 2.090 0.344 
Use of Novolog vs Other insulins 0.866 0.688 - 1.091 0.222 
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Table 8b. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with mean A1C 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; See “Appendix 3” for operational definitions of all variables. 
  
LR-Nep-B OR 95% CI P value 
Mean A1C  1.326 1.209 - 1.455 <0.0001 
Age at Exam (years) 1.032 1.022 - 1.044 <0.0001 
Duration of T1D (years) 0.999 0.988 - 1.010 0.847 
BMI (kg/m2) 1.019 0.997 - 1.042 0.085 
Annual household income: >=100K vs <100K 0.785 0.593 - 1.041 0.092 
Commercial insurance vs Others 0.740 0.566 - 0.967 0.028 
Married vs divorced, separated, single (never 
married), or widowed 
0.985 0.750 - 1.293 0.912 
Smoking status: ever smoked vs never 0.929 0.725 - 1.191 0.562 
Comorbidities at baseline 
   
      Microalbuminuria 6.491 4.497 - 9.369 <0.0001 
      Diabetic retinopathy 1.748 1.315 - 2.323 0.0001 
      Diabetic neuropathy 1.453 1.089 - 1.937 0.011 
      Hypertension 1.347 1.025 - 1.771 0.033 
      Dyslipidemia 0.939 0.729 - 1.209 0.624 
      CAD 1.235 0.789 - 1.935 0.356 
      PVD 1.209 0.495 - 2.952 0.677 
      Hypothyroidism or Hashimoto disease 1.076 0.828 - 1.399 0.583 
      Gastrointestinal diseases 1.520 0.951 - 2.428 0.080 
      Musculoskeletal/connective tissue 
conditions 
1.655 1.119 - 2.447 0.012 
      Depression 1.311 0.969 - 1.776 0.079 
      Anxiety 1.252 0.762 - 2.057 0.375 
Use of Novolog vs Other insulins 0.872 0.692 - 1.098 0.243 
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Table 8c. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with combination single 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; See “Appendix 3” for operational definitions of all variables. 
  
LR-Nep-C OR 95% CI P value 
Single A1C  1.286 1.173 - 1.411 <0.0001 
SD A1C 1.396 1.054 - 1.848 0.020 
Age at baseline (years) 1.033 1.022 - 1.044 <0.0001 
Duration of T1D (years) 1.000 0.989 - 1.010 0.946 
BMI (kg/m2) 1.021 0.998 - 1.043 0.068 
Annual household income: >=100K vs <100K 0.781 0.589 - 1.035 0.085 
Commercial insurance vs Others 0.766 0.585 - 1.003 0.053 
Married vs divorced, separated, single (never 
married), or widowed 
0.987 0.751 - 1.296 0.923 
Smoking status: ever smoked vs never 0.929 0.725 - 1.191 0.560 
Comorbidities at baseline 
   
      Microalbuminuria 6.613 4.575 - 9.559 <0.0001 
      Diabetic retinopathy 1.774 1.335 - 1.359 <0.0001 
      Diabetic neuropathy 1.431 1.072 - 1.910 0.015 
      Hypertension 1.359 1.034 - 1.786 0.028 
      Dyslipidemia 0.951 0.739 - 1.226 0.700 
      CAD 1.229 0.784 - 1.925 0.369 
      PVD 1.202 0.492 - 2.940 0.687 
      Hypothyroidism or Hashimoto disease 1.095 0.842 - 1.424 0.497 
      Gastrointestinal diseases 1.514 0.945 - 2.424 0.084 
      Musculoskeletal/connective tissue 
conditions 
1.641 1.111 - 2.425 0.013 
      Depression 1.292 0.952 - 1.752 0.100 
      Anxiety 1.279 0.777 - 2.105 0.334 
Use of Novolog vs Other insulins 0.869 0.690 - 1.095 0.235 
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Table 8d. Final LR model for prediction of development of diabetic nephropathy using 
predictor set with combination mean 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; See “Appendix 3” for operational definitions of all variables. 
  
LR-Nep-D OR 95% CI P value 
Mean A1C  1.275 1.152 - 1.411 <0.0001 
SD A1C 1.328 1.003 - 1.759 0.047 
Age at baseline (years) 1.033 1.022 - 1.044 <0.0001 
Duration of T1D (years) 1.000 0.989 - 1.011 0.974 
BMI (kg/m2) 1.021 0.999 - 1.044 0.064 
Annual household income: >=100K vs <100K 0.784 0.592 - 1.040 0.091 
Commercial insurance vs Others 0.755 0.577 - 0.988 0.041 
Married vs divorced, separated, single (never 
married), or widowed 
0.980 0.746 - 1.288 0.887 
Smoking status: ever smoked vs never 0.928 0.724 - 1.189 0.556 
Comorbidities at baseline 
   
      Microalbuminuria 6.466 4.473 - 9.346 <0.0001 
      Diabetic retinopathy 1.756 1.321 - 1.335 0.0001 
      Diabetic neuropathy 1.434 1.074 - 1.914 0.014 
      Hypertension 1.338 1.018 - 1.760 0.037 
      Dyslipidemia 0.943 0.732 - 1.215 0.651 
      CAD 1.237 0.790 - 1.938 0.353 
      PVD 1.214 0.499 - 2.954 0.669 
      Hypothyroidism or Hashimoto disease 1.083 0.833 - 1.409 0.549 
      Gastrointestinal diseases 1.519 0.950 - 2.429 0.081 
      Musculoskeletal/connective tissue 
conditions 
1.638 1.108 - 2.421 0.013 
      Depression 1.297 0.958 - 1.758 0.093 
      Anxiety 1.262 0.767 - 2.076 0.360 
Use of Novolog vs Other insulins 0.874 0.694 - 1.101 0.254 
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Table 8e. Final GEE model for prediction of development of diabetic nephropathy using 
predictor set with multiple 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; See “Appendix 3” for operational definitions of all variables.  
GEE-Nep-E OR 95% CI P value 
Individual A1C  1 1.000 - 1.001 0.005 
SD A1C 1.607 1.247 - 2.071 0.0002 
Age at baseline (years) 1.0003 1.0002 - 1.0005 0.0002 
Duration of T1D (years) 1.008 0.997 - 1.018 0.164 
BMI (kg/m2) 1.018 0.996 - 1.040 0.106 
Annual household income: >=100K vs <100K 0.774 0.587 - 1.019 0.068 
Commercial insurance vs Others 0.694 0.529 - 0.909 0.008 
Married vs divorced, separated, single (never 
married), or widowed 
1.153 0.895 - 1.485 0.271 
Smoking status: ever smoked vs never 1.034 0.803 - 1.332 0.793 
Comorbidities at baseline 
   
      Microalbuminuria 6.313 4.337 - 9.188 <0.0001 
      Diabetic retinopathy 1.931 1.442 - 2.586 <0.0001 
      Diabetic neuropathy 1.608 1.203 - 2.149 0.001 
      Hypertension 1.639 1.268 - 2.119 0.0002 
      Dyslipidemia 1.127 0.876 - 1.449 0.351 
      CAD 1.604 0.966 - 2.339 0.070 
      PVD 1.385 0.564 - 3.402 0.477 
      Hypothyroidism or Hashimoto disease 1.163 0.900 - 1.504 0.248 
      Gastrointestinal diseases 1.490 0.926 - 2.397 0.100 
      Musculoskeletal/connective tissue 
conditions 
2.022 1.376 - 2.972 0.0003 
      Depression 1.344 0.993 - 1.821 0.056 
      Anxiety 1.261 0.761 - 2.089 0.367 
Use of Novolog vs Other insulins 0.872 0.693 - 1.099 0.246 
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Predictive Models by SVM 
Using each predictor set, 11 SVM models were developed by Sci-Kit Learn SVC classifier: 
10 from ten-fold cross-validation of the train set and 1 final model based on the entire train 
set and evaluated on the test set. Predictors were pre-processed using RobustScaler but 
without scaling (i.e., removing the median only). SMOTE was used to oversample the 
minority group (cases) so that there were equal numbers of cases and controls for modeling. 
Random state was set to be 42 to ensure repeatable weight initiation. The kernel function was 
set to be ‘rbf’ and γ as ‘scale’ for all models. The hyperparameter Cs used for the final trained 
models with the 5 predictor sets are as follows: a) SVM-Nep-A: C= 10.8; b) SVM-Nep-B: 
C=5.5; c) SVM-Nep-C: C=10.5; d) SVM-Nep-D: C=15.5; and e) SVM-Nep-E: C=4.6.   
Predictive Models by NN 
Using each predictor set, 11 NN models were developed using the TensorFlow.keras 
package: 10 from ten-fold cross-validation of the train set and 1 final model based on the 
entire train set and evaluated on the test set.  
The final hyperparameters were selected based on the loss and accuracy curves of the train 
and validation set through the process of ten-fold cross validation. Each time, one 
hyperparameter was tuned to see how it impacted the loss curve and accuracy. The loss curve 
of the validation set was bumpy but gradually declining until flatten off. The plateau of the 
loss curve of the validation set indicated that the training can be stopped, even though the loss 
curve of the train set was still declining. With larger learning rate, fewer number of epochs 
was needed for reaching the plateau, but the learning curve can be bumpier. However, after 
we tried both ways – smaller learning rate with more epochs of training and larger learning 
rate with fewer epochs of learning – the highest F1 score can be achieved were similar, at 
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around the value of 0.6. Examples of the accuracy and loss curves of the train and validation 
set of NN models using the 5 predictor sets are provided in Appendix 5. 
The final NN models were trained without scaling of the predictors. SMOTE was used to 
oversample the minority group (cases) so that there were equal numbers of cases and controls 
for modeling. All the final NN models comprised 1 input layer, 1 output layer with the 
‘sigmoid’ activation function, and 2 hidden layers with the ‘ReLU’ activation function and a 
𝑙𝑙2 penalty of 0.005. The first hidden layer comprised 128 nodes and the second 64 nodes. The 
connections between the hidden layers and the consecutive layers can be randomly dropped 
by 50%. The Adam optimization algorithm was used for training. The learning rate and 
epochs used for the final NN models with the 5 predictor sets are as follows:  
a) NN-Nep-A: learning rate = 0.01 and epochs = 50;  
b) NN-Nep-B: learning rate = 0.01 and epochs = 50;  
c) NN-Nep-C: learning rate = 0.01 and epochs = 50;  
d) NN-Nep-D: learning rate = 0.00005 and epochs = 200; and  
e) NN-Nep-E: learning rate = 0.00001 and epochs = 300. 
As there are multiple sources of randomness, each model was repeated 10 times and the 
average performance metrics were calculated and reported. 
Model Performance 
The F1 scores of LR, SVM and NN models in the cohort of nephropathy by A1C variability 
are plotted in Figure 11. The performance measures of all models were provided in 




Figure 11. Box plot of F1 scores of nephropathy cohort by modeling method and A1C 
variability 
Cohort of Retinopathy 
Baseline Characteristics 
Among the 3,595 patients in the retinopathy cohort, 659 (18%) developed diabetic 
retinopathy (cases) during the follow-up period. Slightly more than half (53%) were women. 
The mean (±SD) age of patients in the case group was 41 (±14.1) years, significantly older 
than those who did not develop nephropathy during follow-up (controls) (38±14.5, 
p<0.0001). The baseline demographic, clinical, and treatment characteristics between patients 
in the case and control groups were summarized in Table 9.  
Demographics: Univariate analyses indicated that compared to the control group (18±11.1 
years), cases had had T1D for a longer period at baseline (24±10.9 years, p<0.0001). Less 
proportion of the case group than the control group had commercial health insurance (82.4% 
vs 86.8%, p<0.05). A greater proportion of the case group than the control group had below 
$50k household income (26.5% vs 20.0%, p<0.001), worked either full-time or part-time 
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(68.3% vs 66.8%, p<0.0001), and were smoking at baseline (12.4% vs 8.3%, p<0.001) or 
ever smoked (31.7% vs 27.4%, p<0.05). The two groups were similar in other demographics.  
Clinical characteristics: Patients in the case group on average had higher BMI (28±4.9 vs 
27±4.8, p<0.0001), SBP (121±13.7 vs 120±12.8, p<0.05), and triglyceride level (92±66.5 vs 
89±84.3, p<0.05) than the control group. Similar to the nephropathy cohort, more than a third 
(35.2%) of patients had their lipid fasting status unknow.  
Medical history: The case group had a greater percentage of patients with a history of 
microalbuminuria (7.9% vs 3.8%, p<0.0001), diabetic nephropathy (6.5% vs 2.7%, 
p<0.0001) and neuropathy (17.7% vs 8.2%, p<0.0001), cardiovascular conditions including 
hypertension (34.0% vs 24.3%, p<0.0001), dyslipidemia (40.7% vs 24.3%, p<0.01) and CAD 
(4.7% vs 2.0%, p<0.0001), and depression (17.0% vs 11.6%, p<0.001).   
Treatment: The two groups did not differ much in their treatment at baseline except that a 
greater proportion of the case group had used CGM (25.9% vs 22.2%, p<0.05) and ACE 
inhibitors or ARBs (37.0% vs 26.5%, p<0.0001). 
A1C Measures: Measures of A1C were summarized in Table 10. Compared to the control 
group, the case group was on average higher in their most recent A1C level (7.9±1.4 vs 
7.6±1.3, p<0.0001) and mean-A1C (7.9±1.3 vs 7.6±1.2, p<0.0001). But the SD-A1C and CV-
A1C between cases and controls did not differ significantly. The gap between the last two 
A1C measures was on average 6.1 months (range 3.0-130.0 months) with a median gap of 4.0 
months. Among the 2875 patients in the train set, there were only 34 (1%) patients whose gap 




Table 9. Baseline characteristics of patients in the retinopathy cohort  
 
Characteristics  







N % N % N % 
3,595 100.00% 2,936 81.67% 659 18.33% 
Age at baseline             <0.0001 
      Mean (SD) 39 14.49 38 14.53 41 14.07   
      Median (range) 37 18.0 -85.8   
37 18.0 - 
82.2 
39 18.1 - 
85.8 
  
Age group             <0.0001 
      18-27 years 778 21.64% 616 20.98% 162 24.58%   
      28-37 years 1,069 29.74% 930 31.68% 139 21.09%   
      38-47 years 753 20.95% 610 20.78% 143 21.70%   
      48-64 years 852 23.70% 667 22.72% 185 28.07%   
      ≥65 years 143 3.98% 113 3.85% 30 4.55%   
Age at T1D             <0.0001 
      Mean (SD) 20 13.38 20 13.55 17 12.26   
      Median (range) 16 0.0 - 76.0 16 0.0 - 76.0 




      
<0.0001 
      Mean (SD) 19 11.34 18 11.11 24 10.87   
      Median (range) 17 0.6 - 60.0 16 0.6 - 60.0 




      
0.992 
      Female 1,910 53.13% 1,560 53.13% 350 53.11% 
 
      Male 1,685 46.87% 1,376 46.87% 309 46.89% 
 
Race 
      
0.222 
      White  3,294 91.63% 2,691 91.66% 603 91.50% 
 
      Black/African 
American 
87 2.42% 67 2.28% 20 3.03% 
 
      Hispanic or Latino 123 3.42% 107 3.64% 16 2.43% 
 
      Others 
91 2.53% 71 2.42% 20 3.03% 
 
Education Level n = 3,517 n = 2,873 n = 644 0.723 
      Less than bachelor's 
degree 
1,613 45.86% 1,324 46.08% 289 44.88%   
      Bachelor's degree 1,192 33.89% 965 33.59% 227 35.25%   
      Master's, 
professional, or 
doctorate 
712 20.24% 584 20.33% 128 19.88%   
Insurance Coverage    0.013 
      Commercial 
insurance 
3,092 86.01% 2,549 86.82% 543 82.40%   
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Table 9. Continued 
 
Characteristics  







N % N % N % 
3,595 100.00% 2,936 81.67% 659 18.33% 
      Government-
sponsored insurance  
395 10.99% 304 10.35% 91 13.81%   
      Not specified  108 3.00% 83 2.83% 25 3.79%   
Marital Status n = 3,568 n = 2,913 n = 655 0.333 
      Married or living 
together 
2,119 59.39% 1,719 59.01% 400 61.07%   
      Divorced, separated, 
single, or widowed 
1,449 40.61% 1,194 40.99% 255 38.93%   
Annual household 
income 
n = 2,913 n = 2,374 n = 539 0.0007 
      <$50,000 690 23.69% 547 23.04% 143 26.53%   
      $50,000 to < 
$100,000 
1,100 37.76% 873 36.77% 227 42.12%   
      >=$100,000 1,123 38.55% 954 40.19% 169 31.35%   
Employment Status             <0.0001 
      Working full time or 
part-time at baseline 
2,412 67.09% 1,962 66.83% 450 68.29%   
      Student or 
homemaker 
724 20.14% 647 22.04% 77 11.68%   
      Unemployed, 
retired, disabled or other 
459 12.77% 327 11.14% 132 20.03%   
Smoking Status                
      Yes, smoking at 
baseline 
327 9.10% 245 8.34% 82 12.44% 0.0009 
      Not smoking at 
baseline, but smoked 
before 
1,014 28.21% 805 27.42% 209 31.71% 0.027 
BMI (kg/m2) 
      <0.0001 
      Mean (SD) 26.94 4.81 26.78 4.77 27.64 4.93   
      Median (range) 26.27 11.16 - 65.57 
26.15 11.16 - 
65.57 
26.80 15.99 - 
51.16 
  
BMI category       0.0003 
      Under or normal 
weight 
1,376 38.28% 1,156 39.37% 220 33.38%   
      overweight 1,432 39.83% 1,173 39.95% 259 39.30%   
      obese 787 21.89% 607 20.67% 180 27.31%   
Blood Pressure 
(mmHg) 
 n = 3,502  n = 2,857 n = 645  
82 
 
Table 9. Continued 
Characteristics  







N % N % N % 
3,595 100.00% 2,936 81.67% 659 18.33% 
Diastolic blood pressure             0.588 
      Mean (SD) 72.29 8.37 72.26 8.31 72.45 8.62   
      Median (range) 71 40 - 111 71 40 - 111  72  50 - 100   
Systolic blood pressure             0.013 
      Mean (SD) 120.29 
13.01 120.0
0 
12.84 121.49 13.68   
      Median (range) 120 60 - 195 120 84 - 195 120 60 - 174   
Cholesterol Levels        
HDL value   n = 3,183  n = 2,597 n = 586 0.074 
      Mean (SD) 61.54 17.96 61.81 18.05 60.34 17.55   
      Median (range) 59.00 14.00 - 162.00 
59.00 14.00 - 
155.00 
57.00 17.00 - 
162.00 
  
LDL value   n = 3,373 n = 2,748 n = 625 0.999 
      Mean (SD) 91.99 27.51 91.99 27.61 92.00 27.09   
      Median (range) 90.00 3.00 - 266.00 
90.00 3.00 - 
266.00 
88.00 22.00 - 
192.00 
  
Triglycerides value   n = 3,118 n = 2,643 n = 575 0.020‡ 
      Mean (SD) 89.60 81.31 89.04 84.29 92.11 66.52  
      Median (range) 71.00 0.00 - 3000.00 
71.00 0.00 - 
3000.00 
77.00 17.00 - 
941.00 
 
Lipids Fasting Status  
   0.0007 
      Fasting 1538 44.63% 1,279 45.52% 259 40.72%   
      Not Fasting 675 19.59% 567 20.18% 108 16.98%   
      Unknown 1233 35.78% 964 34.31% 269 42.30%   
Microalbuminuria at 
baseline (Yes) 
 163  4.63% 111 3.78% 52 7.89% <0.0001 
Comorbidities at 
Baseline 
              
Diabetic nephropathy 122 3.39% 79 2.69% 43 6.53% <0.0001 
Diabetic neuropathy 359 9.99% 242 8.24% 117 17.75% <0.0001 
Cardiovascular 
conditions 
              
      Hypertension  939 26.12% 715 24.35% 224 33.99% <0.0001 
      Dyslipidemia 1,274 35.44% 1,006 24.26% 268 40.67% 0.002 
      CAD 91 2.53% 60 2.04% 31 4.70% <0.0001 
      PVD 13 0.36% 9 0.31% 4 0.61% 0.274§ 
      Cardiac arrythmia 28 0.78% 25 0.85% 3 0.46% 0.296§ 
      Cerebrovascular 
accident 
9 0.25% 7 0.19% 2 0.30% 0.673§ 
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Table 9. Continued 
 
Characteristics  







N % N % N % 
3,595 100.00% 2,936 81.67% 659 18.33% 
Endocrine diseases               
      Hypothyroidism or 
Hashimoto disease 
795 22.11% 646 22.00% 149 22.61% 0.734 
      Hyperthyroidism or 
Grave's disease 
72 2.00% 59 2.01% 13 1.97% 0.951 
      Other endocrine 
diseases 
21 0.58% 15 0.51% 6 0.91% 0.253§ 
Gastrointestinal 
diseases 
160 4.45% 131 4.46% 29 4.40% 0.945 
Musculoskeletal/Conne
ctive Tissue conditions 
              
      RA or osteoporosis 156 4.34% 124 4.22% 32 4.86% 0.472 
Psychiatric conditions               
      Depression 452 12.57% 340 11.58% 112 17.00% 0.0002 
      Anxiety 155 4.31% 129 4.39% 26 3.95% 0.609 
      ADHD 67 1.86% 53 1.81% 14 2.12% 0.584 
      Psychosis 10 0.28% 6 0.20% 4 0.61% 0.093 
      Eating disorders 21 0.58% 15 0.51% 6 0.91% 0.253 
Skin conditions 79 2.20% 64 2.18% 15 2.28% 0.879 
CGM use             0.037  
      Yes 822 22.87% 651 22.17% 171 25.95%   
      No 2,773 77.13% 2,285 77.83% 488 74.05%   
Insulin use               
Type of insulin analog               
      Insulin lispro 
(Humalog) 
1,834 51.02% 1,488 50.68% 346 52.50% 0.398 
      Insulin aspart 
(Novolog) 
1,658 46.12% 1,370 46.66% 288 43.70% 0.168 
      Insulin detemir 
(Levemir) 
123 3.42% 99 3.37% 24 3.64% 0.731 
      Insulin glargine 
(Lantus) 
1,170 32.55% 950 32.36% 220 33.38% 0.611 
Participant insulin 
delivery method at 
time of most recent 
exam  
      0.537 
      Pump only 2,169 60.33% 1,779 60.59% 390 59.18%  
      Injections/pens only 1,356 37.72% 1,101 37.50% 255 38.69%  
      Both pump and 
injections/pens 
70 1.95% 56 1.90% 14 2.12%  
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Table 9. Continued 
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. 
Abbreviations: SD: standard deviation; BMI: Body mass index, calculated as the body mass 
in kilograms divided by the square of the body height in meters (kg/m2); SD: standard 
deviation; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CAD: coronary 
artery disease; ADHD: Attention-deficit/hyperactivity disorder; RA: rheumatoid arthritis; 
IBD: Inflammatory bowel disease; PVD: peripheral vascular disease; CHF: congestive heart 
failure; CVA: cerebral vascular accident; TIA: transient ischemic attack. See “Appendix 3” 
for operational definitions of comorbidities and treatments. 
Characteristics  







N % N % N % 
3,595 100.00% 2,936 81.67% 659 18.33% 
Use of Other 
Medications for Blood 
Glucose Control  
288 8.01% 226 7.70% 62 9.41% 0.144 
Use of ACE inhibitors 
or ARBs 
1,022  28.43% 778 26.50% 244 37.03% <0.0001 
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Table 10. Baseline A1C measures of patients in the retinopathy cohort  
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. See “Appendix 3” for operational definitions of all 
variables. 
Characteristics  
Cohort of Retinopathy 
Total Retinopathy: No Retinopathy: 
Yes 
  
N % N % N % P-value 
3,595 100.00% 2,936 81.67% 659 18.33%   
Single A1C       <0.0001† 
      Mean (SD) 7.69 1.29 7.63 1.26 7.95 1.40  
      Median 
(range) 
7.50 4.00 - 
15.00 
7.50 4.80 - 
15.00 
7.70 4.00 - 
14.40 
 
Mean A1C        <0.0001† 
      Mean (SD) 7.69 1.23 7.63 1.20 7.95 1.34 
 
      Median 
(range) 
7.50 4.07 - 
14.00 
7.47 4.90 - 
14.00 





      
<0.0001 
      Quartile I  918  25.54% 795 27.08% 123 18.66%  
      Quartile II 907 25.23% 745 25.37% 162 24.58%  
      Quartile III 871 24.23% 718 24.46% 153 23.22%  
      Quartile IV 899 25.01% 678 23.09% 221 33.54%  
SD A1C        0.131‡ 
      Mean (SD) 0.42 0.39 0.42 0.38 0.45 0.43  
      Median 
(range) 
0.32 0.00 - 5.15 0.32 0.00 - 5.15 0.35 0.00 - 
3.76 
 
Quartiles of SD 
A1C 
      0.030 
      Quartile I  1,043  29.01% 862 29.36% 181 27.47%  
      Quartile II 687 19.11% 565 19.24% 122 18.51%  
      Quartile III 942 26.20% 785 26.74% 157 23.82%  
      Quartile IV 923 25.67% 724 24.66% 199 30.20%  
CV A1C       0.575‡ 
      Mean (SD) 0.05 0.04 0.05 0.04 0.05 0.04  
      Median 
(range) 
0.04 0.00 - 0.52 0.04 0.00 - 0.52 0.04 0.00 - 
0.34 
 
Quartiles of CV 
A1C 
      0.199 
      Quartile I  896  24.92% 734 25.00% 162 24.58%  
      Quartile II 901 25.06% 733 24.97% 168 25.49%  
      Quartile III 899 25.01% 752 25.61% 147 22.31%  




Predictors were selected based on univariate and correlation analyses of the train set as well 
as previous literature. Significant characteristics from univariate analyses of the train set were 
similar to those significant factors from univariate of the entire cohort. Pearson’s correlation 
analyses were conducted on the train set to evaluate correlation between predictors and the 
outcome variable as well as test for multi-collinearity of predictor variables. Although most 
predictors were significantly correlated with the diabetic retinopathy, the absolute values of 
correlation coefficient were between 0.02-0.21: the top three correlated predictors were 
history of duration of T1D (ρ=0.207), mean A1C (ρ=0.105), and history of diabetic 
neuropathy (ρ=0.104). 
Among predictors, most recent A1C level was strongly (|ρ|>0.7) correlated with mean A1C 
(ρ=0.925) but weakly correlated with SD-A1C (ρ=0.357); history of hypertension was 
strongly correlated with use of ACE inhibitors and ARBs (ρ=0.717); age and working status 
were moderately correlated with each other (0.4<|ρ|<0.5); age, duration of T1D, history of 
hypertension, history of dyslipidemia, and use of ACE inhibitors or ARBs were also 
moderately correlated with each other (0.4<|ρ|<0.5). 
Considering previous literature, results from univariate analysis and correlation analysis, the 
following 15 variables were selected: A1C variability, age, duration of T1D, BMI, household 
income (>=100k vs <100k), insurance type, smoking status at baseline (yes vs no), 
comorbidities including microalbuminuria or diabetic retinopathy, diabetic neuropathy, 
dyslipidemia, CAD, depression or psychosis, use of CGM, and use of ACE inhibitors or 
ARBs at baseline. When incorporating into machine learning models, multi-level categorical 




Predictive Models by LR 
With each of the 5 predictor sets, a total of 11 LR models were developed: 10 from ten-fold 
cross-validation of the train set and 1 final model based on the entire train set and evaluated 
on the test set. The ORs and their 95% CIs of the final model with each predictor set were 
reported in the following Tables 11a through 11e.  
Final model LR-Ret-A: While controlling for other covariates, unit increase in most recent 
A1C would increase a patient’s odds of developing diabetic retinopathy by 0.24 (OR 1.24, 
95%CI 1.15-1.34, p<0.0001); one year older in age reduced the odds by 0.01 (OR 0.99, 
95%CI 0.98-0.99, p<0.05), whereas one more year having T1D increased the odds of diabetic 
retinopathy by 0.05 (OR 1.05, 95%CI 1.04-1.06, p<0.0001); unit increase in BMI would raise 
the odds by 0.03 (OR 1.03, 95%CI 1.01-1.05, p<0.0001). The odds of developing diabetic 
retinopathy in patients with history of microalbuminuria or diabetic nephropathy were on 
average 1.50 (95%CI 1.05-2.16, p<0.05) times that of patients without these conditions. 
Similarly, a medical history of diabetic neuropathy would put a patient at higher risk of 
developing diabetic retinopathy (1.5 times of the odds) than a patient without diabetic 
neuropathy (Table 11a).      
Final model LR-Ret-B: This model indicates similar associations between predictors and 
diabetic retinopathy. Unit increase in mean A1C would increase a patient’s odds of 
developing diabetic nephropathy by 0.27 (OR 1.27, 95%CI 1.17-1.38, p<0.0001) while 
controlling for other covariates (Table 11b). 
Final model LR-Ret-C, LR-Ret-D & GEE-Ret-E: None of the three models indicate a 
significant association between SD A1C and the outcome of diabetic retinopathy (Tables 11c 
– 11e).  
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Table 11a. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with single A1C  
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; See 





LR-Ret-A OR 95% CI P value 
Single A1C  1.242 1.149 - 1.342 <0.0001 
Age at baseline (years) 0.988 0.978 - 0.998 0.016 
T1D duration (years) 1.050 1.039 - 1.061 <0.0001 
BMI (kg/m2) 1.028 1.007 - 1.049 0.009 
Annual household income: >=100K vs 
<100K 
0.848 0.673 - 1.069 0.163 
Commercial insurance vs Others 0.872 0.651 - 1.168 0.359 
Employment Status   0.0004 
      Working full time or part time 
(reference) 
- - - 
      Student or homemaker 0.573 0.416 - 0.790 0.0007 
      Unemployed, retired, disabled or other 1.323 0.980 - 1.786 0.068 
Smoking status at baseline: yes vs no 1.160 0.836 - 1.610 0.374 
Comorbidities at baseline    
      Microalbuminuria or Diabetic 
nephropathy 
1.502 1.046 - 2.157 0.028 
      Diabetic neuropathy 1.496 1.096 - 2.042 0.011 
      Dyslipidemia 0.831 0.661 - 1.046 0.115 
      CAD 1.126 0.646 - 1.964 0.675 
      Depression or psychosis 1.138 0.858 - 1.509 0.370 
Use of CGM at baseline: yes vs no  1.260 0.999 - 1.590 0.051 
Use of ACE inhibitors or ARBs: yes vs no 1.011 0.792 - 1.290 0.930 
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Table 11b. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with mean A1C 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; See 
“Appendix 3” for operational definitions of all variables. 
  
LR-Ret-B OR 95% CI P value 
Mean A1C  1.275 1.174 - 1.385 <0.0001 
Age at baseline (years) 0.988 0.978 - 0.998 0.024 
T1D duration (years) 1.051 1.040 - 1.062 <0.0001 
BMI (kg/m2) 1.028 1.007 - 1.049 0.009 
Annual household income: >=100K vs 
<100K 
0.862 0.684 - 1.087 0.209 
Commercial insurance vs Others 0.876 0.654 - 1.174 0.375 
Employment Status 1.124 0.809 - 1.561 0.486 
      Working full time or part time 
(reference) 
  0.0003 
      Student or homemaker - - - 
      Unemployed, retired, disabled or other 0.548 0.412 - 0.784 0.0006 
Smoking status at baseline: yes vs no 1.317 0.976 - 1.778 0.072 
Comorbidities at baseline 
   
      Microalbuminuria or Diabetic 
nephropathy 
1.478 1.029 - 2.122 0.035 
      Diabetic neuropathy 1.474 1.080 - 2.012 0.015 
      Dyslipidemia 0.825 0.655 - 1.037 0.099 
      CAD 1.140 0.654 - 1.985 0.644 
      Depression or psychosis 1.118 0.843 - 1.484 0.439 
Use of CGM at baseline: yes vs no  1.245 0.987 - 1.571 0.064 
Use of ACE inhibitors or ARBs: yes vs no 1.009 0.790 - 1.288 0.944 
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Table 11c. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with combination single 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; See 
“Appendix 3” for operational definitions of all variables. 
 
  
LR-Ret-C OR 95% CI P value 
Single A1C  1.224 1.126 - 1.329 <0.0001 
SD A1C 1.144 0.876 - 1.494 0.324 
Age at baseline (years) 0.988 0.978 - 0.998 0.019 
T1D duration (years) 1.051 1.040 - 1.062 <0.0001 
BMI (kg/m2) 1.028 1.007 - 1.050 0.008 
Annual household income: >=100K vs 
<100K 
0.849 0.674 - 1.070 0.166 
Commercial insurance vs Others 0.882 0.658 - 1.184 0.404 
Employment Status   0.0004 
      Working full time or part time 
(reference) 
- - - 
      Student or homemaker 0.576 0.418 - 0.795 0.0008 
      Unemployed, retired, disabled or other 1.316 0.975 - 1.777 0.073 
Smoking status at baseline: yes vs no 1.157 0.834 - 1.606 0.384 
Comorbidities at baseline    
      Microalbuminuria or Diabetic 
nephropathy 
1.494 1.040 - 2.146 0.030 
      Diabetic neuropathy 1.484 1.087 - 2.027 0.013 
      Dyslipidemia 0.831 0.661 - 1.046 0.115 
      CAD 1.128 0.647 - 1.967 0.670 
      Depression or psychosis 1.134 0.855 - 1.505 0.382 
Use of CGM at baseline: yes vs no  1.255 0.994 - 1.583 0.056 
Use of ACE inhibitors or ARBs: yes vs no 1.013 0.794 - 1.293 0.917 
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Table 11d. Final LR model for prediction of development of diabetic retinopathy using 
predictor set with combination mean 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; See 
“Appendix 3” for operational definitions of all variables. 
 
  
LR-Ret-D OR 95% CI P value 
Mean A1C  1.266 1.157 - 1.386 <0.0001 
SD A1C 1.054 0.804 - 1.382 0.704 
Age at baseline (years) 0.988 0.978 - 0.999 0.025 
T1D duration (years) 1.051 1.040 - 1.062 <0.0001 
BMI (kg/m2) 1.028 1.007 - 1.050 0.008 
Annual household income: >=100K vs 
<100K 
0.862 0.684 - 1.087 0.209 
Commercial insurance vs Others 0.879 0.656 - 1.179 0.389 
Employment Status   0.0004 
      Working full time or part time 
(reference) 
- - - 
      Student or homemaker 0.570 0.413 - 0.787 0.0006 
      Unemployed, retired, disabled or other 1.314 0.973 - 1.774 0.075 
Smoking status at baseline: yes vs no 1.123 0.809 - 1.561 0.488 
Comorbidities at baseline    
      Microalbuminuria or Diabetic 
nephropathy 
1.475 1.027 - 2.120 0.035 
      Diabetic neuropathy 1.469 1.076 - 2.006 0.016 
      Dyslipidemia 0.825 0.656 - 1.038 0.101 
      CAD 1.140 0.655 - 1.986 0.642 
      Depression or psychosis 1.118 0.842 - 1.484 0.440 
Use of CGM at baseline: yes vs no  1.243 0.985 - 1.568 0.066 
Use of ACE inhibitors or ARBs: yes vs no 1.010 0.791 - 1.289 0.939 
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Table 11e. Final GEE model for prediction of development of diabetic retinopathy using 
predictor set with multiple 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; See 
“Appendix 3” for operational definitions of all variables. 
 
 
GEE-Ret-E OR 95% CI P value 
Individual A1C  1 1.000 - 1.0001 0.0005 
SD A1C 1.194 0.949 - 1.500 0.13 
Age at baseline (years) 0.969 0.961 - 0.978 <0.0001 
T1D Duration (years) 1.032 1.023 - 1.041 <0.0001 
BMI (kg/m2) 1.026 1.005 - 1.047 0.013 
Annual household income: >=100K vs 
<100K 
0.865 0.688 - 1.087 0.213 
Commercial insurance vs Others 0.826 0.622 - 1.096 0.185 
Employment Status    
      Working full time or part time 
(reference) 
ref - - 
      Student or homemaker 3.259 2.197 - 4.834 <0.0001 
      Unemployed, retired, disabled or other 2.143 1.577 - 2.912 <0.0001 
Smoking status at baseline: yes vs no 1.139 0.820 - 1.582 0.437 
Comorbidities at baseline    
      Microalbuminuria or Diabetic 
nephropathy 
1.523 1.065 - 2.175 0.021 
      Diabetic neuropathy 1.764 1.294 - 2.405 0.0003 
      Dyslipidemia 1.027 0.822 - 1.281 0.816 
      CAD 1.610 0.924 - 2.903 0.092 
      Depression or psychosis 1.213 0.908 - 1.620 0.191 
Use of CGM at baseline: yes vs no  1.254 1.0004 - 1.572 0.049 
Use of ACE inhibitors or ARBs: yes vs no 1.252 0.992 - 1.580 0.058 
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Predictive Models by SVM 
Using each of the 5 predictor sets, 11 SVM models were developed by Sci-Kit Learn SVC 
classifier: 10 from ten-fold cross-validation of the train set and 1 final model based on the 
entire train set and evaluated on the test set. Predictors were pre-processed using 
RobustScaler without scaling (i.e., removing the median only). SMOTE was used to 
oversample the cases so that there were equal numbers of cases and controls for modeling. 
Random state was set to be 42 to ensure repeatable weight initiation. The kernel function was 
set to be ‘rbf’ and γ as ‘scale’ for all models. The hyperparameter Cs used for the final trained 
models with the 5 predictor sets are as follows: a) SVM-Ret-A: C= 2.7; b) SVM-Ret-B: 
C=6.5; c) SVM-Ret-C: C=1.6; d) SVM-Ret-D: C=5.6; and e) SVM-Ret-E: C=0.2.   
Predictive Models by NN 
Using each of the 5 predictor sets, 11 NN models were developed using the TensorFlow.keras 
package: 10 from ten-fold cross-validation of the train set and 1 final model based on the 
entire train set and evaluated on the test set.  
The final hyperparameters were selected based on the loss and accuracy curves of the train 
and validation set through the process of ten-fold cross validation. Each time, one 
hyperparameter was tuned to see how it impacted the loss curve and accuracy. The loss curve 
of the validation set was bumpy but gradually declining until flatten off. The plateau of the 
loss curve of the validation set indicated that the training can be stopped, even though the loss 
curve of the train set was still declining. With larger learning rate, fewer number of epochs 
was needed for reaching the plateau, but the learning curve can be bumpier. However, after 
we tried both ways – smaller learning rate with more epochs of training and larger learning 
rate with fewer epochs of learning – the highest F1 score can be achieved were similar, at 
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around the value of 0.65. Examples of the accuracy and loss curves of the train and validation 
set of NN models using the 5 predictor sets are provided in Appendix 5. 
The final NN models were trained without scaling of the predictors. SMOTE was used to 
oversample the cases so that there were equal numbers of cases and controls for modeling. 
All final NN models comprised 1 input layer, 1 output layer with the ‘sigmoid’ activation 
function, and 3 hidden layers with the ‘ReLU’ activation function and a 𝑙𝑙2 penalty of 0.005. 
The Adam optimization algorithm was used for training. The learning rate, epochs, nodes in 
the 1st, 2nd and 3rd hidden layers, and percentage of randomly dropped connections between 
consecutive layers (indicated as percentages in parentheses after number of nodes) used for 
the final NN models with the 5 predictor sets were as follows:  
a) NN-Ret-A: learning rate = 0.01; epochs = 50; 1st hidden layer: 50 nodes (random drop = 
50%); 2nd hidden layer: 50 nodes (random drop = 50%); 3rd hidden layer: 50 nodes (random 
drop = 50%). 
b) NN-Ret-B: the same as NN-Ret-A. 
c) NN-Ret-C: learning rate = 0.01; epochs = 50; 1st hidden layer: 50 nodes (random drop = 
30%); 2nd hidden layer: 50 nodes (random drop = 30%); 3rd hidden layer: 50 nodes (random 
drop = 30%).  
d) NN-Ret-D: learning rate = 0.01; epochs = 100; 1st hidden layer: 128 nodes (random drop = 
50%); 2nd hidden layer: 64 nodes (random drop = 50%); 3rd hidden layer: 64 nodes (random 
drop = 50%). 
e) NN-Ret-E: learning rate = 0.01; epochs = 40; 1st hidden layer: 128 nodes (random drop = 
50%); 2nd hidden layer: 64 nodes (random drop = 50%); 3rd hidden layer: 64 nodes (random 
drop = 50%). 
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As there are multiple sources of randomness, each model was repeated 10 times and the 
average performance metrics were calculated and reported. 
Model Performance 
The F1 scores of LR, SVM and NN models in the retinopathy cohort by A1C variability are 
plotted in Figure 12. The performance measures of all models are provided in Appendix 6.  
 





Cohort of Neuropathy 
Baseline Characteristics 
Among the 4,072 patients in the neuropathy cohort, 579 (14%) developed diabetic 
neuropathy (cases) during the follow-up period. Slightly more than half (55%) were women. 
The mean (±SD) age of patients in the case group was 49 (±14.5) years, significantly older 
than those who did not develop nephropathy during follow-up (controls) (36±14.2, 
p<0.0001). The baseline demographic, clinical, and treatment characteristics between patients 
in the case and control groups were summarized in Table 12.  
Demographics: Univariate analyses indicated that compared to the control group (18±12.8 
years), cases had had T1D for a longer period at baseline (27±13.5 years, p<0.0001). Less 
proportion of the case group than the control group had commercial health insurance (78.9% 
vs 87.3%, p<0.0001) and worked full-time or part-time (63.6% vs 65.0%, p<0.0001). A 
greater proportion of the case group than the control group were married or living together 
(71.7% vs 54.6%, p<0.0001), had below $50k household income (33.5% vs 23.9%, 
p<0.0001), and had ever smoked (37.8% vs 25.4%, p<0.0001) or were smoking at baseline 
(12.4% vs 8.6%, p<0.01). The two groups were similar in other demographics. 
Clinical characteristics: Patients in the case group on average had higher BMI (28±4.9 vs 
27±5.5, p<0.01) and SBP (123±15.1 vs 120±12.8, p<0.0001) than the control group. Similar 
to the nephropathy and retinopathy cohorts, more than a third (35.3%) of patients had their 
lipid fasting status unknow.  
Medical history: The case group had a greater percentage of patients with a history of 
microalbuminuria (11.4% vs 4.1%, p<0.0001), diabetic retinopathy (31.6% vs 9.6%, 
p<0.0001) and nephropathy (9.1% vs 3.2%, p<0.0001), cardiovascular conditions including 
hypertension (49.0% vs 23.4%, p<0.0001), dyslipidemia (50.4% vs 32.2%, p<0.0001), CAD 
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(8.1% vs 2.0%, p<0.0001), hypothyroidism or Hashimoto disease (25.6% vs 21.3%, p<0.05), 
RA or osteoporosis (10.4% vs 3.6%, p<0.0001), and depression (16.2% vs 10.8%, p<0.0001).   
Treatment: The two groups did not differ much in their treatment at baseline except that a 
greater proportion of the case group had used ACE inhibitors or ARBs (50.8% vs 26.2%, 
p<0.0001) and other medications for blood glucose control (including DPP4 Inhibitors, GLP1 
agonists, metformin, pramlintide or other medications reported by participant or indicated in 
medication records) (10.2% vs 7.6%, p<0.05). 
A1C Measures: Measures of A1C were summarized in Table 13. Univariate analyses 
indicated that compared to the control group, the case group was on average higher in their 
most recent A1C level (7.8±1.4 vs 7.7±1.3, p<0.05) and mean A1C (7.9±1.3 vs 7.7±1.2, 
p<0.05). But the SD A1C and CV A1C between cases and controls did not differ 
significantly. The gap between the last two A1C measures was on average 6.1 months (range 
3.0-130.0 months) with a median gap of 4.0 months. Among the 3257 patients in the train set, 






Table 12. Baseline characteristics of patients in the neuropathy cohort  
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No 
Neuropathy: 
Yes   
P-value 
  
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
Age at baseline             <0.0001 
      Mean (SD) 38 14.98 36 14.21 49 14.53   
      Median (range) 36 18.0 - 86.8   34 18.0 - 86.8 49 18.5 - 85.8   
Age group 
      
<0.0001 
      18-27 years 862 21.17% 770 22.04% 92 15.89%   
      28-37 years 1,317 32.34% 1,269 32.33% 48 8.29%   
      38-47 years 797 19.57% 673 19.27% 124 21.42%   
      48-64 years 899 22.08% 673 19.27% 226 39.03%   
      ≥65 years 197 4.84% 108 3.09% 89 15.37%   
Age at T1D 
Diagnosis             <0.0001† 
      Mean (SD) 18 13.22 18 12.82 22 14.82   
      Median (range) 14 0.0 - 72.0 14 0.0 - 72.0 18 0.0 - 66.0   
T1D Duration 
      
<0.0001† 
      Mean (SD) 20 11.95 18 11.23 27 13.50   
      Median (range) 17 0.6 - 62.6 16 0.6 - 62.6 26 1.2 - 62.4   
Gender 
      
0.385 
      Female 2,239 54.99% 1,911 54.71% 328 56.65% 
 
      Male 1,833 45.01% 1,582 45.29% 251 43.35% 
 
Race/Ethnicity 
      
0.526 
      White Non-
Hispanic 
3,693 90.69% 3,167 90.67% 526 90.85% 
 
      Black/African 
American 
112 2.75% 93 2.66% 19 3.28% 
 
      Hispanic or 
Latino 
158 3.88% 135 3.86% 23 3.97% 
 
      Others 109 2.68% 98 2.81% 11 1.90% 
 
Education Level n = 3,971 n = 3,411 n = 560 0.269 
      Less than 
bachelor's degree 
1,930 48.60% 1,675 49.11% 255 45.54% 
  
      Bachelor's 
degree 
1,284 32.33% 1,089 31.93% 195 34.82% 
  
      Master's, 
professional, or 
doctorate 
757 19.06% 647 18.97% 110 19.64% 
  
Insurance 
Coverage n = 3,741 n = 3,196 n = 545 <0.0001 
      Commercial 
health insurance 




Table 12. Continued 
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No 
Neuropathy: 
Yes   
P-value 
  
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
      Government-
sponsored 
insurance 
415 11.09% 313 9.79% 102 18.72% 
  
      Not specified  106 2.83% 93 2.91% 13 2.39%   
Marital Status n = 4,037 n = 3,460 n = 477 <0.0001 
      Married or 
living together 
2,304 57.07% 1,890 54.62% 414 71.75% 
  
      Divorced, 
separated, single, 
or widowed 




(self-reported) n = 3,182 n = 2,725 n = 457 <0.0001 
      <$50,000 805 25.30% 652 23.93% 153 33.48%   
      $50,000 to < 
$100,000 
1,199 37.68% 1,041 38.20% 158 34.57% 
  
      >=$100,000 1,178 37.02% 1,032 37.87% 146 31.95%   
Employment 
Status             <0.0001 
      Working full 
time or part-time 
at baseline 
2,638 64.78% 2,270 64.99% 368 63.56% 
  
      Student or 
homemaker 
880 21.61% 840 24.05% 40 6.91% 
  
      Unemployed, 
retired, disabled or 
other 
554 13.61% 383 10.96% 171 29.53% 
  
Smoking Status                
      Yes, smoking 
at baseline 
371 9.11% 299 8.56% 72 12.44% 
0.003 
      Not smoking at 
baseline, but 
smoked before 
1,108 27.21% 889 25.45% 219 37.82% 
<0.0001 
BMI (kg/m2)       0.008† 
      Mean (SD) 27.02 4.99 26.93 4.90 27.57 
5.47 
  
      Median (range) 26.26 11.16 - 65.57 





65.57   
BMI category       0.028 
      Under or 
normal weight 




Table 12. Continued 
 
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No 
Neuropathy: 
Yes   
P-value 
  
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
      overweight 1,553 38.14% 1,341 38.39% 212 36.61%   
      obese 930 22.84% 773 22.13% 157 27.12%   
Blood Pressure 
(mmHg)  n = 3,965 n = 3,400 n = 565 
 
Diastolic blood 
pressure             <0.0001† 
      Mean (SD) 72.13 8.40 72.39 8.27 70.54 
9.02 
  
      Median (range) 71.00 42.00 - 
111.00 










      
<0.0001† 

















178.00   
Cholesterol 
Levels 
       
HDL value   n = 3,612  n = 3,105 n = 507 0.852 
      Mean (SD) 61.35 17.84 61.33 17.71 61.49 
18.62 
  
      Median (range) 59.00 14.00 - 162.00 





140.00   
LDL value   n = 3,814 n = 3,263 n = 551 0.100 
      Mean (SD) 92.60 28.00 92.91 27.93 90.78 
28.39 
  
      Median (range) 90.00 3.00 - 281.00 





205.00   
Triglycerides 
value   n = 3,547 n = 3,047 n = 500 0.969‡ 
      Mean (SD) 90.85 81.88 90.77 83.25 91.32 
73.08  
      Median (range) 72.00 0.00 - 3000.00 








Status   n = 3,901  n = 3,345 n = 556 0.908 
      Fasting 1,745 44.73% 1,492 44.60% 253 45.50%   
      Not Fasting 779 19.97% 671 20.06% 108 19.42%   
      Unknown 1,377 35.30% 1,182 35.34% 195 35.07%   
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Table 12. Continued 
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No 
Neuropathy: 
Yes   
P-value 
  
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
Microalbuminuri
a at baseline 
(Yes) 
208 5.11% 142 4.07% 66 11.40% 
<0.0001 
Comorbidities at 
Baseline               
Diabetic 
retinopathy 




166 4.08% 113 3.24% 53 9.15% 
<0.0001 
Cardiovascular 
conditions               
      Hypertension  1,100 27.01% 816 23.36% 284 49.05% <0.0001 
      Dyslipidemia 1,417 34.80% 1,125 32.21% 292 50.43% <0.0001 
      CAD 117 2.87% 70 2.00% 47 8.12% <0.0001 
      PVD 18 0.44% 12 0.34% 6 1.04% 0.033§ 
      Cardiac 
arrythmia 
31 0.76% 20 0.57% 11 1.90% 
0.003§ 
      
Cerebrovascular 
accident 
17 0.42% 9 0.26% 8 1.38% 
0.001§ 
Endocrine 
diseases               
      
Hypothyroidism or 
Hashimoto disease 
893 21.93% 745 21.33% 148 25.56% 0.023 
      
Hyperthyroidism 
or Grave's disease 
81 1.99% 66 1.89% 15 2.59% 0.263 
      Other 
endocrine diseases 
30 0.74% 26 0.74% 4 0.69% 1.000§ 
Gastrointestinal 
diseases 
172 4.22% 142 4.07% 30 5.18% 0.216 
Musculoskeletal/
Connective 
Tissue conditions               
      RA or 
osteoporosis 
185 4.54% 125 3.58% 60 10.36% 
<0.0001 
Psychiatric 
conditions               
      Depression 473 11.62% 379 10.85% 94 16.23% 0.0002 
      Anxiety 170 4.17% 141 4.04% 29 5.01% 0.279 
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Table 12. Continued 
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. 
Abbreviations: SD: standard deviation; BMI: Body mass index, calculated as the body mass 
in kilograms divided by the square of the body height in meters (kg/m2); SD: standard 
deviation; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CAD: coronary 
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No 
Neuropathy: 
Yes   
P-value 
  
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
      ADHD 78 1.92% 71 2.03% 7 1.21% 0.181 
      Psychosis 15 0.37% 12 0.34% 3 0.52% 0.461§ 
      Eating 
disorders 
22 0.54% 19 0.54% 3 0.52% 1.000§ 
Skin conditions 79 1.94% 63 1.80% 16 2.76% 0.121 
CGM use       0.059 
      Yes 897 22.03% 752 21.53% 145 25.04%  
      No 3,175 77.97% 2,741 78.47% 434 74.96%  
Insulin use               
Type of insulin 
analog               
      Insulin lispro 
(Humalog) 
2,103 51.65% 1,804 51.65% 299 51.64% 0.998 
      Insulin aspart 
(Novolog) 
1,856 45.58% 1,607 46.01% 249 43.01% 0.179 
      Insulin detemir 
(Levemir) 
142 3.49% 120 3.44% 22 3.80% 0.658 
      Insulin 
glargine (Lantus) 
1,320 32.42% 1,131 32.38% 189 32.64% 0.900 
Participant 
insulin delivery 
method at time of 
most recent exam  
      0.519 
      Pump only 2,446 60.07% 2,103 60.21% 343 59.24%  
      Injections/pens 
only 
1,545 37.84% 1,317 37.30% 228 39.38%  
      Both pump and 
injections/pens 
81 1.99% 73 2.09% 8 1.39%  




324 7.96% 265 7.59% 59 10.19% 
0.032 
Use of ACE 
inhibitors or 
ARBs 




artery disease; ADHD: Attention-deficit/hyperactivity disorder; RA: rheumatoid arthritis; 
IBD: Inflammatory bowel disease; PVD: peripheral vascular disease; CHF: congestive heart 
failure; CVA: cerebral vascular accident; TIA: transient ischemic attack. See “Appendix 3” 
for operational definitions of predictor variables. 
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Table 13. Baseline A1C measures of patients in the neuropathy cohort  
† Indicates p value was based on t test with unequal variance; ‡ Indicates p value was based 
on Wilcoxon rank sum test because the variable was not normally distributed; § Indicates p 
value was based on Fisher's exact test. See “Appendix 3” for operational definitions of all 
variables. 
Characteristics  
Cohort of Neuropathy 
Total Neuropathy: No Neuropathy: Yes 
P-value 
N % N % N % 
4,072 100.00% 3,493 85.78% 579 14.22% 
Single A1C       0.041† 
      Mean (SD) 7.74 1.30 7.72 1.29 7.85 1.37 
 
      Median (range) 7.50 4.00 - 
15.60 
7.50 4.00 - 
15.60 
7.60 5.10 - 
15.60 
 
Mean A1C        0.011† 
      Mean (SD) 7.74 1.25 7.72 1.23 7.87 1.34 
 
      Median (range) 7.53 4.07 - 
14.00 
7.53 4.07 - 
14.00 
7.63 5.13 - 
13.88 
 
Quartiles of mean 
A1C 
      
0.159 
      Quartile I 1,000 24.56% 865 24.76% 135 23.32%  
      Quartile II 994 24.41% 864 24.74% 130 22.45%  
      Quartile III 1,060 26.03% 912 26.11% 148 25.56%  
      Quartile IV 1,018 25.00% 852 24.39% 166 28.67%  
SD A1C        0.552‡ 
      Mean (SD) 0.43 0.37 0.42 0.36 0.45 0.43  
      Median (range) 0.35 0.00 - 4.60 0.35 0.00 - 
4.42 
0.35 0.00 - 
4.60 
 
Quartiles of SD A1C       0.453 
      Quartile I 1,160 28.49% 1,005 28.77% 155 26.77%  
      Quartile II 861 21.14% 731 20.93% 130 22.45%  
      Quartile III 1,027 25.22% 889 25.45% 138 23.83%  
      Quartile IV 1,024 25.15% 868 24.85% 156 26.94%  
CV A1C       0.874‡ 
      Mean (SD) 0.05 0.04 0.05 0.04 0.05 0.04  
      Median (range) 0.04 0.00 - 0.52 0.04 0.00 - 
0.47 
0.05 0.00 - 
0.52 
 
Quartiles of CV 
A1C 
      0.655 
      Quartile I 1,018 25.00% 868 24.85% 150 25.91%  
      Quartile II 1,021 25.07% 888 25.42% 133 22.97%  
      Quartile III 1,017 24.98% 868 24.85% 149 25.73%  




Predictors were selected based on univariate and correlation analyses of the train set as well 
as previous literature. Significant characteristics from univariate analyses of the train set were 
similar to those significant factors from univariate analyses of the entire cohort. Pearson’s 
correlation analyses were conducted on the train set to evaluate correlation between 
predictors and the outcome variable as well as test for multi-collinearity of predictor 
variables. Although most predictors were significantly correlated with the diabetic 
retinopathy, the absolute values of correlation coefficient were between 0.03-0.30: the top 
three correlated predictors were age (ρ=0.303), history of diabetic retinopathy (ρ=0.228), and 
duration of T1D (ρ=0.242). 
Among predictors, most recent A1C level was weakly correlated with SD A1C (ρ=0.371); 
history of hypertension was strongly correlated with use of ACE inhibitors and ARBs 
(ρ=0.720); age, duration of T1D, history of hypertension, history of dyslipidemia, and use of 
ACE inhibitors or ARBs were moderately correlated with each other (0.4<|ρ|<0.5); age, 
marital status,  and working status were also moderately correlated with each other 
(0.4<|ρ|<0.5). 
Considering previous literature, results from univariate analyses and correlation analyses, the 
following 21 variables were selected: A1C variability, age, duration of T1D, BMI, household 
income (>=100k vs <100k), insurance type, employment status, smoking status (ever smoked 
vs never), comorbidities including microalbuminuria or diabetic nephropathy, diabetic 
retinopathy, hypertension, dyslipidemia, CAD, PVD, cardiac arrythmia, CVA, 
hypothyroidism or Hashimoto disease, gastrointestinal diseases, musculoskeletal/connective 
tissue conditions (RA or osteoporosis) and depression, and use of other medications for blood 
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glucose control (yes vs no). When incorporating into machine learning models, multi-level 
categorical variables were dummy coded (0/1). 
Predictive Models by LR 
With each predictor set, a total of 11 LR models were developed: 10 from ten-fold cross-
validation of the train set and 1 final model based on the entire train set and evaluated on the 
test set. The ORs and their 95% CIs of the final model with each predictor set were reported 
in the following Tables 14a through 14e.  
Final model LR-Neu-A: While controlling for other covariates, unit increase in A1C would 
increase a patient’s odds of developing diabetic neuropathy by 0.23 (OR 1.23, 95%CI 1.13-
1.34, p<0.0001); one year older in age would raise the odds by 0.04 (OR 1.04, 95%CI 1.03-
1.05, p<0.0001); one year longer in having T1D would raise the odds of diabetic neuropathy 
by 0.02 (OR 1.02, 95%CI 1.01-1.03, p<0.0001). The odds of developing diabetic neuropathy 
in patients with history of microalbuminuria or diabetic nephropathy were on average twice 
(95%CI 1.42-2.80, p<0.0001) that of patients without. Having a medical history of diabetic 
retinopathy or depression also increase a patient’s odds of developing diabetic neuropathy. 
Interestingly, history of PVD decreases the odds by 0.72 (OR 0.28, 95%CI 0.08-0.98, 
p<0.05), whereas use of other blood glucose control medication versus not increased the odds 
of diabetic neuropathy (OR 1.51, 95%CI 1.05-2.17, p<0.05) (Table 14a).      
Final model LR-Neu-B: This model indicates similar associations between predictors and 
diabetic neuropathy. Unit increase in mean A1C would increase a patient’s odds of 
developing diabetic nephropathy by 0.28 (OR 1.28, 95%CI 1.17-1.40, p<0.0001) while 
controlling for other covariates (Table 14b). 
Final model LR-Neu-C: This model indicates that in addition to a single A1C, SD A1C is a 
significant predictor for the outcome of diabetic neuropathy. The odds of developing diabetic 
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neuropathy increased by 0.45 with unit increase in SD-A1C (OR 1.45, 95%CI 1.07-1.96, 
p<0.05) (Tables 14c). 
Final model LR-Neu-D: This model did not indicate a significant association between SD 
A1C and the outcome of diabetic neuropathy (Tables 14d). 
Final model GEE-Nep-E: The GEE model indicates that while controlling for other 
covariates, A1C values over time were not significantly associated with diabetic neuropathy. 
Unit increase in SD A1C would increase the odds by 0.36 (OR 1.36, 95%CI 1.03-1.80, 




Table 14a. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with single A1C  
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; CVA: Cerebrovascular accident See “Appendix 3” for operational 
definitions of all variables. 
LR-Neu-A OR 95% CI P value 
Single A1C  1.230 1.127 - 1.342 <0.0001 
Age at baseline (years) 1.042 1.031 - 1.053 <0.0001 
T1D Duration (years) 1.021 1.011 - 1.032 <0.0001 
BMI (kg/m2) 0.985 0.963 - 1.008 0.189 
Annual household income: >=100K vs 
<100K 
0.803 0.623 - 1.035 0.090 
Commercial insurance vs Others 0.832 0.631 - 1.098 0.193 
Employment Status   0.002 
      Working full time or part time 
(reference) 
- - - 
      Student or homemaker 0.514 0.335 - 0.789 0.002 
      Unemployed, retired, disabled or 
other 
1.263 0.942 - 1.694 0.118 
Smoking status: ever smoked vs never 1.355 1.076 - 1.706 0.010 
Comorbidities at baseline 
   
      Microalbuminuria or diabetic 
nephropathy 
1.994 1.422 - 2.796 <0.0001 
      Diabetic retinopathy 1.711 1.295 - 2.262 0.0002 
      Hypertension 1.091 0.846 - 1.407 0.502 
      Dyslipidemia 0.938 0.740 - 1.188 0.594 
      CAD 0.831 0.510 - 1.355 0.458 
      PVD 0.277 0.078 - 0.978 0.046 
      Cardiac arrythmia 1.857 0.780 - 4.422 0.162 
      CVA 1.519 0.473 - 4.880 0.482 
      Hypothyroidism or Hashimoto 
disease 
0.863 0.669 - 1.115 0.260 
      Gastrointestinal diseases 1.262 0.763 - 2.087 0.364 
      Musculoskeletal/connective tissue 
conditions 
0.997 0.658 - 1.509 0.988 
      Depression 1.383 1.027 - 1.862 0.033 
Use of other medications for blood 
glucose control: yes vs no 
1.509 1.049 - 2.170 0.027 
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Table 14b. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with mean A1C 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; CVA: Cerebrovascular accident See “Appendix 3” for operational 
definitions of all variables. 
 
  
LR-Neu-B OR 95% CI P value 
Mean-A1C  1.279 1.167 - 1.402 <0.0001 
Age at baseline (years) 1.043 1.032 - 1.054 <0.0001 
T1D Duration (years) 1.022 1.012 - 1.032 <0.0001 
BMI (kg/m2) 0.984 0.962 - 1.007 0.176 
Annual household income: >=100K vs 
<100K 
0.819 0.635 - 1.056 0.124 
Commercial insurance vs Others 0.835 0.633 - 1.101 0.202 
Employment Status   0.002 
      Working full time or part time 
(reference) 
- - - 
      Student or homemaker 0.508 0.331 - 0.781 0.002 
      Unemployed, retired, disabled or other 1.261 0.940 - 1.691 0.122 
Smoking status: ever smoked vs never 1.340 1.064 - 1.688 0.013 
Comorbidities at baseline 
   
      Microalbuminuria or diabetic 
nephropathy 
1.957 1.394 - 2.746 0.0001 
      Diabetic retinopathy 1.685 1.274 - 2.229 0.0003 
      Hypertension 1.074 0.832 - 1.387 0.581 
      Dyslipidemia 0.927 0.731 - 1.176 0.534 
      CAD 0.832 0.510 - 1.357 0.462 
      PVD 0.267 0.075 - 0.949 0.041 
      Cardiac arrythmia 1.852 0.775 - 4.442 0.165 
      CVA 1.564 0.481 - 5.079 0.457 
      Hypothyroidism or Hashimoto disease 0.855 0.661 - 1.104 0.229 
      Gastrointestinal diseases 1.264 0.765 - 2.091 0.361 
      Musculoskeletal/connective tissue 
conditions 
1.000 0.660 - 1.516 0.998 
      Depression 1.367 1.015 - 1.842 0.040 
Use of other medications for blood 
glucose control: yes vs no 
1.521 1.057 - 2.189 0.024 
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Table 14c. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with combination single 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; CVA: Cerebrovascular accident See “Appendix 3” for 
operational definitions of all variables. 
  
LR-Neu-C OR 95% CI P value 
Most recent A1C  1.182 1.078 - 1.297 0.0004 
SD-A1C 1.447 1.069 - 1.959 0.017 
Age at baseline (years) 1.043 1.032 - 1.054 <0.0001 
T1D Duration (years) 1.022 1.012 - 1.033 <0.0001 
BMI (kg/m2) 0.986 0.964 - 1.009 0.232 
Annual household income: >=100K vs 
<100K 
0.800 0.621 - 1.032 0.086 
Commercial insurance vs Others 0.855 0.647 - 1.130 0.270 
Employment Status   0.002 
      Working full time or part time  - - - 
      Student or homemaker 0.519 0.338 - 0.797 0.003 
      Unemployed, retired, disabled or other 1.262 0.941 - 1.692 0.121 
Smoking status: ever smoked vs never 1.363 1.082 - 1.716 0.009 
Comorbidities at baseline 
   
      Microalbuminuria or diabetic 
nephropathy 
1.962 1.398 - 2.755 <0.0001 
      Diabetic retinopathy 1.706 1.290 - 2.256 0.0002 
      Hypertension 1.091 0.845 - 1.408 0.504 
      Dyslipidemia 0.942 0.743 - 1.195 0.625 
      CAD 0.829 0.509 - 1.352 0.453 
      PVD 0.283 0.081 - 0.993 0.049 
      Cardiac arrythmia 1.739 0.726 - 4.166 0.215 
      CVA 1.468 0.456 - 4.762 0.520 
      Hypothyroidism or Hashimoto disease 0.865 0.669 - 1.117 0.266 
      Gastrointestinal diseases 1.270 0.768 - 2.103 0.352 
      Musculoskeletal/connective tissue 
conditions 
0.984 0.650 - 1.489 0.938 
      Depression 1.266 1.014 - 1.841 0.040 
Use of other medications for blood 
glucose control: yes vs no 
1.504 1.146 - 2.165 0.028 
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Table 14d. Final LR model for prediction of development of diabetic neuropathy using 
predictor set with combination mean 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; CVA: Cerebrovascular accident See “Appendix 3” for 
operational definitions of all variables. 
  
LR-Neu-D OR 95% CI P value 
Mean-A1C  1.232 1.115 - 1.362 <0.0001 
SD-A1C 1.331 0.979 - 1.809 0.068 
Age at baseline (years) 1.044 1.033 - 1.055 <0.0001 
T1D Duration (years) 1.022 1.012 - 1.033 <0.0001 
BMI (kg/m2) 0.986 0.963 - 1.008 0.215 
Annual household income: >=100K vs 
<100K 
0.814 0.631 - 1.051 0.114 
Commercial insurance vs Others 0.851 0.645 - 1.124 0.257 
Employment Status   0.002 
      Working full time or part time (reference) - - - 
      Student or homemaker 0.513 0.334 - 0.789 0.002 
      Unemployed, retired, disabled or other 1.260 0.939 - 1.690 0.123 
Smoking status: ever smoked vs never 1.349 1.070 - 1.700 0.011 
Comorbidities at baseline 
   
      Microalbuminuria or diabetic nephropathy 1.937 1.379 - 2.721 0.0001 
      Diabetic retinopathy 1.684 1.272 - 2.228 0.0003 
      Hypertension 1.076 0.833 - 1.390 0.573 
      Dyslipidemia 0.933 0.735 - 1.184 0.569 
      CAD 0.830 0.509 - 1.354 0.456 
      PVD 0.274 0.078 - 0.966 0.044 
      Cardiac arrythmia 1.765 0.735 - 4.237 0.204 
      CVA 1.518 0.467 - 4.933 0.488 
      Hypothyroidism or Hashimoto disease 0.857 0.663 - 1.107 0.238 
      Gastrointestinal diseases 1.270 0.767 - 2.102 0.352 
      Musculoskeletal/connective tissue 
conditions 
0.990 0.654 - 1.500 0.963 
      Depression 1.358 1.007 - 1.830 0.045 
Use of other medications for blood glucose 
control: yes vs no 
1.515 1.053 - 2.180 0.025 
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Table 14e. Final GEE model for prediction of development of diabetic neuropathy using 
predictor set with multiple 
Abbreviations: OR: odds ratio; CI: confidence interval; CAD: coronary artery disease; PVD: 
peripheral vascular disease; CVA: Cerebrovascular accident See “Appendix 3” for 
operational definitions of all variables. 
LR-Neu-E OR 95% CI P value 
Individual A1C  1 1.000 - 1.0001 0.052 
SD A1C 1.362 1.029 - 1.803 0.031 
Age at baseline (years) 1.009 1.001 - 1.017 0.024 
T1D Duration (years) 0.991 0.983 - 0.999 0.034 
BMI (kg/m2) 0.98 0.958 - 1.003 0.089 
Annual household income: >=100K vs 
<100K 
0.847 0.656 - 1.092 0.199 
Commercial insurance vs Others 0.867 0.668 - 1.125 0.283 
Employment Status    
      Working full time or part time (reference) ref - - 
      Student or homemaker 4.935 3.082 - 7.901 <0.0001 
      Unemployed, retired, disabled or other 2.942 1.954 - 4.429 <0.0001 
Smoking status: ever smoked vs never 1.401 1.114 - 1.761 0.003 
Comorbidities at baseline 
   
      Microalbuminuria or diabetic nephropathy 1.871 1.329 - 2.635 0.0003 
      Diabetic retinopathy 2.659 2.018 - 3.505 <0.0001 
      Hypertension 1.539 1.199 - 1.976 0.001 
      Dyslipidemia 1.191 0.940 - 1.508 0.147 
      CAD 1.201 0.733 - 1.970 0.467 
      PVD 0.410 0.123 - 1.360 0.145 
      Cardiac arrythmia 1.881 0.733 - 4.829 0.189 
      CVA 1.873 0.550 - 6.382 0.316 
      Hypothyroidism or Hashimoto disease 1.095 0.855 - 1.403 0.47 
      Gastrointestinal diseases 1.357 0.848 - 2.169 0.203 
      Musculoskeletal/connective tissue 
conditions 
1.277 0.821 - 1.986 0.278 
      Depression 1.345 0.987 - 1.831 0.060 
Use of other medications for blood glucose 
control: yes vs no 
1.359 0.937 - 1.970 0.106 
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Predictive Models by SVM 
Using each predictor set, 11 SVM models were developed by Sci-Kit Learn SVC classifier: 
10 from ten-fold cross-validation of the train set and 1 final model based on the entire train 
set and evaluated on the test set. Predictors were pre-processed using RobustScaler without 
scaling (i.e., removing the median only). SMOTE was used to oversample the cases so that 
there were equal numbers of cases and controls for modeling. Random state was set to be 42 
to ensure repeatable weight initiation. The kernel function was set to be ‘rbf’ and γ as ‘scale’ 
for all models. The hyperparameter Cs used for the final trained models with the 5 predictor 
sets are as follows: a) SVM-Neu-A: C= 4.3; b) SVM-Neu-B: C=5.8; c) SVM-Neu-C: C=8.4; 
d) SVM-Neu-D: C=6; and e) SVM-Neu-E: C=3.8.   
Predictive Models by NN 
Using each predictor set, 11 NN models were developed using the TensorFlow.keras 
package: 10 from ten-fold cross-validation of the train set and 1 final model based on the 
entire train set and evaluated on the test set.  
The final hyperparameters were selected based on the loss and accuracy curves of the train 
and validation set through the process of ten-fold cross validation. Each time, one 
hyperparameter was tuned to see how it impacted the loss curve and accuracy. The loss curve 
of the validation set was bumpy but gradually declining until flatten off. The plateau of the 
loss curve of the validation set indicated that the training can be stopped, even though the loss 
curve of the train set was still declining. With larger learning rate, fewer number of epochs 
was needed for reaching the plateau, but the learning curve can be bumpier. However, after 
we tried both ways – smaller learning rate with more epochs of training and larger learning 
rate with fewer epochs of learning – the highest F1 score can be achieved were similar, at 
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around the value of 0.6. Examples of the accuracy and loss curves of the train and validation 
set of NN models using the 5 predictor sets are provided in Appendix 4. 
The final NN models were trained without scaling of the predictors. SMOTE was used to 
oversample the cases so that there were equal numbers of cases and controls for modeling. 
All final NN models comprised 1 input layer, 1 output layer with the ‘sigmoid’ activation 
function, and 3 hidden layers with the ‘ReLU’ activation function and a 𝑙𝑙2 penalty of 0.005. 
The 1st hidden layer comprised 128 nodes, the 2nd 64 nodes and the 3rd 64 nodes. The 
connections between each hidden layer and the consecutive layers can be randomly dropped 
by 50%. The Adam optimization algorithm was used for training with a learning rate of 0.01. 
The epochs used for the final NN models with the 5 predictor sets are as follows:  
a) NN-Neu-A: epochs = 50;  
b) NN-Neu-B: epochs = 50;  
c) NN-Neu-C: epochs = 50;  
d) NN-Neu-D: epochs = 40; and  
e) NN-Neu-E: epochs = 40. 
As there are multiple sources of randomness, each model was repeated 10 times and the 
average performance metrics were calculated and reported. 
Model Performance 
The F1 scores of LR, SVM and NN models in the neuropathy cohort by A1C variability are 




Figure 13. Box plot of F1 scores of retinopathy cohort by modeling method and A1C 
variability 
Testing of Statistical Hypotheses 
The F1 scores using predictor set with single A1C are plotted in Figure 14. 
 
Figure 14. Box plot of F1 scores using predictor sets with single A1C by modeling method 
and microvascular complication 
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For statistical hypothesis 1, two-way ANOVA indicated a significant interaction between the 
effects of modeling method and microvascular complication on F1 scores, F(4, 90) = 21.75, 
p<.0001 (Table 15). There was statistically significant difference in F1 scores between ML 
and LR models (F=403.92, p<0.0001).  
Table 15. Two-way ANOVA testing the effect of modeling method and microvascular 
complication on F1 scores (n=99) 
 
An examination of the interaction indicates that the interaction was mainly between the 
modeling methods of SVM and NN (Figure 15).  
 
Figure 15. Interaction plot for F1 scores by microvascular complication and modeling 
method 




F Value P 
Modeling method 2 0.861 0.431 202.08 <.0001 
Microvascular complication 2 0.048 0.024 11.29 <.0001 
Interaction term 4 0.185 0.046 21.75 <.0001 
      
Model 8 1.095 0.137 64.22 <.0001 
Error 90 0.192 0.002   
Corrected Total 98 1.287    
      
Contrast: ML vs LR 1 0.861 0.861 403.92 <.0001 
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Post hoc Tukey-Kramer test was further conducted to determine adjusted pairwise differences 
between modeling methods. There was significant difference between LR and SVM 
(p<0.0001) and between LR and NN (p<0.0001). There was no significant difference 
between the method of SVM and NN (p>0.05) (Figure 16).  
 




For statistical hypothesis 2, three-way ANOVA indicated significant interactions at all levels 
(Table 16). In order to evaluate the effect of A1C variability on the prediction for each 
microvascular complication, two-way ANOVA was further performed within each cohort, 
respectively. 
Table 16. Three-way ANOVA testing the effect of modeling method, microvascular 
complication and A1C variability on F1 scores (n=495)  
 
In the nephropathy cohort, two-way ANOVA indicated significant interaction between 
modeling method and A1C variability (Table 17). There was statistically significant 
difference in F1 scores between ML and LR models (F=119.03, p<0.0001).  
Table 17. Two-way ANOVA testing the effect of modeling method and A1C variability on 
F1 scores of the nephropathy cohort (n=165) 




F Value P 
Modeling method (X1) 2 4.762 2.381 902.37 <.0001 
Microvascular 
complication (X2) 
2 0.174 0.087 32.88 <.0001 
A1C variability (X3) 4 0.010 0.003 0.97 0.423 
X1*X2 4 0.785 0.196 74.37 <.0001 
X1*X3 8 0.057 0.007 2.71 0.006 
X2*X3 8 0.049 0.006 2.33 0.018 
X1*X2*X3 16 0.103 0.006 2.44 0.001       
Model 44 5.940 0.135 51.16 <.0001 
Error 450 1.187 0.003 
  
Corrected Total 494 7.128 
   




F Value P 
Modeling method 2 0.632 0.316 63.27 <.0001 
A1C variability  4 0.032 0.008 1.61 0.173 
Interaction term 8 0.119 0.015 2.98 0.004       
Model 14 0.783 0.056 11.20 <.0001 





An examination of the interaction indicates that the interaction was mainly between the 
modeling methods of SVM and NN (Figure 17).  
 
Figure 17. Interaction plot for F1 scores of the nephropathy cohort by microvascular 
complication and A1C variability 
 
F test indicates that A1C variability had significant effect on F1 score of the nephropathy 
cohort when the modeling method was NN: F=6.78, p<.0001. Post hoc Tukey-Kramer test 
indicates that mean F1 scores of the nephropathy cohort from NN models using d) 
combination mean or e) multiple were significantly higher than using b) mean A1C or c) 
combination single. 
 
Corrected Total 164 1.533 
   
      
Contrast: ML vs LR 1 0.595 0.595 119.03 <.0001 
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In the retinopathy cohort, two-way ANOVA did not indicate significant interaction between 
modeling method and A1C variability (Table 18). There was statistically significant 
difference in F1 scores between ML and LR models (F=119.03, p<0.0001). There is no effect 
of A1C variability on F1 scores of the retinopathy cohort. 
Table 18. Two-way ANOVA testing the effect of modeling method and A1C variability on 
F1 scores of the retinopathy cohort (n=165) 
 
In the neuropathy cohort, two-way ANOVA indicated significant interaction between 
modeling method and A1C variability (Table 19).  
Table 19. Two-way ANOVA testing the effect of modeling method and A1C variability on 
F1 scores of the neuropathy cohort (n=165) 
 




F Value P 
Modeling method 2 3.796 1.898 1652.32 <.0001 
A1C variability  4 0.004 0.001 0.98 0.418 
Interaction term 8 0.004 0.0006 0.49 0.861       
Model 14 3.805 0.272 236.61 <.0001 
Error 150 0.172 0.001 
  
Corrected Total 164 3.977 
   
      
Contrast: ML vs LR 1 0.595 0.595 119.03 <.0001 




F Value P 
Modeling method 2 1.119 0.559 315.79 <.0001 
A1C variability  4 1.119 0.559 315.79 <.0001 
Interaction term 8 0.036 0.004 2.58 0.011       
Model 14 1.178 0.084 47.50 <.0001 
Error 150 0.266 0.002 
  
Corrected Total 164 1.444 
   
      
Contrast: ML vs LR 1 1.118 1.118 631.20 <.0001 
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An examination of the interaction indicates that the interaction was between the modeling 
methods of SVM and NN (Figure 18).  
 
Figure 18. Interaction plot for F1 scores of the neuropathy cohort by microvascular 
complication and A1C variability 
 
F test indicates that A1C variability had significant effect on F1 score of the neuropathy 
cohort when the modeling method was LR: F=8.19, p<.0001. Post hoc Tukey-Kramer test 
indicates that mean F1 score of the neuropathy cohort from LR models using e) multiple was 
significantly lower than using other A1C variability measures. 
In CHAPTER 6, the results of the study, its implications, strengths, and limitations will be 
discussed and future research will be recommended. 
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CHAPTER 6  
Discussion, Recommendation, and Conclusions 
Discussion 
The objectives of this research were to 1) develop predictive models for diabetic 
nephropathy, retinopathy and neuropathy using conventional LR and two ML methods (SVM 
and NN) and compare their performance based on F1 score; and 2) evaluate whether ML 
methods differ from LR in utilizing A1C variability for the prediction of diabetic 
nephropathy, retinopathy, and neuropathy. This chapter begins with a discussion of the key 
findings and their implications. Following that, the strengths and limitations of the study as 
well as recommendation for future research will be discussed. The chapter will end with 
conclusions. 
The study found that mean F1 scores (0.38) of ML models were significantly higher than that 
of conventional LR models (0.19) across predicted outcomes. Specifically, two-way ANOVA 
test indicated that SVM and NN models produced higher F1 scores than LR models in 
predicting diabetic nephropathy, retinopathy, and neuropathy. F1 scores of SVM models and 
NN models did not differ significantly. The difference in F1 score between ML models and 
LRs was larger in the cohort of retinopathy and this may be due to worse performance of LR 
in this cohort.  
When different predictor sets were used for prediction, more specifically, when different 
levels of A1C variability was employed while keeping other covariates the same, no 
significant difference in F1 score was found between ML and LR methods in utilizing A1C 
variability for prediction. In the cohort of diabetic nephropathy, F test indicates that A1C 
variability had significant effect on F1 score when the modeling method was NN. Post hoc 
Tukey-Kramer test indicates that mean F1 scores of the nephropathy cohort from NN models 
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using d) combination mean or e) multiple were significantly higher than using b) mean A1C 
or c) combination single. There is no effect of A1C variability on F1 scores of the retinopathy 
cohort. In the cohort of neuropathy, F test indicates that A1C variability had significant effect 
on F1 score when the modeling method was LR. Post hoc Tukey-Kramer test indicates that 
mean F1 score of the neuropathy cohort from LR models using e) multiple was significantly 
lower than using other A1C variability measures. 
This was among the first studies that developed predictive models for microvascular 
complications in T1D patients with a specific focus on improving the F1 score. This has 
important clinical implications because F1 scores better represented the model’s capability in 
identifying less represented level of a class – patients who were at risk for a disease. If 
applied, these models can help clinicians, hospitals and managed care organizations capture 
high-risk patients and interventions can be followed based on predicted risk scores. Previous 
predictive models for microvascular complications among T1D patients were based on 
accuracy or AUC, which were not good indicators for the model’s ability in identifying high-
risk patients.  
This study explicitly compared the performance between ML models and LR models and 
indicated ML models performed significantly better even when using the same predictor set. 
Between the two ML methods, SVM and NN, no significant difference was found in their 
performance across cohorts. The F1 scores of LR models were rather low: between 0.07 and 
0.24. ML models improved the average F1 scores to an average of 035-0.39, although still 
not satisfactory. However, the sensitivity of predictive models increased from the average of 
0.04-0.14 of LR models to 0.63-0.72 of SVM models and 0.66-0.75 of NN models. This 
suggested that conventional LR models could only identify a maximum of 14% of patients 
who were at risk, whereas ML models improved this number to above 70%. There is much 
room to improve in terms of precision, with the average precision scores of ML models 
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below 0.3. However, laboratory tests are readily available for T1D patients and those who 
were suspected can be easily confirmed by a follow-up lab test.   
When the last 3 A1C values were considered in the models, the prediction of diabetic 
nephropathy was significantly improved using the modeling method of NN. Hence, the 
optimal predictive model for a certain disease would depend on both the predictors used and 
the modeling method. LR models indicated that A1C variability, more specifically, SD-A1C 
was significantly associated with diabetic nephropathy and neuropathy among T1D patients. 
LR models in this study did not indicate a significant association between A1C variability 
and diabetic retinopathy. There was inconsistent evidence of the association between A1C 
variability and microvascular complications among T1D patients. Some suggested positive 
associations (Gorst et al., 2015) whereas other indicate non-association (Lachin et al., 2017). 
This research would add to current evidence and future research is needed to confirm the 
relationship. In future, HCPs can record patients’ last 3 A1C values and calculate their 
standard deviations for risk evaluation. Algorithms can be developed to better understand 
both the magnitude and direction of A1C variability in order to assess how A1C variability 
affect each microvascular complication in T1D patients.  
This study only included patients who had at least 3 A1C values in order to evaluate A1C 
variability. This may introduce sampling bias as patients who get tested more frequently may 
take better care of their health and be healthier than those who do not. This may limit the 
applicability of the developed predictive models to patients who are tested more frequently. It 
was reported that patients who did not take frequent retest for A1C achieved worse A1C 
control (Driskell et al., 2014). A study assessed daily blood glucose monitor frequency and 
glucose control and indicated significant racial health disparity in adolescent patients with 
T1D (Chalew et al., 2018). Specifically, black T1D patients with less social advantage were 
less likely to take blood test regularly and manage their blood glucose well. Since our study 
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sample is mainly composed of white patients who had relatively higher social economic 
status and participated in the T1D exchange clinic registry, the predictive models may not 
produce accurate prediction in less advantaged patient population and other races such as 
black.  
Predictors selected for each microvascular complication was similar to those used in previous 
studies (Aspelund et al., 2011; Kazemi et al., 2016; Lagani et al., 2015; Ravizza et al., 2019; 
Skevofilakas et al., 2010; Vergouwe et al., 2010). This research took into account the 
different insulin regimens used by patients and did not find significant association between 
insulin types and microvascular complications. The overall astounding costs for insulin has 
been heavily debated and there were research suggesting the use of the less expensive 
intermediate acting Neutral Protamine Hagedorn (NPH) insulins instead of insulin analogs 
such as detemir and glargine (Cefalu et al., 2018; Lipska, Hirsch, & Riddle, 2017; Luo, 
Avorn, & Kesselheim, 2015). However, as most T1D patients in this study were using insulin 
analogs, the effect of insulin NPH insulin on microvascular complications among T1D 
patients cannot be determined. This research did not find use of other medications for blood 
glucose control had a significant effect on any microvascular complication among T1D 
patients, either.  
Managing T1D is expensive and two fifths of the costs were reported to be related to 
managing T1D complications (Joish et al., 2020). Predictive models can serve as a useful tool 
for healthcare providers and clinicians. For diabetic retinopathy, it usually takes a long time 
and multiple ophthalmic photography images to confirm its diagnosis. Early prediction can 
help optometrists consider closer monitoring and preventive interventions for at-risk patients. 
Many patients with diabetic neuropathy have no symptoms in its early stages and are left 
undiagnosed until it’s too late. Predictive models with a high capability in identifying patients 
at risk can enable general doctors to refer patients at risk to neurologists earlier and take 
126 
 
proactive interventions. Future research is needed to facilitate the clinical application of 
predictive models. Moreover, prescriptive analytics should accompany the research in 
predictive modelling. Prescriptive analytics can tell us what to do once a prediction is made 
and a diagnosis is confirmed.(Abid, Keshavjee, Karim, & Guergachi, 2017; Islam, Hasan, 
Wang, Germack, & Noor-E-Alam, 2018). Prescriptive analytics can supplement predictive 
modelling by guiding clinicians to choose between difference courses of actions given a 
patient’s risk.  
Strengths & Limitations 
Strengths 
This study was among the first to target F1 score for risk prediction of diabetic nephropathy, 
retinopathy, and neuropathy. We aimed to focus on F1 score because F1 score reflected the 
model’s ability to identify patients who were at risk. The study was also among the first that 
explicitly compared the performance of different modeling methods and different predictor 
sets, and tested the difference using statistical tests. Whereas previous studies only provided 
results of one performance metric and did not make statistical inference of the performance 
between different modeling methods. The prediction models were based on data from the 
largest registry of T1D patients in the United States. Patients were residing across vast areas 
of the U.S. They have been receiving standard care from participating hospitals and clinics 
and followed by the registry once a year. The registry data were updated by information from 
the participant questionnaire as well as from their electronic medical records and are well-
documented in the registry. Thus, the database provides the foundation of valid prediction of 
long-term microvascular complications. In addition to cross-sectional measures, the dataset 
also captures longitudinal measures of A1C levels for each individual patient. This permits us 




Methodological limitations: Due to lack of time to event measures in our data, we cannot 
predict time to progression to microvascular complications in this study. As we tried to 
compare performance of different modelling methods, ensemble of multiple modelling 
methods were not attempted (Geron, 2017). ‘Ensemble learning’ refers to the method of 
aggregating two or more ML algorithms to build even more complex models (Geron, 2017). 
Ensemble or stacking of ML algorithms will assign a weight to multiple algorithms and yield 
a weighted average of their outputs. The predictive models of SVM and NN were difficult to 
interpret. And we were unable to test the predictive models on an external dataset. 
Database limitations: As majority of our patients were White, our study cannot be used to 
identify ethnicity risk groups for any of the three microvascular complications. Nor can we 
identify risk factors for the three types of microvascular complications among other ethnicity 
groups due to lack of data. The diagnosis of peripheral neuropathy may be significantly 
higher than recorded in the database because on one hand, individuals with symptoms of 
neuropathy may not all have been tested for the disease and on the other hand, current tests 
for neuropathy may not cover all forms of the disease and the complexity as well as 
variability of neuropathy symptoms may lead to under- or mis- diagnosis (Peripheral 
neuropathy fact sheet, 2018). Due to limitation of the registry database, we could not obtain 
information of time in range (TIR) among patients who have been using CGM. Other 
lifestyle factors of patients such as alcohol use and safe drinking (Viswanathan, 2015), which 
can contribute to diabetic neuropathy was not captured. Future research is needed to 
incorporate TIR into the models and see how it impacts the prediction performance of the 
models. However, we need to bear in mind the possible false positives reported by CGM for 
prediction of hypoglycemia because the data reported by CGM is also based on mathematical 
algorithms that are not ‘true’ patient data (Cichosz et al., 2015).  
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In CHAPTER 7, a summary of this research will be provided. 
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CHAPTER 7  
Summary 
This study used a factorial experimental design that employed real-world registry data to 
develop predictive models for three types of microvascular complications in T1D patients. 
Three factors, i.e., modelling method, microvascular complication, and A1C variability were 
manipulated and their effect on performance measure was evaluated. Specifically, modelling 
method was operationalized as two levels, conventional statistical method (LR) and ML 
methods, which are further manipulated into two levels, SVM and NN. Microvascular 
complication was manipulated as three levels, i.e., diabetic nephropathy, retinopathy, and 
neuropathy. A1C variability was manipulated as five levels, i.e., a) single A1C, b) mean 
A1C, c) combination single, d) combination mean, and e) multiple. Performance measure was 
operationalized as F1 score. A total of 495 models were developed and their performance in 
terms of F1 score compared. 
Factorial ANOVA indicates that ML methods (SVM and NN) performed significantly better 
than conventional statistical method (LR) irrespective of microvascular complication or A1C 
variability. There is minor interaction between the two ML methods, i.e., SVM and NN. In 
other words, SVM and NN had different effect within different levels of microvascular 
complication and A1C variability. However, the interaction was deemed not important and 
their performance in terms of mean F1 score was not significantly different.  
There is significant difference in model performance for predicting diabetic nephropathy in 
T1D patients when using different A1C variability measures under the modeling method of 
NN. However, A1C variability does not have a significant effect for the prediction of diabetic 
retinopathy or neuropathy, no matter what modeling method was used.  
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This study provides much needed empirical data on the comparison between ML and 
conventional statistical methods and implies that ML methods are superior to conventional 
statistical method in this study and should be used for prediction. NN models were found to 
utilize A1C variability better for predicting diabetic nephropathy. The last 3 A1C measures of 
a patient may be considered by clinicians for managing their T1D patients, especially for 
preventing diabetic nephropathy. Future research is needed to develop algorithms to better 
calculate A1C variability to monitor T1D progression.  
This study focused on predicting microvascular complications in adult T1D patients. Future 
research may apply predictive models to pediatric population, type 2 diabetes, and other 
disease areas. Future research is also needed to develop decision support systems that can 

















Generic Name (Brand Name, Company & Year of 
Initial FDA Approval) 
Onset  Duration of 
Action 
Rapid acting • Lispro (Humalog®, Eli Lilly, 1996; Admelog®, 
Sanofi-Aventis, 2017) 
• Aspart (Novolog®, Novo Nordisk, 2000; Fiasp®, 
Novo Nordisk, 2017) 




Short acting • Insulin human or regular (R) (Humulin® R, Eli Lilly, 






• NPH (N) or isophane insulin (Humulin® N, Eli Lilly, 
1982; Novolin® N, Novo Nordisk, 1991) 
1-3 hours 18-24 hours 
Long acting • Glargine (Lantus® and Lantus® SoloStar®, Sanofi-
aventis, 2000; Toujeo® SoloStar®, Sanofi-Aventis, 
2015; and Basaglar® KwikPen®, Eli Lilly, 2000) 
• Detemir (Levemir®, Novo Nordisk, 2005) 
• Degludec (Tresiba®, Novo Nordisk, 2015) 






• NPH and human insulin (Humulin® 70/30 & 
Humulin® 50/50, Eli Lilly, 1989; Novolin® 70/30, 
Novo Nordisk, 1991) 
• Lispro protamine and Lispro: intermediate-rapid 
insulin mixture: similar to mixing NPH & lispro 
(Humalog® Mix 75/25 and Humalog® Mix 50/50, 
Eli Lilly, 1999) 
• Aspart protamine suspension and insulin aspart 
(Novolog® Mix 70/30 and Novolog® Mix 50/50, 
Novo Nordisk, 2001)  
• Degludec and aspart: long-rapid insulin mixture 




*Pre-mixed insulins combine specific amounts of intermediate-acting and short-acting insulin in 
one bottle or insulin pen. The numbers following the drug brand name indicate the percentage of 
each type of insulin. 
132 
 
Appendix 2. Definition of “definite T1D” 
“Definite T1D” was assessed by the registry and all the participants in the registry are already 
confirmed with definite T1D. Participants need to meet one of the following criteria to be 
classified as having definite Type 1 diabetes: 
1. Age less than 10 years at diagnosis; 
2. Positive pancreatic autoantibodies at any time (GAD-65, IA-2, ICA, or ZnT8) or positive 
anti-insulin autoantibody at diagnosis only (within 10 days of starting insulin); or 
3. The presence of two or more of the following clinical indicators suggestive of T1D: 
• Age at diagnosis less than 40 years; 
• Non-obese at diagnosis according to body mass index (<95th percentile pediatric and 
<30 kg/m2 adult); 
• Diabetic ketoacidosis (DKA) at any time; 
• Plasma C-peptide level below 0.8 ng/ml (with blood glucose   80 mg/dl if available) at 
any time; and 




Appendix 3. Operational definition of study measures 




Defined as “yes”  
if in the subject file (of either follow-up dataset), the patient indicated 
having any of the following conditions:  
• Albuminuria or macroalbuminuria (Albuminuria/macroalbuminuria is 
defined as 2 consecutive ACRs >300 mcg/mg or 2 out of the past 3.) 
• A glomerular filtration rate <60 ml/min  
AND the participants did not indicate if the renal disease was believed to 
be solely due to a cause other than diabetes. 
Or if the medical condition file (of either follow-up dataset) indicated any 
of the following MedDRA condition for the patient:  
• Chronic kidney disease 
• Diabetic nephropathy 
• Protein urine present 
• Proteinuria 
Note: Patients with a MedDRA condition of acute renal failure were 
excluded from the analysis because it can be caused by an injury of kidney 
other than the progression of diabetes; MedDRA conditions of chronic 
renal failure, end stage renal disease (ESRD), kidney failure, kidney 
transplant, renal failure, or renal insufficiency were excluded as well, 
because these conditions usually take a long time (over 20 years) to 
develop. Hence, patient who had a diagnosis of any of these conditions 
should usually already have had diabetic nephropathy at baseline and 
were excluded. Definitions of kidney failure or ESRD can be found at the 
K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: 
Evaluation, classification, and stratification (available at 
https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classific
ation_stratification.pdf, last accessed 07/27/2019). Patients with a history 
of kidney function abnormal, renal disease or renal impairment were not 
considered as indication for diabetic nephropathy, as they may be caused 
by a reason other than diabetes. 
Retinopathy (yes/no) Defined as “yes”  
if in the subject file (of either follow-up dataset), the patient indicated 
having any of the following conditions:  
• Diabetic macular edema 
• Vitreous hemorrhage 
• Non-proliferative retinopathy 
• Proliferative retinopathy 
or receiving any of the following eye treatment:  
• Intravitreal injection (such as Lucentis, Avastin, Macugen, or 
Triamcinolone) 
• Vitrectomy  
• Other treatment (laser treatment to correct nearsightedness or 
farsightedness is not included) 
Or if the medical condition file (of either follow-up dataset) indicated any 
of the following MedDRA condition for the patient:  
• Diabetic macular edema 
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• Diabetic retinopathy 
• Macular edema 
• Non-proliferative diabetic retinopathy 
• Preproliferative diabetic retinopathy 
• Proliferative diabetic retinopathy 
Note: Patients with blindness anytime during the study were excluded 
from the analysis. Operational definition of diabetic retinopathy was 
discussed with and confirmed by three clinicians in optometry (Drs. 
Carolyn R. Carman, Jennifer Tasca, and Joe L. Wheat from University of 
Houston College of Optometry). 
Neuropathy (yes/no) Defined as “yes”  
if in the subject file (of either follow-up dataset), the patient indicated 
having any of the following conditions:  
• Diabetic peripheral neuropathy 
• Autonomic neuropathy 
• Gastroparesis 
Or if the medical condition file (of either follow-up dataset) indicated any 
of the following MedDRA condition for the patient:  
• Peripheral neuropathy NOS 
• Neuropathy 
• Neurogenic bladder 
• Gastroparesis 
• Diabetic peripheral neuropathy 
• Diabetic neuropathy 
• Diabetic mononeuropathy 
• Diabetic polyneuropathy (data does not have this indication) 
• Diabetic gastroparesis 
• Charcot's joint 
• Charcot arthropathy 
Note: Patients who reported to have gastroparesis or who had a history of 
gastroparesis, peripheral neuropathy NOS, neuropathy, neurogenic 
bladder, gastroparesis, diabetic gastroparesis, Charcot's joint, or Charcot 
arthropathy are considered to have diabetic neuropathy during follow-up 
because these conditions are usually caused by diabetic neuropathy in 
diabetic patients. This is based on the assumption that these patients did 
not have any type of these conditions at baseline. But we cannot exclude 
that patients may already have had these conditions but was not 
diagnosed at baseline. Patients with a history of numbness in hand, 
numbness generalized, leg amputation, foot ulcer, foot amputation, 
diabetic ulcer NOS, diabetic foot ulcer, erectile dysfunction or arm 
amputation were not considered as indications of diabetic neuropathy 
because these conditions are more likely to be caused by vascular 
conditions other than diabetic neuropathy. 
Predictors 
Individual Characteristics 
A1C (%) • Single A1C value: most recent A1C value recorded in clinic chart 
• A1C variability: For each patient, a total of 3 A1C values that were 
closest to the consent date were included into the analysis. Each of 
these A1C values had to be at least 3 months apart. If a patient had 
multiple A1C values that were measured within the “3-month gap”, 
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then the mean of these multiple A1C values were calculated to 
impute the point value and the first date that went beyond the 3-
month gap was used to impute the point 
“HbA1cMonthsFromConsent” value.  
o Mean-A1C: The average of the most recent (including some 
“imputed”) 3 A1C values was calculated as the mean A1C 
value for a patient. 
o SD-A1C: For LR, as correlated A1C values cannot be 
incorporated into the model directly, A1C variability was 
defined as standard deviation (SD) of the most recent 
(including some “imputed”) three A1C values that were 
measured at least three months apart.  
o CV-A1C: coefficient of variation of A1C, calculated as SD-A1C 
divided by mean-A1C 
Age at baseline • In years; Defined as age at consent indicated in subject file 
• Age categories: 18-27 years; 28-37 years; 38-47 years; 48-64 years; ≥
65 years based on age distribution 
Duration of T1D  In years; Calculated as the difference between age at consent and age of 
T1D diagnosis indicated in subject file 
Gender Male or female indicated in subject file 
Race Categorized as 1) White non-Hispanic, 2) Black/African American, 3) 
Hispanic or Latino, or 4) others (including native Hawaiian/other Pacific 
Islanders, Asian, American Indian/Alaskan native, or more than one 
race/ethnicity) indicated in subject file 
Education level Categorized as 1) less than bachelor's degree; 2) bachelor's degree; and 3) 
master's, professional, or doctorate 
Insurance coverage Categorized as 1) Commercial health insurance: private or single service 
insurance plan; 2) Government-sponsored insurance (Medicare, 
Medicaid, SCHIP, state, military, Indian, or other government insurance); 
and 3) others: not indicated as any insurance type above;  
When incorporated into predictive models, it was divided into two 
categories: commercial vs others. 
Marital status Categorized as 1) married or living together; or 2) divorced, separated, 
single (never married), or widowed indicated in subject file. 
Annual household 
income  
• Categorized as 1) <$50K, 2) $50K to $100K, or 3) >=$100K as indicated 
in subject file (self-reported). 
• When incorporated into predictive models, it was divided into two 
categories: >=100K vs <100K. 
Employment status • Categorized as 1) Working full time or part-time at baseline; 2) 
Student or homemaker; or 3) Unemployed, retired, disabled or other 
• When incorporated into predictive models, it was dummy coded into 
two variables using ‘Working full time or part time’ as the reference 
group. 
Body mass index 
(BMI) 
• In kg/m2; Calculated by clinic chart indication of weight in kilograms 
divided by height in meters squared. (Height unavailable at baseline 
was imputed from follow-up datasets when available) 
• BMI category: 1) under or normal weight, 2) overweight, 3) obese 
Blood pressure 
(mmHg) 
Blood pressure indicated in clinic chart: 
• Systolic blood pressure (SBP)  





• Low-density lipoprotein (LDL) 
• High-density lipoprotein (HDL) 
• Triglyceride  
• Lipid fasting status (fasting, not fasting, unknown) 
Health Behavioural Factors 
Smoking status 
(yes/no) 
• Ever smoked: defined as “yes” if a participant reported to have 
smoked at least 100 cigarettes (100 cigarettes = 5 packs) in his/her 
entire life   
• Smoking at baseline: defined as “yes” if a participant reported to have 
smoked at least 100 cigarettes (100 cigarettes = 5 packs) in his/her 
entire life and did not indicate that he/she did not smoke at all 
anymore 
Insulin used at 
baseline 
• Insulin delivery method: 1) Pump only, 2) injections (MDI/basal-bolus 
or fixed dose) only, or 3) both pump and injections as indicated in 
subject file. 
• Name/Type of insulin: insulin lispro (Humalog), insulin aspart 
(Novolog), insulin detemir (Levemir), insulin glargine (Lantus) 
Use of CGM (yes/no) At the most recent visit or sometime within the 30 days before the visit, 
was the participant using a continuous glucose monitor (CGM), for real-
time, unblinded diabetes management: Yes or no as indicated in subject 
file. 
Use of other 
medications for 
blood glucose control 
(yes/no) 
Defined as ‘yes’ if participant reported or indicated in HER the use of 
other medications for blood glucose control, including dipeptidyl 
peptidase-4 (DPP4) Inhibitors, glucagon-like peptide-1 (GLP1) agonists, 
metformin, pramlintide or other medications. 
Use of ACE inhibitors 
or ARBs (yes/no) 
• Use of angiotensin-converting enzyme (ACE) inhibitors (yes/no): Use 
of any of the following medications as indicated in medication file at 
baseline: 
o benazepril or benazepril hydrochloride 
o captopril 
o enalapril 




o quinapril  
o ramipril 
o trandolapril 
• Use of angiotensin II receptor blocker (ARBs) (yes/no): Use of any of 








• Use of either ACE inhibitors or ARBs (yes/no): Use of any of the above 
ACE inhibitors or ARBs as indicated in the medication file or reported 
by participants questionnaire. 
137 
 
Note: Use of ACE inhibitors or ARBs may not add up to use of either ACE 
inhibitors or ARBs because the former two was defined using information 
contained in the medication file only whereas the latter was defined using 
information from both the medication file and participant questionnaire. 
Comorbidities at Baseline 
Microalbuminuria 
(yes/no) 
Defined as "yes" if a patient indicated an albumin status of 
microalbuminuria (Microalbuminuria is defined as 2 consecutive 
albumin/creatinine ratios in the range of 30-300 mcg/mg or 2 out of the 




• Diabetic nephropathy: operationalized by measures from the 
participant questionnaire; Defined as "yes" if a patient had an 
albumin status of albuminuria/macroalbuminuria, or had a GFR that 
was below 60, or had a diagnosis of renal failure, or a diagnosis of 
nephropathy due to other causes, or had received ACE or ARB for 
diabetic nephropathy. 
• Diabetic retinopathy: operationalized by measures from the 
participant questionnaire; Defined as "yes" if a patient was legally 
blind or had received ACE or ARB for diabetic retinopathy, or had 
received any treatment for diabetic retinopathy, or had received 
cataract surgery, or had received surgery for glaucoma. 
• Diabetic neuropathy: operationalized by measures from both the 
participant questionnaire and the medical condition file; Defined as 
"yes" if a patient reported that foot ulcer was present, or had a 
history of and history of amputation of toe or knee, erectile or sex 
dysfunction, diabetic neuropathy, Charcot joint, orthostatic 




• Hypertension (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of hypertension 
• Dyslipidemia (yes/no): defined as “yes” if the medical condition file at 
baseline indicated any of the following MedDRA conditions: 
o High Triglycerides 
o Dyslipidemia 
o Dyslipidemia unspecified 
o High LDL 
o Low HDL 
• CAD (coronary artery diseases, yes/no): defined as “yes” if the 
medical condition file at baseline indicated any of the following 
procedures: 
o Coronary artery bypass graft  
o Coronary artery angioplasty 
Or any of the following MedDRA conditions:  
o Myocardial infarction (MI, heart attack) 
o Coronary artery disease, without myocardial infarction 
o Cardiomyopathy 
o Congestive heart failure 
• PVD (Peripheral vascular disease): defined as “yes” if the medical 
condition file at baseline indicated any of the following MedDRA 
conditions: 
o Peripheral vascular disease  
o Peripheral vascular claudication 
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o Amputation of knee or toe 
• Cardiac arrhythmia (yes/no): defined as “yes” if the medical condition 
file at baseline indicated any of the following MedDRA conditions: 
o Atrial fibrillation  
o Other cardiac arrhythmia 
o Cardiac pacemaker 
• CVA (cerebrovascular accident, yes/no): defined as “yes” if the 
medical condition file at baseline indicated any of the following 
MedDRA conditions: 
o Stroke  
o Transient ischemic attack (TIA) 
Endocrine diseases • Hypothyroidism (yes/no): defined as “yes” if the medical condition file 
at baseline indicated any of the following MedDRA conditions: 
o Hypothyroid 
o Hashimoto’s disease 
• Hyperthyroidism (yes/no): defined as “yes” if the medical condition 
file at baseline indicated any of the following MedDRA conditions: 
o Hyperthyroid 
o Grave’s disease 
• Other endocrine diseases (yes/no): defined as “yes” if the medical 
condition file at baseline indicated any of the following MedDRA 
conditions: 
o Autoimmune adrenal disease (Addison’s disease)  
o Autoimmune polyendocrine syndrome (type 2) or Schmidt’s 
syndrome 
o Polycystic ovarian syndrome (PCOS) 
Gastrointestinal 
diseases (yes/no) 
• Defined as “yes” if the medical condition file at baseline indicated any 
of the following MedDRA conditions: 
o Celiac disease   
o Vitamin B12 deficiency/pernicious anemia 





• Arthritis (yes/no): defined as “yes” if the medical condition file at 
baseline indicated any of the following MedDRA conditions: 
o Rheumatoid arthritis  
o Osteoporosis/osteopenia 
• Lupus (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of Lupus 
• Sjogrens (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of Sjogrens 
• Dermatomyositis (yes/no): defined as “yes” if the medical condition 
file at baseline indicated MedDRA condition of dermatomyositis 
Psychiatric conditions • Depression (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of depression 
• Anxiety (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of anxiety 
• Psychosis (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of psychosis 
• ADHD (yes/no): defined as “yes” if the medical condition file at 
baseline indicated MedDRA condition of Attention Deficit 






• Eating disorder (yes/no): defined as “yes” if the medical condition file 
at baseline indicated any of the following MedDRA conditions: 
o Bulimia 
o Anorexia 
o Bulimia and Anorexia   
o Binge eating   
o Eating disorder not otherwise specified (EDNOS)   
o Intentional omission/restriction of insulin for weight loss   
Skin disorders 
(yes/no) 
Defined as “yes” if the medical condition file at baseline indicated any of 
the following MedDRA conditions: 
• Vitiligo 
• Necrobiosis lipoidica diabeticorum (NLD) 
• Psoriasis 
• Alopecia areata 
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Appendix 4. Examples of accuracy and loss curves of the train and validation set using the 5 
predictor sets A through E in cohorts of nephropathy, retinopathy and neuropathy  
Cohort of Nephropathy 
a) ‘Single A1C’ set 
  
b) ‘Mean-A1C’ set 
 
 
c) ‘Single A1C + SD-A1C’ set 
  




e) ‘3 A1C + SD-A1C’ set 
  
Cohort of Retinopathy 
a) ‘Single A1C’ set 
  
b) ‘Mean-A1C’ set 
  




d) ‘Mean-A1C + SD-A1C’ set 
  
e) ‘3 A1C + SD-A1C’ set 
  
Cohort of Neuropathy 
a) ‘Single A1C’ set 
  






c) ‘Single A1C + SD-A1C’ set 
  
d) ‘Mean-A1C + SD-A1C’ set 
  











score Sensitivity Precision Accuracy Specificity AUC 
1 LR Single A1C 0.140 0.075 1.000 0.895 1.000 0.771 
2 LR Single A1C 0.178 0.098 1.000 0.896 1.000 0.756 
3 LR Single A1C 0.292 0.171 1.000 0.904 1.000 0.835 
4 LR Single A1C 0.392 0.244 1.000 0.912 1.000 0.819 
5 LR Single A1C 0.217 0.122 1.000 0.898 1.000 0.784 
6 LR Single A1C 0.178 0.098 1.000 0.895 1.000 0.802 
7 LR Single A1C 0.178 0.098 1.000 0.895 1.000 0.740 
8 LR Single A1C 0.392 0.244 1.000 0.913 1.000 0.757 
9 LR Single A1C 0.360 0.220 1.000 0.908 1.000 0.750 
10 LR Single A1C 0.182 0.100 1.000 0.899 1.000 0.731 
11 LR Single A1C 0.226 0.128 1.000 0.900 1.000 0.751 
12 LR Mean A1C  0.140 0.075 1.000 0.895 1.000 0.768 
13 LR Mean A1C  0.217 0.122 1.000 0.899 1.000 0.749 
14 LR Mean A1C  0.292 0.171 1.000 0.904 1.000 0.809 
15 LR Mean A1C  0.392 0.244 1.000 0.912 1.000 0.820 
16 LR Mean A1C  0.217 0.122 1.000 0.898 1.000 0.779 
17 LR Mean A1C  0.178 0.098 1.000 0.895 1.000 0.805 
18 LR Mean A1C  0.136 0.073 1.000 0.893 1.000 0.751 
19 LR Mean A1C  0.392 0.244 1.000 0.913 1.000 0.763 
20 LR Mean A1C  0.360 0.220 1.000 0.908 1.000 0.757 
21 LR Mean A1C  0.182 0.100 1.000 0.899 1.000 0.736 
22 LR Mean A1C  0.211 0.118 1.000 0.899 1.000 0.749 
23 LR 
Combination 
single 0.140 0.075 1.000 0.895 1.000 0.771 
24 LR 
Combination 
single 0.178 0.098 1.000 0.896 1.000 0.759 
25 LR 
Combination 
single 0.292 0.171 1.000 0.904 1.000 0.841 
26 LR 
Combination 
single 0.360 0.220 1.000 0.910 1.000 0.815 
27 LR 
Combination 
single 0.217 0.122 1.000 0.899 1.000 0.786 
28 LR 
Combination 
single 0.178 0.098 1.000 0.895 1.000 0.803 
29 LR 
Combination 
single 0.178 0.098 1.000 0.895 1.000 0.742 
30 LR 
Combination 
single 0.392 0.244 1.000 0.913 1.000 0.760 
31 LR 
Combination 
single 0.360 0.220 1.000 0.908 1.000 0.752 
32 LR 
Combination 
single 0.182 0.100 1.000 0.899 1.000 0.735 
33 LR 
Combination 





mean 0.140 0.075 1.000 0.895 1.000 0.769 
35 LR 
Combination 
mean 0.178 0.098 1.000 0.896 1.000 0.754 
36 LR 
Combination 
mean 0.292 0.171 1.000 0.904 1.000 0.816 
37 LR 
Combination 
mean 0.360 0.220 1.000 0.910 1.000 0.818 
38 LR 
Combination 
mean 0.255 0.146 1.000 0.901 1.000 0.781 
39 LR 
Combination 
mean 0.178 0.098 1.000 0.895 1.000 0.806 
40 LR 
Combination 
mean 0.178 0.098 1.000 0.895 1.000 0.749 
41 LR 
Combination 
mean 0.392 0.244 1.000 0.913 1.000 0.763 
42 LR 
Combination 
mean 0.360 0.220 1.000 0.908 1.000 0.757 
43 LR 
Combination 
mean 0.182 0.100 1.000 0.899 1.000 0.739 
44 LR 
Combination 
mean 0.211 0.118 1.000 0.899 1.000 0.750 
45 LR Multiple  0.182 0.100 1.000 0.898 1.000 0.743 
46 LR Multiple  0.093 0.049 1.000 0.890 1.000 0.786 
47 LR Multiple  0.292 0.171 1.000 0.904 1.000 0.799 
48 LR Multiple  0.360 0.220 1.000 0.909 1.000 0.760 
49 LR Multiple  0.136 0.073 1.000 0.893 1.000 0.771 
50 LR Multiple  0.000 0.000 0.000 0.000 0.000 0.000 
51 LR Multiple  0.136 0.073 1.000 0.892 1.000 0.723 
52 LR Multiple  0.360 0.220 1.000 0.910 1.000 0.715 
53 LR Multiple  0.423 0.268 1.000 0.914 1.000 0.741 
54 LR Multiple  0.095 0.050 1.000 0.893 1.000 0.715 
55 LR Multiple  0.179 0.098 1.000 0.897 1.000 0.738 
56 SVM Single A1C 0.331 0.600 0.229 0.729 0.745 0.673 
57 SVM Single A1C 0.340 0.625 0.234 0.729 0.742 0.684 
58 SVM Single A1C 0.350 0.585 0.250 0.751 0.773 0.679 
59 SVM Single A1C 0.362 0.610 0.258 0.754 0.773 0.691 
60 SVM Single A1C 0.377 0.634 0.268 0.760 0.776 0.705 
61 SVM Single A1C 0.336 0.585 0.235 0.735 0.754 0.670 
62 SVM Single A1C 0.290 0.512 0.202 0.712 0.738 0.625 
63 SVM Single A1C 0.405 0.805 0.270 0.729 0.719 0.762 
64 SVM Single A1C 0.348 0.683 0.233 0.707 0.710 0.696 
65 SVM Single A1C 0.329 0.561 0.232 0.737 0.760 0.661 
66 SVM Single A1C 0.373 0.627 0.266 0.760 0.777 0.700 
67 SVM Mean A1C  0.329 0.625 0.223 0.715 0.726 0.676 
68 SVM Mean A1C  0.350 0.700 0.233 0.709 0.711 0.705 
69 SVM Mean A1C  0.372 0.659 0.260 0.746 0.757 0.708 
70 SVM Mean A1C  0.354 0.634 0.245 0.735 0.748 0.691 
71 SVM Mean A1C  0.336 0.610 0.231 0.723 0.738 0.674 
72 SVM Mean A1C  0.354 0.634 0.245 0.735 0.748 0.691 
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73 SVM Mean A1C  0.295 0.561 0.200 0.693 0.710 0.635 
74 SVM Mean A1C  0.388 0.805 0.256 0.709 0.697 0.751 
75 SVM Mean A1C  0.320 0.659 0.211 0.679 0.681 0.670 
76 SVM Mean A1C  0.360 0.659 0.248 0.732 0.741 0.700 
77 SVM Mean A1C  0.331 0.698 0.228 0.724 0.741 0.670 
78 SVM 
Combination 
single 0.327 0.600 0.224 0.723 0.739 0.669 
79 SVM 
Combination 
single 0.351 0.650 0.241 0.732 0.742 0.696 
80 SVM 
Combination 
single 0.328 0.537 0.237 0.749 0.776 0.656 
81 SVM 
Combination 
single 0.365 0.610 0.260 0.757 0.776 0.693 
82 SVM 
Combination 
single 0.364 0.634 0.255 0.746 0.760 0.697 
83 SVM 
Combination 
single 0.356 0.634 0.248 0.737 0.751 0.692 
84 SVM 
Combination 
single 0.288 0.512 0.200 0.709 0.735 0.624 
85 SVM 
Combination 
single 0.425 0.829 0.286 0.743 0.732 0.781 
86 SVM 
Combination 
single 0.350 0.683 0.235 0.709 0.713 0.698 
87 SVM 
Combination 
single 0.350 0.585 0.250 0.751 0.773 0.679 
88 SVM 
Combination 
single 0.360 0.608 0.256 0.754 0.773 0.690 
89 SVM 
Combination 
mean 0.329 0.575 0.230 0.737 0.758 0.666 
90 SVM 
Combination 
mean 0.342 0.625 0.236 0.732 0.745 0.685 
91 SVM 
Combination 
mean 0.326 0.537 0.234 0.746 0.773 0.655 
92 SVM 
Combination 
mean 0.385 0.634 0.277 0.768 0.785 0.710 
93 SVM 
Combination 
mean 0.373 0.610 0.269 0.765 0.785 0.698 
94 SVM 
Combination 
mean 0.372 0.659 0.260 0.746 0.757 0.708 
95 SVM 
Combination 
mean 0.308 0.537 0.216 0.723 0.748 0.642 
96 SVM 
Combination 
mean 0.397 0.756 0.270 0.737 0.735 0.746 
97 SVM 
Combination 
mean 0.321 0.634 0.215 0.693 0.700 0.667 
98 SVM 
Combination 
mean 0.329 0.561 0.232 0.737 0.760 0.661 
99 SVM 
Combination 
mean 0.339 0.569 0.242 0.748 0.771 0.670 
100 SVM Multiple  0.325 0.650 0.217 0.698 0.704 0.677 
147 
 
101 SVM Multiple  0.356 0.725 0.236 0.707 0.704 0.715 
102 SVM Multiple  0.378 0.659 0.265 0.751 0.763 0.711 
103 SVM Multiple  0.359 0.634 0.250 0.740 0.754 0.694 
104 SVM Multiple  0.327 0.585 0.226 0.723 0.741 0.663 
105 SVM Multiple  0.340 0.610 0.236 0.729 0.744 0.677 
106 SVM Multiple  0.301 0.561 0.205 0.701 0.719 0.640 
107 SVM Multiple  0.402 0.829 0.266 0.718 0.703 0.766 
108 SVM Multiple  0.345 0.707 0.228 0.693 0.691 0.699 
109 SVM Multiple  0.338 0.610 0.234 0.726 0.741 0.676 
110 SVM Multiple  0.323 0.578 0.224 0.724 0.743 0.660 
111 NN Single A1C 0.361 0.665 0.193 0.611 0.604 0.706 
112 NN Single A1C 0.362 0.810 0.196 0.597 0.571 0.775 
113 NN Single A1C 0.402 0.707 0.211 0.655 0.648 0.757 
114 NN Single A1C 0.421 0.722 0.223 0.650 0.641 0.779 
115 NN Single A1C 0.334 0.790 0.220 0.644 0.625 0.774 
116 NN Single A1C 0.405 0.715 0.196 0.613 0.600 0.744 
117 NN Single A1C 0.354 0.685 0.196 0.599 0.588 0.724 
118 NN Single A1C 0.356 0.968 0.244 0.638 0.595 0.900 
119 NN Single A1C 0.418 0.737 0.185 0.591 0.572 0.737 
120 NN Single A1C 0.397 0.661 0.236 0.705 0.711 0.773 
121 NN Single A1C 0.322 0.675 0.220 0.668 0.667 0.747 
122 NN Mean A1C  0.291 0.703 0.188 0.603 0.590 0.723 
123 NN Mean A1C  0.322 0.770 0.210 0.625 0.607 0.775 
124 NN Mean A1C  0.320 0.732 0.208 0.638 0.626 0.761 
125 NN Mean A1C  0.348 0.724 0.236 0.673 0.667 0.769 
126 NN Mean A1C  0.331 0.754 0.218 0.650 0.636 0.769 
127 NN Mean A1C  0.310 0.693 0.204 0.640 0.633 0.745 
128 NN Mean A1C  0.295 0.754 0.192 0.571 0.548 0.730 
129 NN Mean A1C  0.405 0.934 0.263 0.677 0.643 0.894 
130 NN Mean A1C  0.293 0.712 0.186 0.604 0.590 0.724 
131 NN Mean A1C  0.344 0.734 0.232 0.667 0.658 0.779 
132 NN Mean A1C  0.348 0.600 0.251 0.741 0.759 0.743 
133 NN 
Combination 
single 0.291 0.670 0.190 0.622 0.616 0.714 
134 NN 
Combination 
single 0.327 0.725 0.219 0.645 0.635 0.773 
135 NN 
Combination 
single 0.304 0.710 0.197 0.625 0.614 0.755 
136 NN 
Combination 
single 0.341 0.729 0.232 0.659 0.650 0.782 
137 NN 
Combination 
single 0.359 0.724 0.241 0.706 0.703 0.775 
138 NN 
Combination 
single 0.318 0.676 0.211 0.662 0.660 0.743 
139 NN 
Combination 
single 0.318 0.615 0.219 0.695 0.705 0.729 
140 NN 
Combination 
single 0.399 0.956 0.253 0.661 0.623 0.897 
141 NN 
Combination 






single 0.342 0.727 0.227 0.672 0.665 0.784 
143 NN 
Combination 
single 0.346 0.620 0.245 0.729 0.743 0.748 
144 NN 
Combination 
mean 0.329 0.518 0.248 0.766 0.797 0.746 
145 NN 
Combination 
mean 0.363 0.525 0.281 0.793 0.827 0.753 
146 NN 
Combination 
mean 0.371 0.478 0.314 0.817 0.861 0.787 
147 NN 
Combination 
mean 0.409 0.500 0.350 0.836 0.879 0.819 
148 NN 
Combination 
mean 0.412 0.373 0.474 0.878 0.944 0.855 
149 NN 
Combination 
mean 0.518 0.563 0.506 0.878 0.919 0.885 
150 NN 
Combination 
mean 0.439 0.512 0.402 0.853 0.897 0.871 
151 NN 
Combination 
mean 0.605 0.690 0.564 0.895 0.921 0.919 
152 NN 
Combination 
mean 0.463 0.424 0.546 0.891 0.951 0.877 
153 NN 
Combination 
mean 0.564 0.578 0.590 0.899 0.941 0.899 
154 NN 
Combination 
mean 0.348 0.551 0.251 0.760 0.787 0.729 
155 NN Multiple  0.340 0.598 0.238 0.740 0.758 0.722 
156 NN Multiple  0.356 0.568 0.260 0.772 0.797 0.765 
157 NN Multiple  0.354 0.500 0.275 0.792 0.830 0.757 
158 NN Multiple  0.440 0.585 0.354 0.830 0.862 0.812 
159 NN Multiple  0.499 0.637 0.414 0.855 0.883 0.857 
160 NN Multiple  0.446 0.549 0.377 0.844 0.883 0.870 
161 NN Multiple  0.466 0.507 0.432 0.866 0.912 0.862 
162 NN Multiple  0.551 0.771 0.429 0.856 0.867 0.904 
163 NN Multiple  0.544 0.649 0.471 0.877 0.906 0.886 
164 NN Multiple  0.545 0.507 0.596 0.905 0.956 0.898 
165 NN Multiple  0.356 0.618 0.250 0.744 0.760 0.765 
149 
 







score Sensitivity Precision Accuracy Specificity AUC 
1 LR Single A1C 0.000 0.000 1.000 0.814 0.000 0.666 
2 LR Single A1C 0.073 0.038 1.000 0.822 1.000 0.723 
3 LR Single A1C 0.073 0.038 1.000 0.820 1.000 0.689 
4 LR Single A1C 0.037 0.019 1.000 0.817 1.000 0.656 
5 LR Single A1C 0.074 0.038 1.000 0.824 1.000 0.688 
6 LR Single A1C 0.037 0.019 1.000 0.816 1.000 0.724 
7 LR Single A1C 0.107 0.057 1.000 0.826 1.000 0.696 
8 LR Single A1C 0.107 0.057 1.000 0.824 1.000 0.703 
9 LR Single A1C 0.037 0.019 1.000 0.819 1.000 0.741 
10 LR Single A1C 0.074 0.038 1.000 0.822 1.000 0.697 
11 LR Single A1C 0.114 0.061 1.000 0.826 1.000 0.732 
12 LR Mean A1C  0.000 0.000 1.000 0.814 0.000 0.680 
13 LR Mean A1C  0.073 0.038 1.000 0.822 1.000 0.716 
14 LR Mean A1C  0.073 0.038 1.000 0.820 1.000 0.692 
15 LR Mean A1C  0.037 0.019 1.000 0.816 1.000 0.675 
16 LR Mean A1C  0.109 0.058 1.000 0.827 1.000 0.688 
17 LR Mean A1C  0.037 0.019 1.000 0.816 1.000 0.723 
18 LR Mean A1C  0.107 0.057 1.000 0.825 1.000 0.702 
19 LR Mean A1C  0.073 0.038 1.000 0.821 1.000 0.701 
20 LR Mean A1C   0.000 1.000 0.815 0.000 0.738 
21 LR Mean A1C  0.074 0.038 1.000 0.822 1.000 0.696 


























































































0.114 0.061 1.000 0.827 1.000 0.734 
45 LR Multiple  0.050 0.026 1.000 0.761 1.000 0.602 
46 LR Multiple  0.057 0.029 1.000 0.790 1.000 0.600 
47 LR Multiple  0.107 0.056 1.000 0.792 1.000 0.636 
48 LR Multiple  0.049 0.025 1.000 0.758 1.000 0.686 
49 LR Multiple  0.092 0.048 1.000 0.817 1.000 0.683 
50 LR Multiple  0.083 0.043 1.000 0.792 1.000 0.636 
51 LR Multiple  0.094 0.049 1.000 0.822 1.000 0.679 
52 LR Multiple  0.121 0.065 1.000 0.820 1.000 0.670 
53 LR Multiple  0.154 0.083 1.000 0.830 1.000 0.663 
54 LR Multiple  0.094 0.049 1.000 0.819 1.000 0.641 
55 LR Multiple  0.154 0.083 1.000 0.831 1.000 0.718 
56 SVM Single A1C 0.378 0.717 0.257 0.566 0.532 0.624 
57 SVM Single A1C 0.378 0.717 0.257 0.566 0.532 0.624 
58 SVM Single A1C 0.367 0.679 0.252 0.569 0.545 0.612 
59 SVM Single A1C 0.426 0.755 0.296 0.625 0.596 0.675 
60 SVM Single A1C 0.429 0.736 0.302 0.639 0.617 0.676 
61 SVM Single A1C 0.354 0.673 0.240 0.554 0.528 0.600 
62 SVM Single A1C 0.370 0.673 0.255 0.585 0.566 0.620 
63 SVM Single A1C 0.370 0.712 0.250 0.561 0.528 0.620 
64 SVM Single A1C 0.379 0.679 0.263 0.589 0.568 0.624 
65 SVM Single A1C 0.448 0.774 0.315 0.648 0.620 0.697 
66 SVM Single A1C 0.417 0.758 0.287 0.611 0.578 0.670 
67 SVM Mean A1C  0.371 0.679 0.255 0.576 0.553 0.616 
68 SVM Mean A1C  0.380 0.736 0.257 0.559 0.519 0.627 
69 SVM Mean A1C  0.366 0.642 0.256 0.590 0.579 0.610 
70 SVM Mean A1C  0.426 0.736 0.300 0.635 0.613 0.674 
71 SVM Mean A1C  0.420 0.698 0.301 0.646 0.634 0.666 
72 SVM Mean A1C  0.342 0.635 0.234 0.557 0.540 0.588 
151 
 
73 SVM Mean A1C  0.394 0.712 0.272 0.603 0.579 0.645 
74 SVM Mean A1C  0.381 0.692 0.263 0.592 0.570 0.631 
75 SVM Mean A1C  0.387 0.660 0.273 0.613 0.603 0.631 
76 SVM Mean A1C  0.446 0.736 0.320 0.662 0.645 0.691 
























































































0.415 0.720 0.291 0.628 0.607 0.660 
100 SVM Multiple  0.382 0.717 0.260 0.573 0.540 0.629 
152 
 
101 SVM Multiple  0.392 0.755 0.265 0.569 0.528 0.641 
102 SVM Multiple  0.358 0.679 0.243 0.552 0.523 0.601 
103 SVM Multiple  0.425 0.774 0.293 0.615 0.579 0.676 
104 SVM Multiple  0.453 0.811 0.314 0.639 0.600 0.706 
105 SVM Multiple  0.363 0.712 0.243 0.547 0.511 0.611 
106 SVM Multiple  0.404 0.750 0.277 0.599 0.566 0.658 
107 SVM Multiple  0.394 0.769 0.265 0.571 0.528 0.648 
108 SVM Multiple  0.367 0.679 0.252 0.568 0.543 0.611 
109 SVM Multiple  0.441 0.811 0.303 0.620 0.577 0.694 
110 SVM Multiple  0.422 0.780 0.289 0.608 0.570 0.680 
111 NN Single A1C 0.396 0.819 0.263 0.539 0.476 0.690 
112 NN Single A1C 0.382 0.751 0.260 0.557 0.513 0.666 
113 NN Single A1C 0.343 0.706 0.228 0.506 0.461 0.618 
114 NN Single A1C 0.395 0.770 0.269 0.562 0.515 0.681 
115 NN Single A1C 0.420 0.834 0.283 0.576 0.518 0.725 
116 NN Single A1C 0.344 0.638 0.238 0.562 0.545 0.633 
117 NN Single A1C 0.384 0.746 0.261 0.568 0.529 0.683 
118 NN Single A1C 0.388 0.738 0.269 0.571 0.534 0.693 
119 NN Single A1C 0.390 0.781 0.262 0.549 0.497 0.682 
120 NN Single A1C 0.424 0.887 0.280 0.552 0.476 0.763 
121 NN Single A1C 0.413 0.775 0.285 0.589 0.547 0.716 
122 NN Mean A1C  0.393 0.770 0.265 0.559 0.512 0.690 
123 NN Mean A1C  0.381 0.794 0.255 0.524 0.463 0.672 
124 NN Mean A1C  0.341 0.632 0.237 0.553 0.535 0.625 
125 NN Mean A1C  0.405 0.792 0.275 0.568 0.517 0.694 
126 NN Mean A1C  0.419 0.851 0.280 0.562 0.497 0.723 
127 NN Mean A1C  0.335 0.610 0.232 0.566 0.557 0.639 
128 NN Mean A1C  0.387 0.733 0.266 0.583 0.550 0.695 
129 NN Mean A1C  0.386 0.783 0.260 0.539 0.485 0.667 
130 NN Mean A1C  0.390 0.768 0.263 0.560 0.512 0.669 
131 NN Mean A1C  0.458 0.815 0.323 0.638 0.598 0.748 



























































































0.423 0.783 0.294 0.604 0.564 0.718 
155 NN Multiple  0.397 0.717 0.277 0.600 0.573 0.693 
156 NN Multiple  0.390 0.760 0.263 0.562 0.517 0.670 
157 NN Multiple  0.339 0.681 0.227 0.516 0.478 0.629 
158 NN Multiple  0.405 0.738 0.285 0.601 0.571 0.687 
159 NN Multiple  0.408 0.823 0.275 0.558 0.498 0.723 
160 NN Multiple  0.346 0.638 0.239 0.567 0.551 0.643 
161 NN Multiple  0.393 0.765 0.270 0.577 0.536 0.698 
162 NN Multiple  0.380 0.767 0.255 0.540 0.490 0.696 
163 NN Multiple  0.381 0.711 0.261 0.574 0.542 0.681 
164 NN Multiple  0.447 0.843 0.305 0.611 0.558 0.736 
165 NN Multiple  0.429 0.752 0.303 0.629 0.602 0.723 
154 
 







score Sensitivity Precision Accuracy Specificity AUC 
1 LR Single A1C 0.296 0.174 1.000 0.882 1.000 0.808 
2 LR Single A1C 0.264 0.152 1.000 0.876 1.000 0.777 
3 LR Single A1C 0.351 0.213 1.000 0.885 1.000 0.806 
4 LR Single A1C 0.264 0.152 1.000 0.877 1.000 0.760 
5 LR Single A1C 0.160 0.087 1.000 0.869 1.000 0.790 
6 LR Single A1C 0.259 0.149 1.000 0.876 1.000 0.810 
7 LR Single A1C 0.231 0.130 1.000 0.874 1.000 0.762 
8 LR Single A1C 0.157 0.085 1.000 0.865 1.000 0.768 
9 LR Single A1C 0.160 0.087 1.000 0.871 1.000 0.755 
10 LR Single A1C 0.196 0.109 1.000 0.870 1.000 0.777 
11 LR Single A1C 0.188 0.103 1.000 0.871 1.000 0.779 
12 LR Mean A1C  0.327 0.196 1.000 0.885 1.000 0.811 
13 LR Mean A1C  0.264 0.152 1.000 0.877 1.000 0.782 
14 LR Mean A1C  0.321 0.191 1.000 0.882 1.000 0.806 
15 LR Mean A1C  0.264 0.152 1.000 0.877 1.000 0.760 
16 LR Mean A1C  0.122 0.065 1.000 0.866 1.000 0.791 
17 LR Mean A1C  0.259 0.149 1.000 0.875 1.000 0.806 
18 LR Mean A1C  0.264 0.152 1.000 0.878 1.000 0.762 
19 LR Mean A1C  0.157 0.085 1.000 0.865 1.000 0.769 
20 LR Mean A1C  0.160 0.087 1.000 0.871 1.000 0.766 
21 LR Mean A1C  0.196 0.109 1.000 0.871 1.000 0.779 


























































































0.198 0.103 1.000 0.871 1.000 0.781 
45 LR Multiple  0.231 0.130 1.000 0.876 1.000 0.780 
46 LR Multiple  0.122 0.065 1.000 0.864 1.000 0.715 
47 LR Multiple  0.192 0.106 1.000 0.870 1.000 0.777 
48 LR Multiple  0.196 0.109 1.000 0.872 1.000 0.710 
49 LR Multiple  0.122 0.065 1.000 0.867 1.000 0.755 
50 LR Multiple  0.157 0.085 1.000 0.865 1.000 0.711 
51 LR Multiple  0.083 0.043 1.000 0.864 1.000 0.739 
52 LR Multiple  0.120 0.064 1.000 0.863 1.000 0.777 
53 LR Multiple  0.231 0.130 1.000 0.877 1.000 0.730 
54 LR Multiple  0.083 0.043 1.000 0.863 1.000 0.742 
55 LR Multiple  0.067 0.034 1.000 0.861 1.000 0.737 
56 SVM Single A1C 0.391 0.391 0.263 0.666 0.650 0.705 
57 SVM Single A1C 0.378 0.378 0.263 0.687 0.689 0.682 
58 SVM Single A1C 0.372 0.372 0.248 0.647 0.632 0.686 
59 SVM Single A1C 0.405 0.405 0.276 0.684 0.671 0.716 
60 SVM Single A1C 0.356 0.356 0.244 0.656 0.656 0.658 
61 SVM Single A1C 0.408 0.408 0.266 0.635 0.595 0.734 
62 SVM Single A1C 0.362 0.362 0.241 0.632 0.616 0.670 
63 SVM Single A1C 0.381 0.381 0.262 0.680 0.677 0.687 
64 SVM Single A1C 0.398 0.398 0.267 0.665 0.645 0.714 
65 SVM Single A1C 0.391 0.391 0.268 0.683 0.677 0.697 
66 SVM Single A1C 0.431 0.776 0.298 0.708 0.697 0.740 
67 SVM Mean A1C  0.395 0.739 0.270 0.681 0.671 0.705 
68 SVM Mean A1C  0.390 0.696 0.271 0.693 0.693 0.694 
69 SVM Mean A1C  0.373 0.717 0.252 0.660 0.650 0.684 
70 SVM Mean A1C  0.400 0.761 0.271 0.678 0.664 0.713 
71 SVM Mean A1C  0.349 0.638 0.240 0.656 0.659 0.649 
72 SVM Mean A1C  0.396 0.809 0.262 0.644 0.616 0.712 
156 
 
73 SVM Mean A1C  0.355 0.702 0.237 0.632 0.620 0.661 
74 SVM Mean A1C  0.382 0.717 0.260 0.671 0.663 0.690 
75 SVM Mean A1C  0.398 0.783 0.267 0.665 0.645 0.714 
76 SVM Mean A1C  0.412 0.739 0.286 0.702 0.695 0.717 
























































































0.441 0.750 0.312 0.729 0.725 0.740 
100 SVM Multiple  0.396 0.783 0.265 0.663 0.643 0.713 
157 
 
101 SVM Multiple  0.386 0.696 0.267 0.687 0.686 0.691 
102 SVM Multiple  0.372 0.739 0.248 0.647 0.632 0.686 
103 SVM Multiple  0.416 0.804 0.280 0.681 0.661 0.733 
104 SVM Multiple  0.366 0.681 0.250 0.660 0.656 0.668 
105 SVM Multiple  0.371 0.766 0.245 0.626 0.602 0.684 
106 SVM Multiple  0.351 0.702 0.234 0.626 0.613 0.658 
107 SVM Multiple  0.391 0.739 0.266 0.674 0.663 0.701 
108 SVM Multiple  0.391 0.783 0.261 0.655 0.634 0.709 
109 SVM Multiple  0.412 0.761 0.282 0.692 0.681 0.721 
110 SVM Multiple  0.426 0.759 0.296 0.709 0.701 0.730 
111 NN Single A1C 0.360 0.717 0.244 0.635 0.621 0.755 
112 NN Single A1C 0.366 0.570 0.277 0.728 0.754 0.750 
113 NN Single A1C 0.387 0.848 0.268 0.598 0.558 0.834 
114 NN Single A1C 0.418 0.761 0.294 0.699 0.689 0.823 
115 NN Single A1C 0.347 0.628 0.241 0.660 0.665 0.700 
116 NN Single A1C 0.403 0.840 0.267 0.640 0.606 0.784 
117 NN Single A1C 0.346 0.732 0.229 0.597 0.575 0.739 
118 NN Single A1C 0.361 0.698 0.252 0.644 0.635 0.744 
119 NN Single A1C 0.404 0.861 0.265 0.637 0.600 0.812 
120 NN Single A1C 0.426 0.713 0.308 0.722 0.724 0.785 
121 NN Single A1C 0.384 0.799 0.256 0.628 0.600 0.783 
122 NN Mean A1C  0.354 0.743 0.233 0.616 0.595 0.759 
123 NN Mean A1C  0.391 0.648 0.283 0.718 0.730 0.754 
124 NN Mean A1C  0.409 0.857 0.271 0.644 0.609 0.831 
125 NN Mean A1C  0.414 0.728 0.299 0.707 0.703 0.821 
126 NN Mean A1C  0.328 0.689 0.216 0.588 0.571 0.706 
127 NN Mean A1C  0.403 0.851 0.265 0.636 0.599 0.790 
128 NN Mean A1C  0.348 0.674 0.239 0.632 0.625 0.738 
129 NN Mean A1C  0.361 0.709 0.246 0.642 0.632 0.750 
130 NN Mean A1C  0.410 0.824 0.274 0.660 0.633 0.807 
131 NN Mean A1C  0.407 0.722 0.288 0.695 0.691 0.781 




























































































0.404 0.771 0.275 0.673 0.657 0.786 
155 NN Multiple  0.356 0.763 0.234 0.608 0.583 0.753 
156 NN Multiple  0.377 0.693 0.261 0.674 0.670 0.744 
157 NN Multiple  0.399 0.865 0.261 0.625 0.585 0.826 
158 NN Multiple  0.409 0.774 0.279 0.684 0.669 0.813 
159 NN Multiple  0.349 0.664 0.239 0.645 0.642 0.708 
160 NN Multiple  0.396 0.813 0.263 0.641 0.613 0.767 
161 NN Multiple  0.344 0.657 0.235 0.637 0.633 0.726 
162 NN Multiple  0.353 0.674 0.240 0.650 0.646 0.733 
163 NN Multiple  0.392 0.802 0.261 0.646 0.620 0.793 
164 NN Multiple  0.365 0.735 0.245 0.634 0.617 0.771 
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